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The intestinal IgA response has features that are different to those of the systemic 
humoral response, which is dominated by IgG.  Although the IgA response, like the IgG 
response, includes an antigen specific component, it is also associated with 
polyspecificity and autoimmunity. The profile of intestinal immunoglobulins changes in 
inflammatory bowel disease (IBD) where there is a disproportionate increase in IgG 
production and in ulcerative colitis (UC), this includes the production of autoantibodies. 
In this thesis, two immunoregulatory T cell subsets that could influence the intestinal B 
cell response have been studied; T follicular helper cells (TFH) and regulatory T cells 
(Treg). 
Results in chapter 3 show that there is a higher density of TFH in gut associated 
lymphoid tissue (GALT) compared to peripheral lymphoid tissue due to a higher 
density of CD57- TFH. The expression of cytokines and CD40L was almost comparable 
between CD57+ and CD57- TFH. However, culturing experiments suggest that CD57- 
TFH may develop into CD57+ TFH and there is a constant turnover of TFH in the gut. 
Experiments in chapter 4 attempted to seek evidence for a developmental 
relationship between TFH and Treg by analysis of T cell receptor sequences. No evidence 
of plasticity between these subsets was observed. 
Experiments in chapter 5 set out to characterise TFH in IBD. In the appendix of UC 
patients, nearly all TFH were CD57+ and at a high density within germinal centres (GC).  
This thesis concludes that TFH are more phenotypically diverse and denser in GALT 
compared to peripheral lymphoid tissue. This may reduce the threshold for GC B cell 
survival in the gut permitting the propagation of plasma cells that secrete polyspecific 
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and autoreactive IgA. TFH are denser still in the small GC in UC appendix. This may be 
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1 Chapter 1 Introduction 
This thesis will describe investigations of two different immunoregulatory T cell 
subsets in the gut and peripheral lymphoid tissues. Three chapters of experimental data 
will investigate possible differences in T follicular helper cell (TFH) populations in the 
gut compared to peripheral lymphoid tissue, the possibility of clonal relationships 
between TFH and regulatory T cells (Treg) and changes in these T cell subset 
populations that occur in inflammatory bowel disease (IBD). 
 To introduce this data, TFH and Treg will be described in the context of T cell 
development, function and interaction with B cells. The function of gut associated 
lymphoid tissue (GALT) will be discussed to consider how differences in B cells 
generated in GALT compared to the peripheral lymphoid tissue might be modulated by 
differences in immunoregulatory T cells. Features of IBD will be discussed to consider 
how aberrant function of immunoregulatory T cells might contribute to the disease 
pathogenesis.  
1.1 T cell development 
T cells develop in the thymus from bone marrow derived pluripotent progenitors 
that have the ability to give rise to T cells, B cells or natural killer (NK) cells (Kondo et 
al., 1997). The importance of the thymus for T cell development was originally 
demonstrated by the development of immunodeficiency in mice that had undergone a 
neonatal thymectomy (Miller, 2002, Miller, 1961). 
When haematopoietic progenitors arrive in the thymus they receive signalling 
through Notch that modifies gene expression and commits the cell to a T cell lineage 
(Pui et al., 1999, Radtke et al., 1999, Hayday and Pennington, 2007, Naito et al., 2011). 
Two distinct lineages of T cells develop in the thymus that differs in their T cell 
receptor (TCR).  They express either an αβTCR or a γδTCR. The αβ T cells can be 
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further sub divided by their surface expression of either CD4 or CD8 and the choice 
between CD4 and CD8 expression is also made within the thymus (Germain, 2002).  
The stages of T cell development within the thymus can be defined by the 
expression of CD4 and CD8. The thymocytes begin development double negative for 
CD4 and CD8 (DN) and during the DN stage the TCR genes, except for α, rearrange. 
Commitment to either an αβ or γδ lineage is made just before the end of the DN stage 
(Fig 1.1) (Ciofani et al., 2006, Ciofani and Zúñiga-Pflücker, 2010, Hayday and 
Pennington, 2007). 
 
Copyright 2007 from Janeway’s Immunobiology, Seventh Edition by Murphy.  Reproduced by permission of Garland 
Science/Taylor & Francis LLC. 




1.1.1 TCR rearrangement 
T cell diversity and specificity for peptides arises from the genetic rearrangement of 
the genes encoding the TCR (fig 1.2). There are four different genes encoding the TCR: 
Tcra, Tcrb, Tcrg and Tcrd.  Diversity is generated by recombination of variable (V), 
diversity (D) and joining (J) gene segments at the tcr loci (Krangel, 2009). The TCR 
chains produced from these genes are expressed on the cell surface as a pair, as either an 
αβ TCR or a γδ TCR. The TCR β and δ chains are produced from V, D and J segments 
whereas the α and γ chains are made up of only V and J segments (Bassing et al., 2002). 
There are several V, (D) and J segments within each locus and joining these segments in 
different combinations produces combinatory diversity of the TCR. 
 Within the thymus, thymocytes express RAG-1 and RAG-2 which make up the 
RAG recombinase (Oettinger et al., 1990). RAG proteins recognise specific sites called 
recombination signal sequences (RSSs) at V, (D) and J segments within the tcr loci 
(Bassing et al., 2002, Krangel, 2009, Santagata et al., 1999). The RSS consist of a 
conserved heptamer and an AT rich nonamer separated by a 12 or 23 bp spacer 
(Grawunder et al., 1998). A segment with a RSS containing a 12 bp spacer can only join 
with a segment with a RSS containing 23bp spacer ensuring that segments join together 
in the correct order of VDJ or VJ (Bassing et al., 2002).  
V, (D) J recombination begins when the RAG proteins, which have endonuclease 
activity,  makes nicks at the RSS of the two segments to be joined (van Gent et al., 
1996). RAG catalyses the formation of a hair pin loop where the 3’ end of the break 
invades the opposite strand (Gent et al., 1996). The coding region ends are held together 
by Ku70:Ku80 heterodimeric complex and the hairpins are opened up by a complex of 
Artemis and DNA-dependent protein kinase (DNA-PK) (Gu et al., 1997, Moshous et 
al., 2001, Ma et al., 2002, Gellert, 2002). DNA repair enzymes remove nucleotides at 
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the open ends while terminal deoxynucleotidyl transferase (TdT) adds nucleotides 
before the ends are joined together by DNA ligase IV and Xrcc4 (Ma et al., 2002, 
Benedict et al., 2000, Gellert, 2002, Murphy et al., 2008). This results in imprecise 
joining of the coding regions between V, D and J segments, which adds another level of 
diversity between TCRs and creates a unique sequence which is carried by the T cell 
and its clonal progeny. When two RSSs are joined together the region in between is 
excised and precisely joined together creating an excision circle (Bassing et al., 2002). 
If the sequence generated by V(D)J recombination is out of frame or non-coding, 
recombination can occur on the second allele (Bassing et al., 2002).  
1.1.2 Lineage commitment 
During the double negative thymocyte stage, the TCRδ, TCRγ and TCRβ rearrange 
(Blom et al., 1999, Hayday and Pennington, 2007). After successful rearrangement of 
these TCR loci the thymocytes either express a pre-TCR or γδTCR on the cell surface 
(Ciofani and Zúñiga-Pflücker, 2010). The pre-TCR is made up of the rearranged TCRβ 
chain and a pre-TCR alpha chain, as the TCRα chain has yet to undergo recombination. 
At this stage there is a checkpoint and if signalling occurs through the pre-TCR or γδ 
TCR expressed on the cell surface, then the thymocyte continues in development 
(Ciofani and Zúñiga-Pflücker, 2010). Though the γ and δ chains are thought to 
rearrange before the β chain, the majority of thymocytes commit to an αβ lineage (Livák 
et al., 1999). The exact mechanism for commitment to either a γδ or αβ lineage is not 
known. However one model suggests that the strength of signal through the pre-TCR 
and γδ TCR determines the cells fate (Ciofani and Zúñiga-Pflücker, 2010). From this 
point the γδ thymocytes continue on a separate developmental path from αβ thymocytes 
and the γδ thymocytes do not revise their TCR any further (Prinz et al., 2006). The γδ T 
cells mostly remain CD4-CD8- double negative (Ciofani and Zúñiga-Pflücker, 2010).  
The thymocytes committed to an αβ lineage continue their development by rearranging 
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the α chain and become CD4+CD8+ double positive (DP) (Ciofani and Zúñiga-
Pflücker, 2010).  
 
Copyright 2007 from Janeway’s Immunobiology, Seventh Edition by Murphy.  Reproduced by permission of Garland 
Science/Taylor & Francis LLC. 
Figure 1-2 The αβ T cell receptor complex. 
The TCR complex as a whole is need for efficient signalling. The TCR α and β chains are expressed 
on the cell surface as a TCR heterodimer. The TCR complex is associated with a homodimer of ζ chains. 
The CD3 complex consists of heterodimers of CD3 ɛ and δ chains and γ and ɛ chains. Both ζ chains and 
CD3 chains contain ITAM signalling motifs (Murphy et al., 2008). 
1.1.3 Using TCR chain rearrangements to detect clonally related T cells 
1.1.3.1 Detection of T cell clones by analysis of TCRγ chain rearrangements 
As described above, recombination of the TCRβ, γ and δ chains occurs before 
thymocytes commit to either a γδ or αβ T cell lineage. Therefore virtually all T cells of 
both γδ or αβ T cell lineages have undergone rearrangement of TCR and TCR in their 
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history. The rearranged TCR locus is located within the TCR locus and is therefore 
deleted when the TCR subsequently rearranges in  T cells. However, the rearranged 
TCRγ chain is retained. The tcrg locus has relatively few V and J exons compared to the 
other TCR genes and only one junctional region is formed where the V and J segments 
join. By detecting TCRγ rearrangements in T cells through PCR and sequencing the 
product, the junctional region can be analysed. Cells with the same V and J segments 
and junctional regions can be assumed to be clonally related. Thus the sequence of 
rearranged tcrg locus can serve as a signature of clone of both γδ or αβ T cell lineages.  
This method has been used diagnostically for the detection of T cell malignancy and T 
cell clonality (McCarthy et al., 1991, McCarthy et al., 1992, Diss et al., 1995, Golby et 
al., 1999). 
1.1.3.2 Detection of T cell clones in large and diverse polyclonal populations. 
Rearrangements of the TCRchain can also be used to identify T cell clonality 
(McCarthy et al., 1991, Dogan et al., 1996).  However, whether either TCR or TCR 
are targeted, it can be difficult to detect a minor population of clonally related cells in a 
large and diverse polyclonal background because the sequenced PCR products 
following amplification may be all different and the probability of detecting two 
members of a clone is low.  
One method to detect members of a T cell clone in polyclonal T cell background is 
to use PCR primers specific for a TCR gene rearrangement to selectively amplify the 
same TCR gene rearrangement.  Clone specific primers designed to bind to the unique 
junctional region of the TCRγ chain gene rearrangements can be used to efficiently 
detect clonally related T cells. Using this method, Golby et al. (1999) detected clonally 
expanded TFH within tonsil tissue. 
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Detection of minor subsets of clonally related B cells in a polyclonal background 
has been achieved by specifically targeting members of a clone that have rearranged one 
of the many potentially used variable region gene segments. Related B lineage cells 
were detected within the intestinal mucosa in this way (Boursier et al., 2005). 
Comparing the sequences within a small fraction of the repertoire gives a greater 
probability of detecting related clones. This method has been adapted to the study of T 
cell clonality in Chapter 4 of this thesis, where a fraction of the TCRβ repertoire was 
analysed to increase the probability of detecting clonally related sequences.  
1.2 Positive and negative selection 
At the DP stage after the TCRα chain has successful rearranged, low levels of the αβ 
TCR are expressed on the thymocyte surface (Ohashi et al., 1990). The DP thymocytes 
undergo positive selection that is dependent on an inherent germline-encoded specificity 
of the TCR and CD4 or CD8 co-receptor for MHC and also the recognition of self-
peptide MHC complexes expressed by the thymic stromal cells (Morris and Allen, 
2012, Germain, 2002, Murphy et al., 2008). 
A cell that survives positive selection then expresses either CD4 or CD8 to become 
SP and commit to either class II or class I restriction respectively. 
The developing thymocytes have highly variable TCR specificities and some of the 
thymocytes generated recognise self-peptides presented by thymic stromal cells.  
Negative selection ensures that thymocytes with TCR that have high affinity for self-
peptides are clonally deleted by TCR mediated apoptosis. This mechanism limits the 
number of autoreactive T cells from entering the periphery and responsiveness to self-
antigens (Palmer, 2003, Morris and Allen, 2012).  
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After passing positive and negative selection, 3 subsets of  T cells are exported to 
the periphery: MHC class I restricted CD8 T cells, MHC class II restricted T cells and 
natural regulatory T cells (nTregs) that express the transcription factor forkhead box P3 
(Foxp3) (Germain, 2002, Murphy et al., 2008).  
1.3 T cell activation 
The initial phase of a class II restricted immune response involves the processing 
and presentation of peptides by antigen presenting cells (APC) such as dendritic cells 
(DC). T cells with TCRs specific for the peptide become activated, proliferate and 
differentiate. This requires 3 separate signals from the APC (Kapsenberg, 2003). The 
first signal occurs through the TCR and co-receptor binding to the peptide:MHC 
complex on the APC (Kapsenberg, 2003). The second signal involves co-stimulatory 
signals such as the activation of CD28 on the surface of the T cell (Bour-Jordan and 
Bluestone, 2002). The third polarising signal promote differentiation into a certain T 
cell subset, depending on the pathogen, through modified cytokine secretion (Fig 1.3) 
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Figure 1-3 Activation of naive T cells by antigen presenting cells requires three signals. 
T cell TCR binding a foreign antigen presented on MHC class II complex by the APC. 2- Co-
stimulatory signal, for example CD28 on T cell binding to B7 molecules on the APC. 3- Differentiation 
signal by cytokines (Murphy, Travers et al. 2008). 
1.4 T cell subsets 
During an infection, activated CD4 T cells differentiate into different T cell subsets 
that secrete specific cytokines depending on the pathogen and the microenvironment in 
which the activation took place, to provide a tailored immune response. The specialist 
function of each T cell subset is controlled by transcriptional factors that direct the 
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cytokines produced and surface molecules expressed by the T cell (Murphy and 
Stockinger, 2010).  
T cell activation results in the activation of important tyrosine kinases leading to the 
downstream activation of serine/threonine kinase proteins such as protein kinase C that 
subsequently activates the MAP kinase cascade and NFκB. Also calcium signalling 
pathways are activated, such as the activation of calcineurin and consequently the 
dephosphorylation of nuclear factor of activated T cells (NFAT). Signalling culminates 
in the activation of three main groups of transcription factors: NFAT, NFκB and AP1. 
NFAT and NFκB translocate to the nucleus where they bind to gene targets and activate 
their transcription. The activation stimulus influences the genes that are targets and 
ultimately the type of T cell the cell will become. Master transcription factors are 
associated with each T cell subset and control the transcription of genes within the cell 
to polarise the cell to a particular phenotype (Murphy et al., 2008).  
The first T cell subsets to be identified were Th1 and Th2 that were identified by the 
cytokines they produce (Mosmann and Coffman, 1989). Since the identification of Th1 
and Th2 cells several other functional CD4 T cell subsets have been identified including 
inducible regulatory T cells (iTreg) Th17 and T follicular helper cells (TFH) that are 
associated with expression of different transcription factors (Fig1.4). 
Th1 cells express the transcription factor T-bet and produce IFNγ. The IFNγ 
produced by Th1 cells activates macrophages to kill intracellular pathogens (Murphy 
and Stockinger, 2010). IFNγ also promotes B cell immunoglobulin class switching to 




Th2 cells express the transcription factor Gata3 and produce the cytokines, IL-4 and 
IL-5 (O’Shea and Paul, 2010, Abbas et al., 1996). Th2 cells response to helminth 
infections by activate eosinophils through IL-5 secretion and  IL-4 promotes class 
switching to IgE (Abbas et al., 1996). 
Th17 cells express the transcription factor Rorγt and produce the cytokines IL-17a 
and IL-17f (O’Shea and Paul, 2010). Th17 cells recruit and intensify neutrophil activity 
in response to extracellular pathogens (Pelletier et al., 2010). 
iTregs express the transcription factor foxp3 and produces cytokines such as IL-10 
and TGF-β (O’Shea and Paul, 2010). ITregs suppress immune responses and will be 
discussed in more detail bellow.  
TFH express the transcription factor Bcl-6 and are associated with the production of 
the cytokine IL-21 (O’Shea and Paul, 2010). They provide help to B cells during 
affinity maturation to T cell dependent antigens (O’Shea and Paul, 2010). However 
there is still debate over whether TFH are a distinct T cell subset or part of other T cell 
subsets as TFH have the ability to produce Th1, Th2 and Th17 cytokines (Murphy and 
Stockinger, 2010). 




Figure 1-4 T cell subsets, master regulators and cytokines. 
Adapted from O’Shea and Paul (2010). 
1.5 Regulatory T cells 
Regulatory cells are involved in controlling of immune responses and regulating 
immune homeostasis. Several different cell types with this ability have been identified 
including regulatory CD4 T cells, regulatory CD8 T cells and regulatory B cells. This 
thesis will concentrate on regulatory CD4 T cells (Tregs). 
1.5.1 Regulatory T cell development 
Treg were first identified by Sakaguchi et al. (1995) as a subset of CD4+CD25+ T 
cells which controlled immune tolerance. Depletion of this subset resulted in 
autoimmune disease (Sakaguchi et al., 1995). 
There are two developmental pathways that generate Tregs. As discussed above, 
nTregs develop in the thymus during T cell development (Curotto de Lafaille and 
Lafaille, 2009). The exact events that lead to nTreg development over conventional 
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CD4 T cells (Tconv) development or clonal deletion are still unknown. Tregs have been 
shown to have self-reactive TCRs yet do not undergo negative selection possibly due to 
their TCR specificity, affinity, avidity and co-receptor signalling (Wirnsberger et al., 
2011, Hsieh et al., 2004).  nTreg are thought to have an avidity and affinity for self-
antigens which is on the threshold between negative and positive selection (Wirnsberger 
et al., 2011). 
During T cell development in the thymus, foxp3 is upregulated in the cells fated to 
become nTregs and this normally occurs during the SP stage (Lee and Hsieh, 2009). 
Foxp3 is both a repressor and activator of genes that contribute to Treg function and 
surface phenotype (Zheng et al., 2007). Maintained expression of foxp3 is crucial for 
Treg development and function which is demonstrated in foxp3 mutant scurfy mice that 
have a deficiency in Tregs and develop lethal autoimmune disease (Fontenot et al., 
2003). Foxp3 controls the transcription of a number of genes including promoting the 
transcription of genes encoding CTLA-4 and CD25 and the repression of  IL-7Rα. 
Foxp3 also represses cyclic nucleotide phosphodiesterase 3B (PDE3B) and down 
regulation of PDE3B allows the cell to adapt to chronic TCR and IL-2 signalling which 
are important features of Tregs (Gavin et al., 2007). Though functional foxp3 is not 
essential for Treg survival, it is important in maintaining regulatory function (Gavin et 
al., 2007). 12. Interestingly, in humans and not mice, a spliced variant of foxp3 is 
expressed as well as the full length protein. The spliced variant mRNA lacks exon 2 but 
retains its ability to induce functional anergy but not to the same extent as the full length 
foxp3 (Ziegler, 2006).    
The second developmental pathway for Tregs occurs in the periphery and these 
Tregs are termed induced Tregs (iTreg). In vitro studies have demonstrated that iTregs 
can arise from Tconv by TCR signalling in the presence of  IL-2 and TGFβ which 
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drives the upregulation of foxp3 (Davidson et al., 2007). Analysis of the TCR repertoire 
between Tregs and Tconv suggests that only a small fraction of the Treg population is 
generated in the periphery and the majority of Tregs are generated in the thymus 
(Lathrop et al., 2008). 
1.5.2  Regulatory T cell function. 
 Treg suppressive function is elicited through cell to cell contact and secreted 
molecules and involves CTLA-4, transforming growth factor-β (TGF-β) and IL-10.  
CTLA-4 is constitutively expressed on Tregs. Mice with CTLA-4 knocked out 
specifically on Tregs developed systemic lymphocyte proliferation and fatal T cell–
mediated autoimmune disease which demonstrates the importance of Treg CTLA-4 
mediated interactions in controlling immune responses (Wing et al., 2008). Several 
mechanism have been proposed to explain the regulatory effects of CTLA-4 including 
competing with CD28, down regulating CD80 and CD86, regulating signalling 
components and inhibiting lipid raft and microcluster formation needed for efficient 
signalling (Rudd, 2008, Wing et al., 2008).  Rudd (2008) proposed that the cell intrinsic 
inhibitory function of CTLA-4 is through a “reverse stop-signal” mechanism.  T cells 
need reduced motility to form long interactions with APC and reduced motility is 
initiated through TCR ligation. It is thought that CTLA-4 is able to reverse the stop 
signal that reduced T cell motility and therefore prevents stable immunological synapse 
formation (Rudd, 2008).  
Recently Qureshi et al. (2011) proposed a new cell extrinsic mechanism of 
inhibition by CTLA-4. By tracking GFP tagged CD86, it has been suggested that 
CTLA-4 binds to and internalises its ligands CD80 and CD86 from opposing cells 
through trans-endocytosis. The depletion of CD80 and CD86 then prevents T cell 
activation through CD28 (Qureshi et al., 2011). 
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TGF-β has a number of suppressive effects including suppressing the production of 
IFN-γ by Th1 cells, inhibiting IL-2 receptor expression and inducing apoptosis in T 
cells (Prud'homme and Piccirillo, 2000). TGF-β also exerts inhibitory effects on 
macrophages and B cells (Prud'homme and Piccirillo, 2000). The suppressive effect of 
TGF-β was demonstrated in a T cell transfer mouse model of colitis. Neutralising 
antibodies to TGF-β eliminated the protective effect of CD45RBlow T cells in 
CD45RB
high
 T cell mediated colitis suggesting that TGF-β plays a role in regulating T 
cell responses (Powrie et al., 1996). TGF-β exerts its effects by binding to the TGF-β 
receptor complex on the cell surface of target cells leading to the activation of SMAD 
proteins which transduce TGF-β signalling. Activated SMAD proteins translocate into 
the nucleus where they are targeted to specific genes by transcriptional factors 
(Massague, 2012, Heldin et al., 1997). SMAD proteins then recruit other enzymes that 
modify histones and remodel chromatin to regulate gene expression (Massague, 2012). 
IL-10 is a cytokine secreted by Tregs under certain antigenic stimulation and has a 
suppressive effect by reducing T cell proliferation and the production cytokines such as 
IL-2 (Sundstedt et al., 2003, O’Garra et al., 2004). Through knocking out Treg specific 
IL-10 in mice it has been shown that IL-10 is important in controlling immune 
responses at exposed surfaces such as the lungs and colon but is not essential for 
controlling autoimmune disease (Rubtsov et al., 2008).  
1.5.3 Identification of Regulatory T cells 
Tregs contribute to 5-10% of the peripheral CD4+ T cell population in a healthy 
individuals (O'Garra and Vieira, 2003). 
Flow cytometry is often used to isolate lymphocytes and the capacity to detect 
several markers at once on a cell surface improves the purity of a population. Early 
studies used high expression of CD25, the alpha chain of the IL-2R, to identify Tregs 
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(Sakaguchi et al., 1995, Stephens et al., 2001). Foxp3 has since been identified as the 
transcriptional regulator of Treg cells and often CD4+foxp3+ are identified as Tregs 
(Fontenot et al., 2003, Lee et al., 2007, Wang et al., 2011b). However foxp3 can be 
transiently expressed by activated T cells (Ziegler, 2007, Bernardo et al., 2012a, Wang 
et al., 2007). 
 Isolation of a pure Tregs population from human lymphoid tissue without fixing 
and risking damaging the cellular DNA by intranuclearly staining for foxp3, has proved 
to be challenging. Liu et al. (2006) discovered that low expression of CD127, the IL-7 




 CD4 T cells 
have a high suppressive function in peripheral blood. The inhibitory molecule, PD-1, 
has also been reported to be expressed on Tregs, especially after viral infection (Shen et 
al., 2011, Franceschini et al., 2009) 
Miyara et al. (2009) identified three subsets of Tregs by their expression of 
CD45RA and foxp3. Resting Tregs express CD45RA and intermediate levels of foxp3, 
memory Tregs express intermediate levels of foxp3 and are CD45RA- and activated 
Tregs express high levels of foxp3 and are also CD45RA-. As the level of CD25 
expression correlates with the level of foxp3 expression, CD25 expression can be used 
instead of foxp3 when identifying T reg subsets (Miyara et al., 2009). 
1.6  B cells 
B cells are part of the adaptive immune system and contribute to antigen specific 
immune responses. Maturation of B cells to plasma cells results in the secretion of 
antibodies that have a variety of functions including neutralisation of extracellular 
pathogens or toxins, complement activation and opsonisation. Alternatively, activated B 




1.6.1  B cell generation 
B cells arise in the bone marrow from common lymphoid progenitor cells (Kondo et 
al., 1997).  During development the B cell receptor (BCR) is formed which gives the B 
cells its unique antigenic specificity. The BCR is made up of Ig heavy and light chains 
that are similar in structure to TCR chains (Bassing et al., 2002). The Ig heavy chains 
are made up of V,D and J segments whereas the Ig light chains are made up of only V 
and J segments (Bassing et al., 2002).  
 B cell development begins with the induction of the transcription factor E2A, which 
specifies a B cell fate and gives rise to progenitor B cells (Pro-B cell) (Singh et al., 
2005). E2A regulates gene expression in the pro-B cell that results in Ig heavy chain 
gene rearrangement (Singh et al., 2005). Once a heavy chain has successfully 
rearranged it is tested by being expressed on the cell surface along with surrogate light 
chain to form a pre-B cell receptor (Nishimoto et al., 1991).  If signalling occurs 
through the pre-B cell receptor then the B cells continues development as a precursor B 
cell (pre-B cell) and the Ig light chains are rearranged (Herzog et al., 2009). Once a 
successful light chain is rearranged it is paired with a µ chain and expressed on the cell 
surface along with the heavy chain as IgM (King and Monroe, 2000).  At this stage the 
pre-B cell becomes an immature B cell and undergoes negative selection (King and 
Monroe, 2000). Only immature B cells with low affinity for self-antigens in the bone 
marrow continue with development (Nemazee, 2006). As the immature B cells are only 
tested against self-antigens in the bone marrow, the negative selection at this point  
results in central tolerance (Nemazee, 2006).  
 The immature B cells emerge from the bone marrow as new emigrant B cells 
and undergo negative selection resulting in peripheral tolerance (Samuels et al., 2005). 
It is suggested that tolerance to self-antigen results in the deletion of autoreactive B cells 
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or they enter an anergic state (Goodnow et al., 1988, Russell et al., 1991). However 
even after undergoing the peripheral checkpoint approximately 20% of mature naïve B 
cells expressed immunoglobulins that are HEp-2 reactive (Samuels et al., 2005). 
The mature naïve B cells recirculate through lymphoid tissue where they may 
encounter antigen and mature to give rise to plasma and memory B cells. By using 
transgenic mouse models expressing hen egg lysozyme (HEL) and rearranged anti-HEL 
immunoglobulin genes it was demonstrated that self-reactive B cells that slip through 
the peripheral checkpoint usually have a short life span (Fulcher et al., 1996). However 
self-reactive B cells can mature and secrete antibody when sufficient T cell help is 
provided (Fulcher et al., 1996). This suggests that the regulation of autoreactive B cells 
in the periphery is to some extent regulated by T cell tolerance.  
1.6.2  B cell activation 
The consequences of B cell activation depend on the nature of the immunising 
antigen. Antigens that include a protein component such as cholera toxin B, enable B 
cells to recruit cognate T cell help and are therefore called T cell dependent (TD) 
(Campbell and Munson, 1987, Cerutti et al., 2011). Antigens that do not have a protein 
component but which are able to activate B cells by their ability to bind an innate 
receptor, such as unmethylated CpG repeats in bacterial DNA, or by the repetitive 
nature of their antigenic structures, such as microbial polysaccharides, are referred to as 
T cell independent (TI) antigens (Cerutti et al., 2011, Peng, 2005). This thesis will focus 
on T cell dependent activation of B cells. 
TD activation of B cells requires multiple signals. The first signal is from antigen 
binding to the BCR. The antigen is then internalised while bound to the BCR, degraded 
and presented as peptides in peptide:MHC class II  complexes on the cell surface 
(Parker, 1993). Pre-primed cognate T helper cells that have TCRs specific for the 
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peptide presented by the B cell (Parker, 1993) deliver multiple signals including 
delivery of cytokines into the synapse and cross linking of CD40 by CD40 ligand 
(CD40L) expression (Jaiswal and Croft, 1997). CD40-CD40L signalling induces B cells 
proliferation and the upregulation of co-stimulatory molecules (Bishop and Hostager, 
2003). 
Activation of B cells causes B cells to proliferate along with T cells. Some of the B 
cells differentiate into plasmablasts and secrete antibodies encoded by germline 
immunoglobulin gene rearrangements. This forms a rapid response to pathogens but the 
plasma cells are short lived. Some activated B cells migrate to the follicle and either 
form or enter existing germinal centres (GC). Within the GC the B cells rapidly 
proliferate and undergo somatic hyper mutation (SHM) and class switching before 
differentiating into long lived plasma cells or memory B cells. This thesis will focus on 
the GC generated plasma cells (Shapiro-Shelef and Calame, 2005). 
1.7  Formation of plasma cell precursors in germinal centre 
reactions 
GCs are the sites of extensive B cell proliferation and immunoglobulin 
diversification to generate antibodies with potentially greater affinity for the antigen.  
B cells upregulate CXCR5 when they are activated and some of these B cells retain 
the expression of CXCR5 (Zotos and Tarlinton, 2012). CXCR5 is the chemokine 
receptor for CXCL13. CXCL13 is produced by follicular dendritic cells (FDC) and 
expression of CXCR5 on the cell surface allows migration of a cell in the B cell follicle 
and GC (Gunn et al., 1998, Legler et al., 1998). The CXCR5+ activated B cells enter the 
B cell follicle along with antigen specific preTFH cells, possible originating from the 
interfollicular zone (Fuller et al., 1993, Kerfoot et al., 2011, Zotos and Tarlinton, 2012).  
After the initiation of a GC, a dark and light zone form (Zotos and Tarlinton, 2012). The 
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dark zone is proximal to the T cell zone and is where actively proliferating B cells 
reside, called centroblasts (Victora and Nussenzweig, 2012). In the dark zone the 
centroblasts undergo SHM and immunoglobulin class switching (Victora and 
Nussenzweig, 2012). The centroblasts then differentiate into centrocytes and are 
selected for high affinity for antigen (Victora and Nussenzweig, 2012).  
The majority of centrocytes reside in the light zone and this is where selection of B 
cells with high affinity receptors generated by somatic hypermutation is mainly thought 
to occur. The light zone contains a network of FDC that retain antigen on their cell 
surface complex with complement and antibody.  Many of the TFH reside in the light 
zone (Victora and Nussenzweig, 2012, Zotos and Tarlinton, 2012). However, some 
proliferation of GC B cells can be observed within the light zone and less movement is 
seen between the light and dark zone than previously predicted. It has therefore been 
suggested that proliferation and selection may occur in both the light and dark zone 
(Zotos and Tarlinton, 2012).  
Centrocytes sample antigen from the surface of FDCs by their altered BCR 
(MacLennan, 1994). The antigen bound to the BCR is internalised and presented to TFH 
on the surface of the centrocyte as peptides:MHC class II complexes. This provides cell 
to cell contact and cytokines that contribute to the centrocyte survival (Vinuesa et al., 
2009). If, after this process the centrocytes have high affinity for the antigen they may 
differentiate into plasma cells or memory cells and leave the lymphoid follicle (Zotos 
and Tarlinton, 2012). However if they do not produce high affinity antibodies they 
either die or may re-enter into the centroblast pool to start the process again (Fig 1.5 and 




Figure 1-5 Cellular interactions in a Germinal Centre. 
1.7.1  Selection of germinal centre B cells 
 The survival of high affinity B cells over low affinity B cells is thought to be due to 
a restriction of available antigen, cytokines and T cell interactions that creates a 
competitive environment. However a mathmatical model and a mouse model that 
allows tracing of B cells expressing photoactivatable fluorescent proteins, suggests that 
competition for T cell interaction is key to the selection of high affinty B cells and not 
the avaliability of antigen (Meyer-Hermann et al., 2006, Victora et al., 2010).  
T cells have been demonstrated to polarise to B cells with the highest density of 
peptide-MHC II complex expression (Depoil et al., 2005). Therefore centrocytes with 
high affinity BCRs are able to bind and process more antigen and therefore are more 
likely to receive help from TFH (Zotos and Tarlinton, 2012). TFH provide centrocytes 
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with a number of contact dependent signals. CD40L on the T cell binds to CD40 on the 
centrocyte.  The outcome of CD40-CD40L signalling precisely within the germinal 
centre is not known but one possibility is that CD40-CD40L signalling causes the 
centrocyte to enter into the cell cycle (Vinuesa et al., 2010). GCs do not form in the 
absence of CD40:CD40L interaction and blocking CD40L signalling abolishes 
established GCs (Fig 1.6) (Han et al., 1995, Noelle et al., 1992).  
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Figure 1-6 Germinal Centre B cells are selected for higher affinity by TFH. 
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1.8  T follicular helper cells 
TFH are essential for the initiation of germinal centres and the formation of GC B 
cells (Vinuesa et al., 2010).  
1.8.1  T follicular helper cell development 
TFH cells are thought to arise from naive CD4 T cells in response to receiving strong 
TCR signalling or repeated encounters with APC (Fazilleau et al., 2009, Baumjohann et 
al., 2011). This leads to the stable expression of the transcription factor Bcl-6 which in 
turn induces upregulation of CXCR5 (Baumjohann et al., 2011). The expression of 
CXCR5 allows migration of the TFH cell into the GC (Yu et al., 2009a). Interaction with 
cognate B cells is also required to maintain TFH in the GC (Qi et al., 2008). SAP 
deficiency prevents stable interaction occuring between T and B cells (Qi et al., 2008). 
In SAP deficient mice, TFH still develop as they are still able to form interactions with 
APC but the TFH can not be recruited or retained in the GC leading to a GC deficiency 
(Qi et al., 2008).   
IL-21 is important in the development of TFH cells as well as being highly expressed 
by TFH cells and it has been suggested that IL-21 might act in an autocrine manner 
(Vogelzang et al., 2008). IL-21-/- mice have defective TFH generation due to insufficient 
expression of CXCR5 suggesting that IL-21 is need for high expression of CXCR5 on 
TFH (Vogelzang et al., 2008).  
It has recently been suggested that TFH cells can also arise by T cell plasticity, for 
example from Treg in the gut-associated lymphoid tissue of mice (Lu et al., 2011, Tsuji 
et al., 2009). This will be discussed in more detail on chapter 4.1. 
1.8.2  Features of T follicular helper cells 
TFH are defined by their residence in GCs and although several surface markers and 
the transcription factor Bcl-6 have been associated with TFH, no defining marker has 
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been found. Several subsets of TFH have already been identified including CD8 TFH and 
follicular T reg cells (Tfr) (Linterman et al., 2011, Quigley et al., 2007). However, 
approximately 80% of GC T cells are the classical CD4 TFH effector cells with B cell 
helper abilities and the main focus of this thesis will be on this subset of TFH (Linterman 
et al., 2011). The surface markers associated with TFH are CXCR5, PD-1, CD57, and 
ICOS though one marker alone is not sufficient to characterise TFH.  
1.8.2.1  CXCR5/CXCL13 
CXCR5 expression allows migration towards the chemokine CXCL13. CXCL13 is 
produced by FDC which reside in the GC and B cell follicle and entry into this 
microenvironment is dependent on the expression of CXCR5 (Gunn et al., 1998). 
Without CXCR5, it has been shown in mice that the structure of lymphoid tissues are 
disrupted and GCs fail to form (Förster et al., 1996). Antigen activation through the 
TCR induces the upregulation of CXCR5 and migration to the T-B cell border. 
However not all CXCR5+ T cells enter the follicle and GC (Ansel et al., 1999). It is 
suggested that other interactions between the T cells and B cells enable a select few of 
CXCR5+ T cells to enter the follicle and then the GC where they can be defined a TFH. 
TFH can be distinguished from activated T cells at the T-B cell border, by their high 
expression of CXCR5 (Yu and Vinuesa, 2010).There are some discrepancies in the 
literature as to the phenotype of TFH due to some groups defining TFH as CXCR5+ and 
some as CXCR5
high
. However it is clear that TFH are only found in the CXCR5+ and not 
in the CXCR5- compartment of T cells demonstrated by the ability of CXCR5+ T cells 
to induce antibody production. Therefore CXCR5 expression is a defining feature of 
TFH (Schaerli et al., 2000). 
The chemokine CXCL13 has also been reported to be expressed by TFH. mRNA for 
CXCL13 is expressed by PD-1
high
 tonsil T cells and CXCL13 protein is detected within 
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these cells by IHC (Wang et al., 2011a, Yu et al., 2009b). It is possible that CXCL13 
production by TFH is induced once they have entered the GC and this may act in an 
autocrine manner to maintain their position or to recruit more cells.  
1.8.2.2  CD57 
CD57 was first found to be expressed by NK cells (Abo and Balch, 1981). However 
CD57 is expressed on a wide variety of cell types including neuronal cells, NK and NK 
T cells and T cells- both CD8 and CD4 (Focosi et al., 2010). 
On NK cells, NK T cells, CD8 T cells and CD4 T cells, CD57 has been associated 
with replicative senescence (clonal exhaustion) where the cells are unable to proliferate 
but can still secrete cytokines (Brenchley et al., 2003). An increase in CD57 expression 
on lymphocytes is associated with chronic immune activation and a variety of diseases 
such as cancer, autoimmune diseases and HIV (Focosi et al., 2010). 
Expression of CD57 on TFH has been known for a long time but the function on TFH, 
if any, is still unknown. Both CD57+ and CD57- TFH can be observed in GCs but in-
depth analysis of the two population has not yet been done (Poppema et al., 1983). It 
has been suggested that CD57+ and CD57- TFH are functionally different with CD57- 
fated to become Th2 memory cells (Johansson-Lindbom et al., 2003) or that the CD57- 
T cells in GCs are precursors of the CD57+ T cells (Vinuesa et al., 2005). At first it was 
believed that only T cells positive for CD57 were able to stimulate B cells to produce 
antibodies (Kim et al., 2005). However subsequent studies have demonstrated that 
CD57+ and CD57- TFH have the same B cell stimulatory capacity but the precise 
function of the CD57- TFH is unknown (Rasheed et al., 2006).  
CD57 expression by human TFH in peripheral lymphoid tissues such as tonsil, spleen 
and lymph nodes has been described (Poppema et al., 1983, Rasheed et al., 2006), but 
there is little research into CD57 expression in GALT.  CD57 is not expressed by 
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murine TFH and therefore mouse model cannot be used to investigate CD57 (Zheng et 
al., 1996).  
1.8.2.3  ICOS 
Inducible co-stimulator (ICOS) was first described as a T cell specific cell surface 
receptor that enhanced T cell responses to antigens by increasing proliferation, cytokine 
secretion and antibody secretion (Hutloff et al., 1999). ICOS is a co-stimulatory 
molecule that modifies the T cell response to activation and its ligand, LICOS, is 
expressed on activated dendritic cells, monocytes and B cells (Murphy et al., 2008). 
ICOS is highly expressed on TFH within GCs and TFH are depleted in ICOS deficient 
patients and mice (Hutloff et al., 1999, Bossaller et al., 2006). However there are 
differences in the expression of ICOS between humans and mice. In humans TFH have 
high expression of ICOS but in mice TFH and non-TFH express similar levels of ICOS 
(Yu and Vinuesa, 2010). 
1.8.2.4  PD-1 
PD-1 mRNA transcript was first isolated from murine cell lines undergoing 
programmed cell death and identified as a member of the immunoglobulin superfamily. 
It is the surface receptor for PD-L1 (B7-H1) and PD-L2 (B7-DC) and it is involved in 
the regulation of immune responses (Ishida et al., 1992, Latchman et al., 2001, Freeman 
et al., 2000). PD-1 expression can be induced in T cells and B cells by stimulation 
through the antigen receptor (Agata et al., 1996).  
PD-1 is expressed in lymphoid tissues and particularly co-localises with TFH (Iwai et 
al., 2002). This is thought to be a mechanism to control antibody production through 
preventing TFH proliferation and their B cell helper activity (Wang et al., 2011a). 
In mice, PD-1, PD-L1 and PD-L2 expression can be found on GC B cells and 
interaction between PD-1 on TFH and PD-L on B cells are thought to contribute to high 
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affinity antibody production (Good-Jacobson et al., 2010). It is suggested that this 
pathway regulates the number of TFH, therefore limiting the TFH-B cells interactions to 
only B cells expressing high affinity BCRs so that a selective pressure is maintained 
(Hams et al., 2011). As it is suggested that PD-L-PD-1 pathway has a greater inhibitory 
effect on weaker TCR signalling, therefore TFH cells with the higher affinity for the 
antigen will remain (Keir et al., 2008).  
Without PD-L1/ PD-1 interaction, TFH expand leading to an elevated Ig response. 
An increase in TFH has been associated with many autoimmune diseases which 
demonstrates the importance of PD-1 in regulating the humoral response (Hams et al., 
2011). 
1.8.2.5 CD40L  
CD40L is the ligand for the co-stimulatory molecule CD40. CD40L is part of the 
TNF superfamily and expression of CD40L is induced on activated T cells and is 
functionally important for their ability to activate B cells and macrophages (Murphy et 
al., 2008). CD40L is highly associated with TFH cells and is key for their ability to 
promote the survival of antigen specific GC B cells as described earlier. This is 
demonstrated by hyper IgM syndrome in patients with deficiencies in the CD40L gene 
as there is a failure to produce class switched B cells (Allen et al., 1993). Also in mice, 
administration of anti-CD40L antibody prevented GC formation in response to TD 
antigen challenge (Han et al., 1995). CD40L has been shown to be rapidly upregulated 
on TFH cells upon stimulation by transfer from the cytoplasm to the surface and 
therefore CD40L may not be expressed on resting TFH (Casamayor-Palleja et al., 1995).  
1.9  Lymphoid tissues 
Secondary lymphoid tissues include lymph nodes, spleen and mucosa associated 
lymphoid tissues (MALT) and are the major sites for lymphocyte priming and the GC 
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reaction (Murphy et al., 2008). Different lymphoid tissues receive antigens from 
different tissue sites.  
The spleen is not connected to the lymphatic system but instead the lymphocytes 
and antigens arrive via the blood (Cesta, 2006). The white pulp is the area of lymphoid 
tissue surround arterioles and where adaptive immune responses to blood borne 
pathogens takes place (Cesta, 2006, Mebius and Kraal, 2005). 
In MALT, lymphocytes respond to antigens sampled from the mucosal surface. 
Antigens from the mucosa are sampled at specific sites along the epithelium where there 
are microfold ‘M’ cells (Neutra et al., 2001). The DC sample the antigens at the follicle 
associated epithelium and prime T cells in the subepithelial dome regions and the T cell 
zone of the follicle (Neutra et al., 2001). DC are able to open up the epithelial barrier 
but keep the epithelial integrity by the expression of tight junction proteins (Rescigno et 
al., 2001). In mice a subset of DC expressing CD103 migrate to the mesenteric lymph 
nodes after sampling antigen and induce tolerance instead of priming (Pabst et al., 
2007). A population of DC similar to the CD103+ DC in mice have been identified in 
humans lymph nodes and may have the same function (Jaensson et al., 2008). Antigen 
presentation in the mesenteric lymph node is associated with tolerance induction by the 
generation of α4β7 and CCR9 expressing iTreg, whereas antigen presentation by DCs in 
MALT is associated with priming (Pabst and Mowat, 2012).  ITreg contribute to 
maintenance of immunological homeostasis in the gut and also oral tolerance. 
MALT can be further sub characterised by the anatomical location of the lymphoid 
tissue. Gut associated lymphoid tissue (GALT) includes the appendix, Peyer’s patches 
and isolated lymphoid follicles (ILF) along the colon and ileum. Peyer’s patches are 
concentrated in the terminal ileum and are made up of clusters of follicles. ILF are 
single follicles distanced along the length of the intestine. In mice, ILF are derived from 
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cryptopatches in response to recognition of the microbiota by epithelial NOD (Bouskra 
et al., 2008). Nasal-associated lymphoid tissue (NALT) in humans consists of the 
Waldeyer’s ring which is made up of the adenoids, and palatine tonsils (Brandtzaeg, 
2011). Rodents have similar NALT structures to humans except they lack tonsils 
(Brandtzaeg, 2011).  
Most of the plasma cell progeny generated by B cell activation generally occupies 
two different microenvironments; the intestinal lamina propria (LP) and the bone 
marrow. Plasma cells induced at peripheral lymphoid tissue (spleen, lymph nodes and 
tonsils) mostly localise in the bone marrow but would rarely enter the gut.  The majority 
of plasma cells induced in GALT are imprinted with a set of homing receptors and 
chemokine receptors that permit them to return the intestinal immune effector site in the 
LP. Imprinting is dependent on the activity of local DCs (Stagg et al., 2002). GALT 
DCs express the enzyme retinaldehyde dehydrogenase (RALDH) that generates retinoic 
acid from vitamin A. Retinoic acid then upregulates α4β7 integrin and chemokine 
receptor CCR9 on B cells and T cells activated in GALT that facilitate homing to the 
gut LP. Return to the LP effector site is mediated by binding of α4β7 integrin to 
endothelial mucosal addressin cell adhesion molecule-1 (MAdCAM1) and in response 
to the epithelial derived chemokine CCL25 (Mora et al., 2003, Mora and von Andrian, 
2009).  Differential homing between the colon and small intestine is mediated in part by 
differential expression of CCR9 that mediates migration towards CCL25 that is 
produced mostly in the small bowel and CCR10 that mediates movement towards 
CCL28 that is produced mostly in the colon (Sundström et al., 2008, Kunkel and 
Butcher, 2003).   In addition to cells derived from the gut that localise in the LP, some 
have also been shown to localise in the bone marrow  (Mei et al., 2009).  In contrast 
homing of plasma cells to bone marrow includes expression of CXCR4 that mediates 
homing in response to bone marrow derived CXCL12 (Kunkel and Butcher, 2003). 
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1.9.1 Differences between NALT and GALT 
 NALT is sometimes considered to be mid-way between mucosal and systemic 
immunity.  Anatomically it is situated in a mucosal site on the oropharynx with a high 
antigenic load.  However, it is covered by a stratified or pseudostratified epithelium and 
not the single epithelial layer that covers MALT throughout the gastrointestinal tract 
(Brandtzaeg, 2011). Tonsil high endothelial venules express peripheral lymph node 
addressin which is normally expressed in lymph nodes and binds to L-selectin on the 
naive lymphocytes and recruits the lymphocytes into the tissue (Brandtzaeg, 2011). In 
contrast, GALT high endothelial venules expresses MAdCAM-1 (Brandtzaeg, 2011). 
The tonsil lymphoid tissue generates plasmablasts that are around 55–72% IgG and 13–
18% IgA (Brandtzaeg, 2011). This ratio of plasmablasts is similar in other peripheral 
lymphoid tissues and is distinct from GALT which generates a high proportion of IgA 
plasmablasts. Therefore tonsil, due to having features of a systemic lymphoid tissue, is 
considered to be part of the peripheral immune system in this thesis. 
1.10  Antibody generation in the gut. 
1.10.1  Antibody distribution 
In humans, the gut mucosa contains approximately 80% of all antibody secreting 
cells (Brandtzaeg et al., 1999). The features of the antibodies secreted at the gut mucosa 
differ substantially from those circulating in the blood and extra cellular fluid.  IgG is 
the main class of antibody circulating in the blood, however in the gut and other 
mucosal surfaces, a high proportion of IgA is secreted. The secreted IgA in the gut is 
mainly dimeric. IgA is able to dimerise due to a cysteine residue at the tail end of the C 
region. Disulphide bonds from the cysteine residues form between the two IgA 




The ratio of IgA1 to IgA2 differs in the different anatomical sites. In peripheral 
lymphoid tissues such as the spleen and lymph nodes, the majority of IgA produced is 
IgA1. However in the gut the proportion of IgA2 increases and so that IgA1 only 
constitutes approximately 60% of the IgA secreted in the ileum and approximately 36% 
in the colon (Kett et al., 1986, Brandtzaeg et al., 1999).  
One of the hypotheses to explain the difference in the distribution of IgA subclass 
through the gut is the difference in the distribution of antigens. Antibodies against food 
antigens tend to be IgA1 and therefore are found at a higher frequency in the upper GI 
tract whereas IgA2 tend to be against gram negative bacteria which is more abundant 
than food antigens in the colon (Brandtzaeg et al., 1999).  It has been suggested that 
class switch to IgA2 in the colon is driven by a proliferation inducing ligand (APRIL) 
produced by colonic epithelium in response to the TLR ligation by bacterial flagellin 
from the lumen of the colon (He et al., 2007).  This will be discussed in more detail 
below. 
1.10.2  AID in the generation of IgA plasma cells 
Activation-induced cytidine deaminase (AID) is important for antibody 
diversification and enables somatic hypermutation of germline immunoglobulin 
sequences and class switch recombination. AID deaminates cytidine to uridine. The 
uridine can be replicated over if the cell divides, in which case it will appear as a C to T 
(or G to A) transition. Alternatively it may be excised by the base excision repair 
enzyme uracil DNA glycosylase, leaving an abasic site where mutations can be 
introduced.  Further enzymatic activity may generate a double strand break allowing 
class switch recombination (Murphy et al., 2008). Mouse models of k/o and mutated 
aicda show the importance of AID in the generation of functional IgA.  Aicda k/o mice 
have a deficiency in both CSR and SHM and therefore no IgA+ B cells were generated 
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in AID K/O mice. As a result of no IgA being secreted into the intestinal lumen, the gut 
bacteria become dysregulated with an accumulation of anaerobes. This in turn caused a 
continuous stimulation of B cells which resulted in large protruding lymphoid follicles 
in the gut (Fagarasan et al., 2002).  Mice carrying a mutated form of AID which is able 
to initiate CSR but not SHM showed a similar phenotype to aicda k/o mice with 
enlarged lymphoid follicles in the gut. Therefore this shows that not only is the 
secretion of IgA important in gut homeostasis but mutations introduced by SHM in 
GALT is also needed for the regulation of gut flora (Wei et al., 2011). 
1.10.3  Lamina propria as an effector site and not an inductive site 
LP B cells are mainly of a differentiated memory phenotype, or immediate 
precursors of plasma cells demonstrated by the expression of CD27 on their cells 
surface in humans which contributes to the idea of the LP as an effector site.  The 
CD27+ B cells in the LP tend to be CD20-, IgA+ whereas in the GALT the majority of 
B cells are CD20+, IgM+ (Farstad et al., 2000). 
The CD27+ SIgA+ memory B cells were demonstrated to be able to expand and 
proliferate in response to selected stimuli in vitro and therefore mount a response to a 
pathogen at the effector site (Farstad et al., 2000).  Evidence of proliferation in LP has 
been suggested by PCR based studies but not cell and tissue based studies (Boursier et 
al., 2005, Yuvaraj et al., 2009, Di Niro et al., 2012). 
Fagarasan et al. (2001) suggested that in mice plasma cells are able to undergo CSR 
in the LP.  They showed that a proportion of LP B220+IgA+ plasma cells had recently 
classed switched by the presence of AID and circular DNA transcripts which are looped 
out during CSR (Fagarasan et al., 2001). It is possible that these cells are the mice 
equivalent to the CD28+ CD19+IgA+ plasma blasts found in humans (Farstad et al., 
2000). B220+IgM+ cells from AID-/- mice were shown to be able to undergo CSR to 
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IgA when AID was transfected into the cells and this process was dependent on LP 
stromal cells, suggesting that the LP is an important inductive site (Fagarasan et al., 
2001). This has since been shown to most probably be due to contamination with B 
cells from ILF when sampling LP. When the LP was reinvestigated in mice after careful 
removal of all organised lymphoid tissue, no evidence of AID transcripts was found 
(Shikina et al., 2004). 
1.10.4  Induction of an immune response in the gut 
 The intestinal IgA response is produced through a germinal centre response in 
humans where AID is expressed and CSR can occur. Plasma cell precursors are 
imprinted as described previously and migrate to the effector site of the LP. The 
involvement of T cells (TFH cells) in the germinal centre response is well characterised. 
However it has been demonstrated there are IgA plasma cells residing in the LP of the 
gut in CD40 deficient mice. Therefore IgA production can be induced independent of 
cognate T cell interaction. This T cell independent pathway of generation of IgA plasma 
cells was demonstrated to occur through ILF but not PP and is dependent on RORγt LTi 
cells which are needed for ILF formation in mice. Therefore the T cell independent 
induction of the IgA response in the gut still requires secondary lymphoid tissue (Tsuji 
et al., 2008). 
 In CD40-/- mice CSR to IgA is still able to occur but is restricted to GALT in the 
absence of GCs and is suggested to be T cell independent as the CD40L-CD40 
interaction in lymphoid tissues is normally from CD40L on T cells (Korthauer et al., 
1993). Interestingly, though CSR is able to occur in these mice, the SHM rate is very 
low and this is reflected in the inability to raise an affinity matured response to T cell 
dependent pathogens (Bergqvist et al., 2010, Bergqvist et al., 2006).  There is evidence 
that suggests that induction of IgA plasma cells in the human gut can also be T cell 
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independent. In humans it is thought that T cell independent class switching can be 
initiated by DCs and is dependent on BAFF and APRIL but  independent of CD40L as 
it is in mice (Litinskiy et al., 2002, He et al., 2007).  
It has been suggested that the LP B cells are not solely derived from GALT in mice, 
but that there is also a substantial contribution from the peritoneal B cell population 
(Bos et al., 1996). However, in the human gut LP the presence of peritoneal derived B1 
cells is uncertain. Some groups have claimed to have found populations of B cells 
mirroring the peritoneal derived B1 population in mice but their contribution to the LP 
B cell population is a lot smaller than in mice (Farstad et al., 2000). Others have seen no 
evidence for this in humans (Boursier et al., 2002). 
1.10.5  Specificity of gut antibodies 
Engagement of the BCR on B cells has been shown to be crucial for the GC 
response in the gut (Barone et al., 2011). TLR mediated signals may be involved, but no 
more than in peripheral immune responses (Barone et al., 2011). It has been suggested 
that in GALT the specificity of the BCR for antigen is not such a stringent requirement 
for GC formation as it is in the periphery. Therefore this would generate mature B cells 
which are able to respond to a range of antigens very quickly and which would reside in 
the effector sites of the gut. This would result in a diverse population of B cells and not 
necessarily a specific response to antigen (Casola et al., 2004). 
Monoclonal antibodies made from IgA secreting cells originating from PP of 
unimmunised, pathogen free mice, were able to bind to a variety of antigens. These 
polyreactive ‘natural’ antibodies which are continually produced to protect the host 
from commensial bacterial like natural IgM in the serum (Wijburg et al., 2006, Shimoda 
et al., 1999). But interestingly this polyreactivity includes autoreactive antibodies in the 
gut of healthy humans. However, the ability to generate highly specific IgA through a 
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gut mucosa response was demonstrated by Di Niro et al. (2010) who isolated IgA 
secreting plasma cells specific for rotaviruses from the gut and tested antibody 
specificity from single cells. In the human gut 25% of the antibodies produced are 
innate polyreactive antibodies from plasma cells and the rest are specific (Benckert et 
al., 2011, Di Niro et al., 2010). 
However, regardless of the specificity of the antibodies, the majority of intestinal  
plasma cells have been through organised lymphoid tissue such as PP and ILF as the 
variable regions of the immunoglobulin genes encoding the secreted immunoglobulin 
was heavily mutated by somatic hypermutation (Barone et al., 2011, Benckert et al., 
2011). As some of the polyreactive antibodies are also somatically mutated this leads to 
the conclusion that autoreactive antibodies are a product of the GC response.  
The balance between specificity and autoimmunity in germinal centre responses has 
been shown to be regulated by TFH (Linterman et al., 2009).  It has recently been shown, 
since the work for this thesis was initiated, that TFH have a crucial role in the 
determining the specificity of IgA responses in mice (Kawamoto et al., 2012).  
1.11  Inflammatory Bowel Disease 
The term ‘inflammatory bowel disease’ (IBD) refers to a group of chronic 
inflammatory conditions that mainly affect the gastrointestinal tract. The main types of 
IBD are ulcerative colitis (UC) and Crohn’s Disease (CD) (Xavier and Podolsky, 2007).  
UC affects only the colon and the inflammation is diffuse and extends proximally 
from the rectum. The colonic mucosa becomes infiltrated by neutrophils and 




CD can affect any part of the gastrointestinal tract but the inflammation extends 
through the full thickness of the bowel wall and is segmental. CD can also involve the 
ileum as well as the colon. Aggregations of macrophages form granulomas as a 
component of the inflammatory lesion (Xavier and Podolsky, 2007).  
1.11.1  Factors contributing to the pathogenesis of IBD 
A complex interplay of genetics, environmental factors and the host immune system 
contribute to the development of both CD and UC. Recent analysis of several genome 
wide association studies (GWAS) found over 25,000 SNPs and 110 genetic risk loci 
associated with CD, UC or IBD in general (Jostins et al., 2012). 50 loci are shared 
between CD and UC suggesting that they have similar disease pathways (Jostins et al., 
2012). SNPs in genes involved in innate immunity and autophagy such as ATG16L1, 
IRGM and NOD2 are associated CD (Kaser and Blumberg, 2011). The profile of risk 
alleles in UC includes the IL-2/ IL-21 loci and several SNPs in IBD are also associated 
with autoimmune diseases such as Type I diabetes (Festen et al., 2009, Todd et al., 
2007). Genetic loci associated with IBD also overlap with ankylosing spondylitis and 
psoriasis and the loci associated with IBD are enriched for genes associated with 
primary immunodeficiency, in particular Mendelian susceptibility to mycobacterial 
disease (MSMD) (Jostins et al., 2012). These risk loci highlight the role of microbes and 
host responses in the development of IBD.  
Several other studies have also implicated intestinal microbiota in the development 
of IBD. The human gut contains over 10
14 
micro-organisms and they are important for 
the development of both the systemic and intestinal immune response (Kaser et al., 
2010). Microbiota is able to both induce an immune response and also prevent an 
inflammation (Round and Mazmanian, 2009). There is increasing evidence that 
microbiota shape the immune system just as the immune system determines the 
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composition of the colonising bacteria. For example germ free mice have small peyer’s 
patches and fewer IgA+ lamina propria plasma cells suggesting that the microbiota is 
needed in part for the development of GALT (Macpherson et al. 2001). In a gnotobiotic 
mouse model it was demonstrated that IgA specific to the microbiota prevented an 
innate inflammatory immune response to the bacteria so that the microbiota could 
continue to colonise the host (Peterson et al., 2007). Due to the synergistic relationship 
between microbiota and the immune system, dysbiosis of the microbiota could in part 
contribute to the development of IBD (Round and Mazmanian, 2009).  The role of 
microbiota in IBD is demonstrated by the dependence of microbiota in mouse models of 
IBD and differences in the composition of microbiota between IBD patients and healthy 
individuals have been observed (Damman et al., 2012). Faecal microbiota 
transplantation has been used to treat several patients with IBD in an attempt to 
recolonize the intestinal tract with microbiota from a healthy individual. The majority of 
patients who received a faecal microbiota transplant remained in remission for several 
months and in some cases years (Damman et al., 2012).   
Other environmental factors such as smoking can affect the probability of 
developing disease in UC and CD differently. Whereas smoking is protective in CD, 
appendectomy is thought to be protective in UC and will be discussed in more detail 
below (Danese et al., 2004).  This suggests that events in the appendix might be directly 
involved in the pathogenic process in UC, or alternatively the benefit may be purely a 
consequence of removing a mass of active lymphoid tissue. 
The host immune defences also play a crucial role in IBD. Both the innate and 
adaptive immune responses have been shown to be altered in IBD. Paneth cells are 
found within the epithelium of the small intestine and secrete antimicrobial peptides 
such as α-defensins and are part of the innate intestinal host defences (Koslowski et al., 
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2010). 30-40% of CD patients have polymorphisms in NOD2 and some NOD2 
polymorphisms are thought to effect paneth cell differentiation and the secretion of 
antimicrobial defensins (Kaser et al., 2010, Koslowski et al., 2010). There is a large 
body of research into the role of the adaptive immune system in IBD.  The changes 
observed in T cells and B cells are outlined below. 
1.11.2  T cells and cytokines in inflammatory bowel disease. 
The chronic inflammation in IBD is associated with the production of cytokines 
produced by different T cell subsets.  
CD has been described as a Th1 mediated disease due to the prevalence of Th1 
associated cytokines such as IFN-γ and TNF secreted by LP T cells. Whereas in UC 
cytokines secreted by LP T cells include IL13 leading to UC being considered a Th2 
mediated disease (Fuss et al., 1996, Sarra et al., 2010b). 
An increase in intestinal IL-12 is observed in CD and IL-12 was first thought to 
drive the aberrant Th1 response associated with CD (Matsuoka et al., 2004). The source 
of IL-12 in CD is in part intestinal DCs (Hart et al., 2005). However, recently Th17 
cells and IL-23, have been implicated in the pathogenesis of CD and UC (Strober and 
Fuss, 2011). In a mouse models of helicobacter hepaticus induced T cell dependent 
colitis, it was demonstrated that more severe intestinal inflammation was dependent on 
IL-23 more than IL-12 (Kullberg et al., 2006). IL-23 deficient mice demonstrate the role 
of IL-23 in the development of Th17 cells and IL-23 also promotes T cell proliferation 
and IFN-γ production (McGeachy et al., 2009, Oppmann et al., 2000). Kobayashi et al. 
(2008) demonstrated that IL-23p19 mRNA expression was upregulated in both CD and 
UC and observed a higher increase in IL-17 mRNA in UC LP T cells and a higher 
increase in IFN-γ mRNA in CD LP T cells and also both UC and CD mucosal T cells 
produced the same high level of IL-17 when stimulated with anti-CD3 and anti-CD28 
57 
 
compared to normal controls. However, Sakuraba et al. (2009) observed a higher 
production of IL-17 by T cells from MLNs in CD compared to UC. Anti-IL-12p40 
antibodies have been shown to improve symptoms in CD patients (Mannon et al., 
2004). However, as both IL-12 and IL-23 share the p40 subunit, the beneficial effects of 
this antibody could be from neutralising either or both of these cytokines (Oppmann et 
al., 2000). 
Mouse models of IBD and studies of human IBD have suggested that numerical or 
functional deficiencies in Tregs could contribute to the pathogenesis of IBD. In 
SAMP1/YitFc (SAMP) mice that spontaneously develops ilelitis similar to human CD, 
Tregs have been demonstrated to be functionally deficient in vivo (Ishikawa et al., 
2012). Mice lacking Treg derived IL-10 develop spontaneous colitis, while transfer of 
Tregs into the CD4+ CD45RB
high
 T cell mouse model of colitis eliminated disease 
(Mottet et al., 2003, Kuhn et al., 1993). However human studies on Tregs in IBD are 
inconsistent and will be discussed in more detail in chapter 5.1.   
1.11.3 Dysregulation of B cells in inflammatory bowel disease. 
Dysregulation of the mucosal B cell response can be seen in IBD.  SIgA normally 
elicits immune exclusion of pathogens to maintain the integrity of the gut epithelial 
barrier. However in IBD lesions, both IgA+ and IgG+ plasma cells are increased but 
with a  particular disproportionate increase in the production of IgG (Brandtzaeg, 2010).  
 In UC the increase in IgG is predominantly due to an increase in IgG1 whereas in 
CD, there is an overall increase in all IgG subclasses and in particular IgG2 (Scott et al., 
1986).  
 Serum antibodies to particular microbial and auto antigens are associated with IBD 
and can be used as a diagnostic tool. In UC several autoantibodies have been identified, 
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including perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) in patients 
serum and antibodies to tropomycin 5 in colonic epithelial cells (Hibi et al., 1990, 
Targan et al., 1995, Onuma et al., 2000, Abad et al., 1997). 
Systemic anti-Saccharomyces cerevisiae antibodies (ASCA) are a feature of CD but not 
UC. ASCA are thought to be against components of the S. cerevisiae cell wall mannan 
(Sendid et al., 1996). Landers et al. (2002)  reported that 55% of CD patients had serum 
antibodies to bacterial outer-membrane porin C (OmpC) found on E.coli and anti-cBir1 
antibodies reactive to clostridium flagellin are associated with a subset of CD patients 
with more complicated disease (Targan et al., 2005).  
 Recently genetic variants in autophagy and microbial pattern recognition genes have 
been linked to the production of anti- microbial antibodies in CD. In particular variants 
in NOD2 and ATG16L1 are associated with ASCA production implicating autophagy 
pathways in the development of these antibodies (Murdoch et al., 2012). The presence 
of these antibodies in the serum of patients with IBD reflects the breakdown of 
immunological tolerance but their relevance to the pathogenesis of the disease has not 
yet been established. 
It has been suggested that the inflammatory response in IBD is associated with a 
disturbance in lymphocyte traffic and the alteration in profile of antibodies secreted 
described above is consistent with this. Lymphocyte entry into tissue compartments 
depends on interactions between the lymphocytes and venular endothelium involving, 
integrins, selectins and chemokines and their receptors (Hart et al., 2010). The homing 
properties of lymphocytes are orchestrated by DCs and differences in the imprinting of 




In IBD an influx of lymphocytes is observed in the effected intestinal mucosa and 
α4β7 is increased on circulating activated T cells in CD patients (Meenan et al., 1997). 
Antibodies against α4 have been tested in the treatment of  CD and therefore has 
implicated aberrant gut homing as possibly contributing to the disease (Ghosh, 2003). 
1.12 The Appendix 
 The human appendix is a tubular organ of approximately 8-10 cm, attached to the 
caecum and is commonly thought to be a vestigial organ (Humes and Simpson, 2006). It 
contains a large amount of lymphoid tissue which is part of the GALT. There has been 
very little research into the immunological role of the human appendix, however a 
higher number of IgG+ B cells have been observed in the appendix compared to the 
colon suggesting that perhaps the two sites are responding to different antigens or are 
generating different immune responses (Bjerke et al., 1986). In some mammals such as 
rabbits, the appendix is proposed to be a primary site of B cell generation and plays a 
key role in mucosal responses. This is demonstrated by a reduction of intestinal 
antibodies after neonatal appendectomy (Dasso and Howell, 1997). However, this does 
not seem to be the case for the human appendix as no detrimental changes to the 
mucosal immune system has been reported after removal of the appendix as treatment 
for appendicitis.    
1.12.1 Appendicitis 
 Acute appendicitis is the inflammation of the appendix and accounts for 40,000 
hospital admissions each year in England. It is most common in individuals between 10 
and 20 years of age (Humes and Simpson, 2006). The cause of appendicitis is still 
unknown but it is thought to be a combination of factors including diet and obstruction 
(Humes and Simpson, 2006).  
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Acute appendicitis is also thought to have a genetic element as a significant number 
of patients with acute appendicitis had a family history of appendectomy compared to 
surgical controls (Basta et al., 1990). In this cohort the relative risk of developing 
appendicitis was 10 and the heritability was calculated to be 56% (Basta et al., 1990).    
Acute appendicitis is most commonly treated by early appendectomy however 
studies are being conducted into treating uncomplicated acute appendicitis with 
antibiotic therapy (Paajanen et al., 2013). 
1.12.2 The role of the appendix in the development of UC 
A negative correlation between appendectomy and the development of UC has been 
demonstrated in several studies. Patients who underwent an appendectomy for 
appendicitis before the age of 20 had a lower risk of developing UC but patients who 
had an appendectomy of non-specific abdominal pain were as likely to develop UC as 
controls (Andersson et al., 2001). Also appendectomy prior to the onset of disease is 
rare in patients with UC (Andersson et al., 2001). One explanation for the negative 
correlation between appendectomy and the development of UC is that removing the 
appendix which contains a large amount of GALT, modulates the mucosal immune 
system  (Radford-Smith et al., 2002).  
Several studies have demonstrated immunological associations between the 
appendix and inflamed tissue in UC. It has been observed that a number of UC patients 
with distal colitis also had peri-appendiceal red patch (PARP). The presence of PARP 
was also associated with progression to more extensive disease (Rubin and Rothe, 2010, 
Matsumoto et al., 2002). T cell clones have been identified in both the appendix and the 
inflamed colon of patients with UC and CD. Also autoantibodies associated with UC 
were found in the appendix of TNFα mutant mice leading to the possibility that the 
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autoantibodies could be generated in the appendix (Chott et al., 1996, Radford-Smith et 
al., 2002). 
In light of these studies, several patients with UC have undergone appendectomies 
as treatment for the disease. The beneficial effects of this surgery seem to be variable. 
Okazaki et al. (2000) reported that a patient with UC with inflamed appendix and 
rectum, improved significantly after an appendectomy and remained in remission 3 
years post-surgery. Bolin et al. (2009) reported that 27 out of 30 patients with ulcerative 
proctitis who underwent an appendectomy had an improved clinical activity index after 
surgery. However for 3 of the patients appendectomy did not improve their symptoms 
(Bolin et al., 2009).  
Overall there is mounting evidence to suggest that the appendix plays a vital role in 





1.13  Aims 
The experiments in this thesis aim to investigate the properties of TFH in the gut 
compared to the peripheral immune system, the possibility of a developmental 
relationship between TFH and Treg, and the profile of these immunomodulatory T cells 
in inflammatory bowel disease.  Ulcerative colitis includes an autoimmune component 
and this was considered to be of particular interest.  The specific aims of the three 
chapters of results are as follows: 
In chapter 3 the frequency and functional parameters of TFH will be explored and 
compared between peripheral lymphoid tissues and GALT. 
In chapter 4 the possibility of a developmental relationship between TFH and Tregs 
will be explored by sequence analysis of rearranged TCR genes. 
In chapter 5 the frequency and distribution of TFH and Treg in tissue and peripheral 




2 Chapter 2 Methods 
2.1 Samples 
All fresh peripheral blood and tissue was taken from healthy individuals and cancer 
and IBD patients with informed consent. Consent was obtained under the ethically 
approved projects 10/H1111/014 and 04/Q0702/81. 
Tonsil specimens were collected from Guy’s Hospital ENT day surgery unit from 
patients undergoing a tonsillectomy but who were otherwise healthy at the time of 
surgery. Tonsils were removed from patients with sleep apnoea or recurrent tonsillitis 
but all tonsils used were not inflamed at the time of surgery. Paired blood was also 
collected from some of the patients before surgery.   
Healthy control blood was obtained from both male and female individuals who 
were well at the time of donation. 
Patients who attended the IBD clinic at Guy’s Hospital were invited to take part in 
the study by donating blood after informed consent. All patients had either CD or UC 
(see table 2.1 and 2.2). Disease activity was assessed clinically at the time of donation 
in each case. Active CD was indicated by a Harvey Bradshaw index (HBI) of ≥5 and 
active UC was defined with a Simple Colitis Clinical Activity index (SCCAI) of ≥5 
(Harvey and Bradshaw, 1980, Walmsley et al., 1998). Disease activity was also 
corroborated by endoscopic (colonoscopy) or radiological (small bowel MRI) 
assessment close to the time of blood sampling. Patients with inactive disease had no 
symptoms at the time of sampling. 
Fresh cancer appendix was obtained from patients with bowel cancer undergoing a 
right hemicolectomy to remove the cancerous tissue but where the appendix itself and 
surrounding tissue were not cancerous. Fresh IBD appendix were obtained from patients 
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with a clinical diagnosis of either CD or UC and were undergoing a right 
hemicolectomy. Patients gave informed consent before surgery. A small section of the 
appendix not needed for diagnosis was removed from the surgically excised specimen 
by pathologists.  
Paraffin-embedded tissues were retrieved from the archives of the Histopathology 
Department of the Guy’s and St Thomas’ Hospital Trust or were from previous research 
projects stored under REC approval 04/Q0702/81. In chapter 5 paraffin embedded 
tissue from IBD and cancer patients who had undergone a right hemicolectomy was 
analysed. A diagnosis of CD or UC was made based on histological analysis of the 
resected tissue. Blocks of ileum and colon of involved but not acutely inflamed tissue 
were selected from the tissue available from IBD patients. For the cancer patients, tissue 
blocks furthest away from the tumour were selected. As the resected specimens varied 
in length in all patient groups, the specific section of ileum and colon selected for 
analysis varied between patients. The whole appendix was contained within a single 



































CD304 15/05/1985 f L1 B1 Active current prednisolone 













CD308 20/07/1983 f L3 B1 Remission current azathioprine 


























CD315 30/11/1967 f L2 B1(p) Active current nil 
















CD320 01/09/1986 f L3 B2 Active current azathioprine 























CD326 26/01/1963 f L2 B1(p) Active current prednisolone 


























UC303 22/09/1970 m E1 Remission current mesalazine 








UC306 31/12/1940 m E2 Remission current mesalazine 








UC309 25/10/1984 f E1 Remission smoker mesalazine 












UC313 17/11/1987 f E2 Active current azathioprine, ciclosporin 
UC314 13/12/1981 m E3 Remission current nil 
















































2.2 Solutions  
2.2.1 Solutions in Immunohistochemistry 
2.2.1.1  TBS wash 
6.05g Trisma base (sigma), 80g sodium chloride and 38ml 1M HCl was dissolved in 
10l dH2O and mixed well. The solution was adjusted to pH 7.6. 
2.2.2 Solutions in Flow cytometry 
2.2.2.1 2% FACS Buffer 
2ml Heat inactivated 0.2µm filtered FCS and 1ml Tris EDTA (Fluka) were added to 
47ml sterile 1xPBS and kept at 4°C until use. 
2.2.2.2 Medium 
500ml RPMI Medium with GlutaMax (gbco) was fortified with 10% FCS and 1% 
penicillin-streptomycin.  
2.2.3 Solutions in Electrophoresis 
2.2.3.1 2.6.3 10x TBE buffer  
108g of trizma base (sigma), 55g boric acid and 8.3g EDTA (sigma) were dissolved 
in 1l dH2O by mixing vigorously.  
2.2.3.2 Agarose gel electrophoresis 
PCR products were run on a 3% or 1.5% agarose gel. Agarose gel was prepared 
with 6g or 3g 3:1 agarose (Flowgen) and 200ml 1x TBE buffer. The gel was heated in a 
microwave on a high setting for 4 min or until all bubbles had dispersed. 1ul 50µg/ml 
ethidium bromide was added to the liquid gel before pouring. The gel was left to set for 
30 min. 6μl of PCR product was mixed with 2μl of dye, and then loaded into gel. 6μl of 
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phiX174 DNA markers (Promega) was used to identify the size of products. The gel 
was run at 125V for 60 minutes in 1x TBE before being visualised under UV light.  
2.2.3.3  10% Polyacrylamide mini-gel 
10% Polyacrylamide mini-gel was used to visualise for low molecular weight DNA 
samples. 13ml of dH2O, 2ml of 10x TBE, 5ml of Acrylamide 37:1 ratio (Sigma), 200μl 
of 10% Ammonium Persulphate (freshly made) and 20μl of TEMED were added by 
order, mixed and then pour out quickly to make the gels. 6 μl of PCR product was 
mixed with 2μl of dye, and then loaded into gel. 6μl of low molecular weight DNA 
ladder (BioLabs) was used to identify the size of products The gel was run at 125V for 
60 minutes in 1x TBE and then stained in 0.5μg/ml ethidium bromide solution for 30 
minutes before being visualised under UV light. 
2.2.4 Solutions in cloning 
2.2.4.1 2.6.4 SOC medium 
2g of Tryptone, 0.5g Yeast extract, 1ml 1M NaCl and 0.25 ml 1M KCl were added 
to 97ml dH2O and autoclaved at 120°C for 20 min. The SOC medium was left to cool to 
room temperature before adding 1ml of filter-sterilised 2M Mg
2+
. 
2.2.4.2  LB Agar 
1g Tryptone, 0.5g Yeast extract, 0.5 NaCl and 1.5g Bacto agar were dissolved in 
100ml dH2O and autoclaved at 120°C for 20 mins. The Agar was allowed to cool for 10 
min before adding 200µl 0.5µl/ml Ampicillin, 200µl 0.5µl/ml XGAL (Promega) and 
0.5ml 0.1M IPTG. Mix well and pour 20ml into each plate while agar is still warm. 
2.3  Immunohistochemistry 
2.3.1  Tissue sectioning 
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All tissues for immunohistochemical analysis had been removed during surgery and 
formalin fixed and paraffin embedded prior to use in this study. Serial tissue sections 
were cut 3µm thick using a microtome.  
2.3.2  Staining  
All wash steps were with TBS and each slide was washed 3 times for a total of 5 
min Formalin fixed sections underwent antigen retrieval in Target retrieval solution 
(DAKO) for 40 min at 95°C, left to cool to room temperature and washed. A wax pen 
was used to draw around the tissue and create a well. For single stains, peroxidise 
blocking solution (DAKO) was applied to the tissue for 10 min and then washed. 
Primary antibody was diluted in antibody diluents (DAKO) at the concentration show in 
the table below and the tissue was incubated for the time specified in table. At the end 
of the incubation time the slides were washed. Anti-Mouse/ Rabbit HRP Envision 
(Dako) was used as the secondary antibody and the tissue was incubated with the 
antibody for 30min before being washed (when primary goat antibodies were used, the 
tissue was first incubated with Rabbit anti-goat antibody for 30 min before the addition 
of mouse/rabbit HRP). The stain was developed by using DAB (Dako) for 1-5 min. 
Slides were then counterstained with haematoxylin before being rehydrated through 
water, 70% IMS, 100% IMS and twice through xylene and mounted with coverslips. 
Double stains were done using DAKO EnVision Double Staining System. 
 
2.3.3  Antibodies 










Mouse 1/50 1 hour 40 mins 
CXCL13 
(R and D 
AF801) 
Goat  1/30 overnight 40 mins 
CD21 
(Dako) 




mouse 1/100 1 hour 40 mins 
Foxp3 
(abcam) 




rabbit 1/150 30 min - 
Table 2-3 Table of antibodies used in IHC 
2.3.4 Cell counting in tissue sections 
Cell counting in IHC stained tissue sections was done by eye using a light microscope. 
The cell counts are either expressed as the number of cells per high power field or as a 
ratio of positive cells. For example the ratio of CD57+ cells out of all the CD3+ cells 
within a high power field.  
2.3.4.1 Detection of cell densities in a germinal centre 
 All cells of interest were counted in the entire GC. The average of up to 3 different GCs 
was plotted for each tissue. 
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2.3.4.2 Detection of cell densities in a specified microenvironment. 
 The number of cells within an eye piece graticule, at a set magnification, was counted.  
The average of three different areas counted at random was plotted for each tissue. 
2.4  Flow Cytometry 
2.4.1 Cell isolation 
Peripheral blood mononuclear cells (PBMC) were prepared from fresh blood using 
Ficoll (GE Healthcare). The blood was diluted 1:1 in medium and up to 35ml of diluted 
blood was carefully layered over the top of 15ml of Ficoll in a 50ml falcon tube and 
centrifuged at 400G for 30 min with the brake and acceleration set at the lowest level or 
off. The PBMC layer above the Ficoll was carefully extracted with a pipette and 
deposited in medium. The PBMCs were centrifuged at 400G for 5 min before being 
resuspended in fresh medium. 
 Cell suspensions from tonsil and appendix were made by scrapping the tissue with 
a sterile surgical scalpel into fresh medium. The cell suspension was then passed 
through a 0.45µm cell strainer before mononuclear cells were separated using Ficoll as 
described above and resuspended in fresh medium. 
2.4.2  Surface staining 
All wash steps were performed by centrifuging at 400G for 5mins at 4°C and then 
pouring of the supernatant. The whole staining process was done on ice including 
incubation steps.  




 To identify TFH cells the cells were incubated with antibodies to CD3, CD4, CD57, 
CXCR5 and PD-1. CD40L was also added to the antibody cocktail when analysing IBD 
patient bloods and controls in chapter 5 and CD40L expression experiment chapter 3. 
T reg cells were identified using antibodies to CD14, CD4, CD127, CD25, CD45RA 
and PD-1. 
 The antibodies were diluted in 2% FACS buffer with a final volume of 100µl. The 
cells were incubated for 25 min in the antibody solution. The cells were washed in 2% 
FACS buffer and then resuspended in 400µl of 2% FACS buffer.  
2.4.3  Intracellular cytokine staining 
Tonsil mononuclear cells were cultured in for 3 hours at 37°C in a 24 well flat 
bottomed plate at a concentration of 2x 10
6
 cells/well in a total of 1ml of medium alone 
or medium containing 50ng/ml PMA, 750pg/ml ionomycin and Golgi Stop containing 
monensin (BD) (used as directed by manufacturer). The 24 well culturing plate was 
placed on ice for 5 min before harvesting the cells. All steps for surface staining were 
performed on ice. Multiple wells of stimulated cells or unstimulated cells were pooled 
and distributed between tests and controls. Both stimulated and unstimulated cells were 
washed and stained for TFH cell markers as previously described for 25 min in the dark 




 Sample CD3 APC-H7 
CD4 Qdot 605 
CXCR5PerCP Cy5.5  
CD57 PB  
PD-1 APC 
CD3,CD4 control CD3 APC-H7  
CD4 Qdot 605  
 
Unstained cells N/A 
Table 2-4 Antibodies used to detect surface TFH markers in intracellular cytokine staining experiment. 
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The stained cells were incubated in 1ml of 2% Paraformaldehyde for 15 min at 
room temperature in the dark. They were then washed with 1x biolegend Perm wash 
buffer. Cells were resuspended in a total of 100µl 1x biolegend Perm wash buffer, 
vortexed and equal amounts of cells from the sample tube were distributed between 
each of the three cytokine staining conditions and a surface stain only control. 
Condition 1 included antibodies against IL-21 and IL-4, condition 2 included antibodies 
against IL-17 and IFN-γ and condition 3 included antibodies against IL21 and IFNγ.  
Antibodies to cytokines were diluted with 1x biolegend Perm wash buffer with a final 
volume of 100µl and incubated on ice for 30 min. Cells were washed with 2ml 1x 
biolegend Perm wash buffer then 2% FACS buffer and resuspend in 200ul of 2% FACS 
















Unstained cells N/A 
CD3,CD4 control CD3 APC-H7  
CD4 Qdot 605  
 
 Surface stain control CD3 APC-H7 
CD4 Qdot 605 
CXCR5 PerCP CY5.5  
CD57 PB  
PD-1 APC 
Il21, IL4 sample CD3 APC-H7 
CD4 Qdot 605 
CXCR5 PerCP CY5.5  
CD57 PB  
PD-1 APC  
IL-21 PE 
IL-4 FITC 
Il17, IFNγ sample CD3 APC-H7 
CD4 Qdot 605 
CXCR5 PerCP CY5.5  
CD57 PB  
PD-1 APC  
IL-17 PE 
IFN-γ FITC 
IL21, IFNγ sample CD3 APC-H7 
CD4 Qdot 605 
CXCR5 PerCP CY5.5  
CD57 PB  
PD-1 APC  
IL21 PE 
IFNγ FITC 
Table 2-5 Antibodies used for controls and samples in intracellular cytokine staining experiment. 
2.4.4  Foxp3 staining 
 In figure 4.1 tonsil mononuclear cells were surface stained antibodies against 
CD14-APC-H7, CD4-Qdot605, CD127-PerCP Cy5.5, both CD25-PE and PD-1-APC. 
In figure 5.9 PBMCs were surface stained with antibodies against CD14-APC-H7, 
CD4-PB, CD127-PerCP Cy5.5, both CD25-PE and CD45RA-AF488. After a 20 min 
incubation the cells were washed with 2% FACS buffer and the pellet pulse vortexed. 
The cells were resuspended in 1ml of Foxp3 1x fix/perm buffer (ebioscience) and pulse 
vortexed. Samples were incubated at room temperature in the dark for 45 min. 2 ml of 
1x Perm buffer (ebioscience) was added to each sample and centrifuged at 400G for 5 
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min. The pellet was resuspended in 1x perm buffer and half transfered to a clean FACS 
Tube for Foxp3 FMO. Foxp3 antibody was added to the sample only and the cells were 
incubated at room temperature for 30 min. In figure 4.1 foxp3 PB was used, in figure 
5.9, foxp3-APC was used. 2 ml of 1x Perm buffer was added to each sample before 
centrifuging at 400G for 5 min. 2 ml of 2%FACS buffer was added to each sample 
before centrifuge at 400G for 5 min. The pellet was resuspended in 2% FACS buffer 
and analysed on BD FACS Canto II 3 laser flow cytometer. 
Tube Antibodies 
Unstained control N/A 
Treg isotype PE isotype 
PercP cy5.5 isotype 
CD45RA FMO CD14 APC-C7  
  
CD4 Pacific blue 
CD25 PE (M-A251) 
CD25 PE (2A3)  
CD127 PerCP Cy5.5 
Foxp3 FMO CD14 APC-C7  
CD45RA AF488  
CD4 Pacific blue 
CD25 PE (M-A251) 
CD25 PE (2A3)  
CD127 PerCP Cy5.5 
Sample CD14 APC-C7  
CD45RA AF488  
CD4 Pacific blue 
CD25 PE (M-A251) 
CD25 PE (2A3)  
CD127 PerCP Cy5.5 
Foxp3 APC 








Unstained control N/A 
Treg isotype PE isotype 
PercP cy5.5 isotype 
PD-1 FMO CD14 APC-C7  
CD4 Qdot605 
CD25 PE (M-A251) 
CD25 PE (2A3)  
CD127 PerCP Cy5.5 
Foxp3 FMO CD14 APC-C7  
CD4 Qdot605 
CD25 PE (M-A251) 
CD25 PE (2A3)  
CD127 PerCP Cy5.5 
PD-1 APC 
Sample CD14 APC-C7  
CD4 Qdot605 
CD25 PE (M-A251) 
CD25 PE (2A3)  
CD127 PerCP Cy5.5 
PD-1 APC 
Foxp3 Pacific Blue 
Table 2-7 Antibodies used for controls and samples in foxp3 experiment in chapter 4.1 
2.4.5   CD40L time point expression analysis 
For detection of basal levels of CD40L expression tonsil lymphocytes were isolated 
and labelled with flow cytometry antibodies to CD3, CD4, CXCR5, CD57, PD-1 and 
CD40L with appropriate controls and analysed on BD FACS Canto II 3 laser flow 













CD40L FMO control CD3 APC-H7  
CD4 Pacific blue  
CXCR5 PercP Cy5.5 
CD57 FITC  
PD-1 APC 
CD57 FMO control CD3 APC-H7 
CD4 Pacific blue  
CXCR5 PercP Cy5.5 
PD-1 APC 
CD40L PE 
PD-1 FMO control CD3 APC-H7  
CD4 Pacific blue  
CXCR5 PercP Cy5.5 
CD57 FITC  
CD40L PE 
Sample  CD3 APC-H7  
CD4 Pacific blue 
CXCR5 PercP Cy5.5 
CD57 FITC  
PD-1 APC 
CD40L PE 
Table 2-8 Antibodies used for controls and samples in CD40L experiment 
 2 million cells per well were seeded in a 24 well flat bottomed plate in a total of 
1ml of medium and incubated at 37°C for 3 hours. PMA and ionomycin were added to 
make a final concentration of 50ng/ml and 750pg/ml in consecutive wells at time 0, 1h, 
2h, 2h30min and 2h45min so that cells were stimulated for 3h, 2h, 1h, 30min and 
15min. The plate was put on ice for 10min to detach adherent cells before transferring 
the cells from each well into separate FACS tubes. Each tube was washed with 
2%FACS buffer and cells labelled with antibodies CD3-APC-H7, CD4-PB, CD57-
FITC, CXCR5-PerCP Cy5.5, PD-1-APC and CD40L-PE for 25 min. The cells were 
washed and resuspended in 500µl of 2%FACS buffer before being analysed on BD 
FACS Canto II 3 laser flow cytometer.  
2.4.6 CFSE labelling and culturing experiment 
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Tonsil cell suspensions were labelled with antibodies CD3-APC-H7, CD4-Qdot605, 
CD57-PB, CXCR5-PerCP Cy5.5 and PD-1-APC. PD-1+ CD57+ and PD-1+ CD57- TFH 






CXCR5 FMO control CD3 APC-H7  
CD4 Qdot605  
CD57 Pacific blue 
PD-1 APC 
CD57 FMO control CD3 APC-H7 
CD4 Qdot605  
CXCR5 PE 
PD-1 APC 
PD-1 FMO control CD3 APC-H7  
CD4 Qdot605  
CXCR5 PE 
CD57 Pacific blue 
Sample  CD3 APC-H7  
CD4 Qdot605  
CXCR5 PE 
CD57 Pacific blue 
PD-1 APC 
Table 2-9 Antibodies used for controls and samples when sorting TFH subsets in CFSE labelling and 
culturing experiment 
Sorted cells were washed twice in 1x PBS and the pellet was dislodged. 1ul/ml 
CFSE in PBS was freshly made and 250ul of 1ul/ml CFSE was added to each pellet of 
sorted cells and incubated at 37°C for 7 min and shaken once half way through. 250µl 
of FCS was added to each tube to quench the CFSE and each tube was topped up with 2 
ml of medium. The cells were washed and resuspended the in sterile medium. In a 
sterile 96 round bottomed plate 1x10
5 
unlabelled autologous tonsil cells were added to 
the mixed culture wells and unlabelled control wells. Equal numbers of CFSE cells 
were added to wells containing unlabelled and unsorted whole tonsil mononuclear cell 
suspension and wells with media alone. The cells were cultured for 4 days at 37°C and 
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FACS all the wells separately for CD57-PB and 7AAD before analysis on BD FACS 
canto II 3 laser and flowjo. 
                             CFSE labelled      CFSE unlabelled      Mixed 
                                       only 
               PD-1+CD57- 
              PD-1+CD57+ 
 




2.4.7 FACS  Antibodies 
Antigen Fluorochrome Company Clone 
CD3 APC-H7 BD SK7 
CD4 Pacific Blue Biolegend RPA-T4 
CD4 Qdot 605 Invitrogen S3.5 
CD14 APC-cy7 Biolegend HCD14 
CXCR5 
 
PE R and D 51505.11 
CD185 
(CXCR5) 
PerCP Cy5.5 Biolegend TG2 
CD57 FITC BD NK-1 
CD57 Pacific Blue Biolegend HC57 
CD279 (PD-1) APC BD MH4 
CD127 PerCP Cy5.5 eBioscience BioRDR 
CD25 PE BD 2A3 
CD25 PE BD M-A251 
CD45RA Alexa fluor488 Biolegend HI100 
CD154 
(CD40L) 
PE eBioscience 24-31 
IL-21 PE Biolegend 3A3-N2 
IL-4 FITC Biolegend MP4-25D2 
IL-17 PE Biolegend BC168 
IFN-γ FITC Biolegend B27 
Foxp3 Alexa fluor 647 BD 259D/C7 
Foxp3 Pacific Blue Biolegend 206 





PE BD MOPC-21 
Mouse isotype 
IgG1κ 
PerCP-Cy5.5 eBioscience P3.6.2.8.1 
Mouse isotype 
IgG1κ 
APC BD MOPC-21 
Table 2-10 All antibodies used for flow cytometry 
2.5  Nucleotide extraction and PCR 
All nucleotide extraction and PCR preparation was carried out in UV sterilised hoods in 
specially designated rooms. PCR master mix preparation was performed in separate 
rooms to nucleotide extraction to prevent contamination of primers and buffers. All 
equipment such as pipettes, plates and tubes were UV sterilised before use. Nuclease 
free water was used in all PCR experiments and aliquots were UV sterilised before each 
use. 
2.5.1 DNA extraction 
DNA was extracted from sorted cells using a DNA extraction kit (Qiagen) according 
to manufactures instructions. 
DNA was stored at -20°C. 
2.5.2 RNA extraction 
RNA was extracted from sorted cells using the RNeasy Mini kit (Qiagen) according 
to manufactures instructions. 




2.5.3  Reverse Transcription 
14µl extracted RNA, 6µl H2O and 2µl OligoDT were added to a sterile PCR tube on 
ice and vortex before a hot start for 10min at 95°C. The PCR tubes were immediately 
placed back on ice for 5 min, vortexed and replaced back on ice for a further 5 min. 8µl 
M-MLV buffer, 6µl H2O, 2µl RT reverse transcriptase, 1µl RNAse inhibitor and 1µl 
dNTPs was added to the RNA solution on ice. The PCR tubes were placed in the PCR 
machine and run at 42°C for 60min and 70°C for 15 min. The resulting cDNA was then 
stored at -20°C. 
2.5.4  Real-time PCR 
In a 384 well plate 5.5ul TaqMan Gene expression master mix (Applied 
Biosystems), 0.5ul primer and 4ul cDNA were add per well and run on the standard 
setting on 7900HT sequence detection system (Applied Biosytems). Each sample was 
run in duplicate for both the house keeping gene and the target gene. The house keeping 
gene used in this study was GAPDH. 
GAPDH (Applied biosystems) Hs02758991_g1 
Bcl-6 (Applied biosystems) Hs00153368uml 
2.5.5  TCRγ PCR 
The TCRγ chain was amplified by PCR using Vγ11, Vγ101 and Jγ11 primers. Each 
reaction consisted of 30µl nuclease free H2O, 10µl 5x flexi buffer, 3µl MgCl2, 0.5µl 
20mm dNTPs, 0.5µl 20mm of each primer and 3µl DNA. 2µl of taq polymerase was 
added after the hot start.  After a hot start of 7min at 95°C ,40 cycles of 93°C for 1 min, 
55°C for 1 min and 73°C for 1 min were performed, followed by a final extension time 




2.5.6  TCRβ PCR 
The TCRβ chain from the T cell subsets was amplified by a semi nested PCR using 
primer to the V03 and J1.5 regions. Each first round reaction consisted of 23.5µl 
nuclease free H2O, 10µl 5x flexi buffer, 3µl MgCl2, 0.5µl 20mm dNTPs, 0.5µl 20mm 
of V03 external primer and J1.5 primer and 10µl DNA.  After a hot start of 7 min at 
93°C ,30 cycles of 95°C for 1 min, 50°C for 1 min and 73°C for 1 min 30 sec were 
performed, followed by a final extension time of 10 min at 73°C. 3µl of the first round 
product was added to the second round PCR reaction which contained of 30.5µl 
nuclease free H2O, 10µl 5x flexi buffer, 3µl MgCl2, 0.5µl 20mm dNTPs, 0.5µl 20mm 
of V03 external primer and J1.5 primer and 2µl of taq polymerase was added after the 
hot start. The PCR program was the same as the first round.  PCR products were 
visualised on an agarose gel. 
2.5.7  Primers 
Vγ11 primer 5’ TCTGGRGTCTATTACTGTGC 3’ 
Vγ101 primer 5’ CTCACACTCYCACTTC 3’ 
Jγ11 primer 5’CAAGTGTTGTTCCACTGCC 3’ 
Vβ03 External primer 5’CCCAGACTCCAAAATACCTGG 3’ 
Vβ03 Internal primer 5’CCTGGTCACACAGASGGG 3’ 
Jβ1.1 primer 5’ TGAGTCTGGTGCCTTGTCC 3’ 
Jβ1.5 primer 5’ AGAGTCGAGTCCCATCACC 3’ 
M13 Forward 5’ GTAAAACGACGGCCAGT 3’ 
M13 Reverse 5’ GGAAACAGCTATGACCAGT 3’ 
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2.6 Cloning of PCR products 
2.6.1  Purification of PCR products 
PCR products to be used in cloning were purified with MiniElute PCR purification 
Kit (Qiagen) according to the manufacturers protocols and stored at -20 °C until use. 
2.6.2  Ligation 
The pGEM-T Vector Kit (Promega) was used to ligate the PCR products. The 
ligation reaction contained 5µl buffer, 3µl purified PCR product, 1µl T4 DNA ligase, 1 
µl vector and these were mixed together on ice. The ligation reaction was then 
incubated at room temperature for 2 hours. 
2.6.3 Transformation 
2.5µl of ligation reaction was added to 25µl of bacteria (JM109 competent cell, 
Promega) in a sterile 1.5ml centrifuge tube and incubated on ice for 20 minutes. The 
vector was inserted into the bacteria by heat shock in a water bath at 42°C for 45 
seconds and then placed immediately back on ice for 2 minutes. 950µl of cold SOC 
medium was added and incubated at 37°C, shaking at 150rpm for 2 hours. To collect the 
bacteria the solution was centrifuged at 200rpm for 10 minutes at room temperature. 
The supernatant was discarded and the bacteria pellet was resuspended in 100µl of cold 
SOC medium. All 100µl of bacterial suspension was spread onto an LB Agar plate. The 
plates were inverted and incubated over night at 37°C.  
2.6.4  Picking up colonies 
Bacteria with a vector containing a DNA insert grew as white colonies and the 
bacteria with a vector without a DNA insert grew as blue colonies. The white colonies 
were picked up at random with a pipette tip and transferred to a gridded plate and 
incubated at 37°C overnight. The remaining bacteria on the tip was washed off in 15µl  
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dH2O. The samples were boiled for 10 min to release the vector and denature the 
DNAse and then centrifuged at 400 G for 10 min. Samples were stored at -20°C until 
use. 
2.6.5  Screening clones by PCR 
5µl of bacterial supernatant was amplified by PCR using M13 forward and M13 
reverse primers. One PCR reaction contained 9.46µl nuclease free dH2O, 4µl 5x flexi 
buffer, 1.2µl MgCL2, 0.2µl 20mm dNTPs, 0.02µl of each 100mm M13 primers, 0.1µl 
taq polymerase. PCR products were run on a 3% agarose gel to screen for inserts of the 
correct size. 
2.6.6  DNA sequencing 
200µl of agar containing ampicillin only was added to each well in 96 round or flate 
bottomed culture plate and left to cool and set. Colonies with appropriately sized DNA 
inserts were stabbed and transferred to a well in the 96 well plate. The plate was sealed 
with a sticker lid and bound with paraffin tap and sent for template prep and sequencing 
by Beckman Coulter sequencing services. 
2.7 Sequence analysis 
Using Gene Jockey sequence analysis program, the V and J regions were identified 
and primers and vector sequences were removed. Cut sequences were aligned and 
compared. Identical sequences originating from the same PCR were considered to be 
possibly the result of PCR amplification from one cell and considered as representing 
one cell. Sequences with the same J and V genes and the exact same nucleotides in the 




2.8  Statistics 
Statistically significant differences between groups of data are indicated by a bar 
over the data. Data sets that are not significantly different to each other have been left 
blank. Statistical tests were carried out using GraphPad Prism 4. Gaussian or non-
Gaussian distribution was established by D’Agostino and Pearson omnibus normality 
test. Unpaired data with Gaussian distribution were analysed by an unpaired t test. 
Unpaired data with a non-Gaussian distribution were analysed by a Mann-Whitney test. 
Paired data with Gaussian distribution were analysed by a paired t test. Paired data with 
non-Gaussian distribution were analysed by a Wilcoxon matched pairs test. Populations 







3 Chapter 3: TFH cells in Peripheral and Gut Associated 
Lymphoid Tissue 
3.1  Introduction 
The plasma cells of the intestinal humoral immune system are largely located in the 
intestinal LP throughout the small bowel and colon, though some are known to reside in 
the bone marrow. In contrast, the long-lived plasma cells of the peripheral immune 
system, most of which secrete IgG, are largely restricted to the bone marrow (Mei et al., 
2009). Immunoglobulins secreted by plasma cells in these different locations have 
different features in their antigen binding profile. Recent studies that construct human 
monoclonal antibody secreting cell lines by engineering the sequences encoding the 
used heavy and light chains of isolated single cells into expression systems, have 
demonstrated that approximately 26% of the IgA and IgG secreting LP plasma cells are 
polyreactive to two or more antigens, including self-antigens (Benckert et al., 2011). 
Although autoreactive and polyreactive antibodies circulate in the blood of healthy 
individuals (Dighiero et al., 1986), the antibodies secreted by human IgG bone marrow 
plasma cells tend to have a lower frequency of autoreactive or polyspecificity than those 
in the gut.  
The differences in specificity in the intestinal and bone marrow plasma cell 
populations are likely to reflect the properties of the different lymphoid tissue that 
generate them. Whereas the IgA response is driven by the diverse and abundant 
microbial flora in the gut lumen, the bone marrow IgG plasma cells are derived from 
affinity matured responses to antigen encountered systemically (Brandtzaeg et al., 
1999).  B cells activated in GALT become plasmablasts that enter the blood via the 
lymphatic system. They then mostly home back to the intestine by a system mediated by 
the expression of chemokine receptors CCR9, CCR10 and the integrin α4β7 where they 
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differentiate into plasma cells in the LP (Pabst et al., 2004, Hieshima et al., 2004, 
Farstad et al., 1995). In contrast IgG plasma cells home to the bone marrow by 
chemokine receptors including CXCR4 (Kunkel and Butcher, 2003). The majority of 
the plasma cells that home to the gut LP secrete dimeric IgA that binds to the polymeric 
immunoglobulin receptor (pIgR) and is actively transported across the epithelial barrier 
into the intestinal lumen (Brandtzaeg, 1974). This compartmentalisation of the IgA 
system which results in IgA secretion to the outside of the body may explain why 
polyspecificity and autoreactivity can be tolerated in the IgA system but not by IgG 
produced in the bone marrow that provides a long-lived protection in serum and body 
fluids that could be proinflammatory and potentially pathogenic if not tightly regulated.    
The IgV genes used by human intestinal plasma cells are almost all mutated by 
somatic hypermutation suggesting that they are derived from germinal centre responses 
in GALT (Barone et al., 2011, Dunn-Walters et al., 1997). Such diversity in the IgA 
repertoire has been shown to be essential for intestinal health (Wei et al., 2011). The 
presence of  IgV gene mutations in polyreactive and autoreactive mucosal 
immunoglobulins suggests that these plasma cells were also generated through a GC 
reaction (Benckert et al., 2011). Although there is good evidence that IgA responses can 
be T cell independent and GC independent, the prevalence of T cell independence in the 
human IgA system is not understood, but the vast majority of plasma cells appear to be 
germinal centre derived (Bergqvist et al., 2006, Bergqvist et al., 2010). 
The process of affinity maturation in GCs is regulated in part by TFH.  TFH aid the 
selection and maturation of clonally expanded B cells within the GC. Newly formed 
centrocytes in the GC present antigen to the TFH via cognate interactions and the TFH 
provides survival signals through CD40L and cytokines to the centrocytes that have 
higher affinity for the antigen (Breitfeld et al., 2000, Bryant et al., 2007).  Production of 
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cytokines including IL-21, IL4 and IFNγ by TFH have been reported (Luthje et al., 
2012). A selective pressure favouring the development of plasma cells secreting high 
affinity antibodies is in part controlled by restricting the number of TFH (Linterman et 
al., 2011). In mice it has been demonstrated that an uncontrolled increase in TFH leads to 
systemic autoimmunity (Linterman et al., 2009).   
TFH are themselves thought be associated with several different pathways of T cell 
development.  Although TFH in humans express the antigen CD57 that is associated with 
end-stage differentiation, TFH in mice have recently been shown to be able to  
differentiate along multiple effector T cell pathways (Luthje et al., 2012). TFH are 
regulated by subsets of regulatory CD4 and CD8 T cells. Approximately 10% of human 
and murine TFH have a regulatory properties and express foxp3 and are termed follicular 
regulatory T cells (Tfr) (Linterman et al., 2011, Lim et al., 2005). In mice it is proposed 
that a regulatory subset that resides within the CD8 T cell compartment regulates TFH to 
maintain self-tolerance (Kim et al., 2010). It has been suggested that a reduction in 
follicular regulatory cells leads to an increase in TFH, an increase in output of non-
specific and a reduction in the antigen specific GC response (Linterman et al., 2011). 
PD-1 is highly expressed by TFH and expression of PD-1 by TFH has been associated 
with the development of high affinity B cells in GCs (Good-Jacobson et al., 2010). 
Signalling through PD-1 negatively regulates T cell proliferation and cytokine 
production (Freeman et al., 2000). Disruption of PD-L1 expression or blockade of PD-
L1 or PD-1 lead to an increase in TFH, an increase in antibody production, and 
development of autoimmune disease (Hams et al., 2011, Nishimura et al., 1999). Data 
from a PD-1 deficient mouse model has demonstrated that PD-1 regulates the 
specificity of IgA responses and hence the integrity of the mucosal barrier (Kawamoto 
et al., 2012). In PD-1 deficiency the number and nature of TFH are altered (Kawamoto et 
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al., 2012).  PD-1 expression is therefore interesting in the context of B cell selection in 
GCs from different anatomical locations in humans, and of particular relevance to the 
regulation of the IgA plasma cell population.  
The relatively high frequency of poly and autoreactive plasmablasts found in the gut 
suggests that selection for antigen specificity may be less stringent in GALT GCs 
compared to those in peripheral lymphoid tissues. Investigations reported in this chapter 
aim to determine if there is evidence for differences in TFH in the gut versus systemic 
lymphoid tissue that may be involved in regulating the stringency of humoral responses 
differently in these sites. 
 To determine if there is any difference in the number or phenotypic diversity of 
TFH in the germinal centres of GALT versus peripheral lymphoid tissues that 
might reflect a role of TFH in determining the functional profile of mucosal 
immunoglobulins. 
 To determine whether there is any difference in functional parameters of subsets 
of TFH that could be related specifically to germinal centre function. 
 To determine if subsets of TFH might be developmentally related.  
 To determine if there is any difference in regulatory factors which effect TFH 
frequency. 
3.2  Results 
3.2.1 Phenotypic diversity of TFH in germinal centres of GALT vs. 
peripheral lymphoid tissues  
3.2.1.1  Frequency of CD57+ TFH in GALT and peripheral lymphoid tissues. 
In lymphoid tissue sections, TFH can easily be identified as the T cells within the GC 
microenvironment. To explore the frequency of TFH, tissue sections of different human 
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lymphoid tissues were double stained for CD3 and CD57. TFH were identified as all 
cells positive for CD57/CD3 or CD3 alone within the GC (Fig 3.1A).  
From counting the CD57+ and CD3+ only cells within the GC, the percentage of 
CD57+ TFH was generated as a number of CD57+ cells/ number of CD57+ cells + 
number of CD3+ only cells. On average 92% of peripheral lymphoid tissue (tonsil and 
spleen) TFH were CD57+ (Fig 3.1C) and the percentage of CD57+ TFH cells was 
consistent between tonsil and spleen (Fig 3.1B). However, a lower percentage of TFH 
were CD57+ in GALT (ileum, appendix and colon), where on average around 60% of 
TFH were CD57+ (Fig 3.1C). The percentage of CD57+ TFH was consistently lower 
throughout the gut compared to peripheral lymphoid tissues (Fig 3.1B). Therefore two 
TFH subsets have been identified which can be distinguished by their expression of 
CD57 and a greater proportion of TFH express CD57+ TFH in peripheral lymphoid tissue 









Figure 3-1 Frequency of CD57+ and CD57- TFH within GCs of secondary lymphoid tissues 
A- Examples of tissue sections of tonsil and colon stained for CD57 (brown) and CD3 (pink). Left 
GC x40 and right GC x100 magnification. B- Average percentage of CD57+ TFH found within 1, 2 or 3 
GCs of tonsil (n=7), spleen (n=3), mLN (n=2), appendix (n=8), colon (n=7) and ileum (n=8). C - Average 
percentages of CD57+ TFH within GC of peripheral lymphoid tissues (tonsil and spleen) and GALT 
(ileum, colon and appendix). Mann Whitney statistical test performed on B and C. 
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3.2.1.2 Relative TFH density in GALT and peripheral lymphoid tissues. 
With the identification of two subsets of TFH which differ in proportion in GALT 
and peripheral tissues, the ratio of TFH subsets to other GC cells was investigated. By 
using tissue sections double stained for CD57 and CD3, the number of CD57+, CD3+ 
and  unstained but haematoxylin positive cells (non T cells), such as B cells, follicular 
dendritic cells and stromal cells, within GCs were counted. This was then used to 
generate ratios of TFH cells to non T cells as a measure of relative TFH density. 
 The relative density of total TFH was significantly higher in appendix and ileum 
compared to tonsil (Fig 3.2A). Overall GALT had a higher average relative TFH density 
(0.47) than in peripheral lymphoid tissues (0.27) (Fig 3.2D).  
A significantly higher relative density of CD57- TFH is observed in GALT compared 
to peripheral lymphoid tissue, however, the relative density of CD57+ TFH was 
comparable (Fig 3.2E and F). The relative density of CD57- TFH is consistent higher 
throughout GALT compared to tonsil (Fig 3.2C). Thus, the higher frequency of CD57- 
TFH is probably responsible for the higher frequency of TFH in GALT compared to 










Figure 3-2 Ratio of TFH subsets to other non T cells within peripheral and GALT GCs. 
Ratio generated by comparing the total number of CD3+, CD57+ or both to the number of 
haematoxylin only stained cells within GCs. >3 GCs were counted and the average ratio plotted.  A-C 
Relative frequency of TFH subsets within GCs of tonsil (n=7), spleen (n=3), ileum (n=4), appendix (n=9) 
and colon (n=4). D-F Relative frequency of TFH within GC of peripheral lymphoid tissues (tonsil and 
spleen) and GALT (ileum, colon and appendix). A and D- Relative frequency of total T cells to all other 
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cells within GCs. B and E- Relative frequency of CD57+ T cells to all other cells within GCs. C and F 
Relative frequency of CD57- cells to all other cells within GCs. Mann-Whitney statistical test performed 
on A-C and F. Unpaired T test performed on D and E. 
To explore the positioning of the two subsets of TFH within the GC, the relative density 
of total T cells, CD57+ T cells and CD57- T cells to non T cells was explored in the 
light and dark zones of the GC (Fig 3.3A). Tonsil tissue was used as an example of 
peripheral lymphoid tissue and appendix as an example of GALT. As the GC in the 
tissue section has to be in the right orientation to determine these relative densities, a 
smaller data set was obtained. 
 CD57- T cells were present in both the light zone and dark zone of appendix GCs (Fig 
3.3D and G). However, there was no significant difference in the relative density of TFH 
subsets in either the light or dark zone of the GC between tonsil and appendix tissues 














Figure 3-3 Ratio of TFH with in the light and dark zone of GCs 
A-Diagram of a germinal centre depicting the light and dark zones. A-G Average ratio of 1, 2 or 3 
GCs from tonsil (n=5) and appendix (n=4). B and E- Relative frequency of T cells to non T cells in either 
the light or dark zone. C and F- Relative frequency of CD57+ T cells to non T cells in either the light or 
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dark zone. D and G- Relative frequency of CD57- T cells to non T cells in either light or dark zone. Mann 
Whitney statistical test performed on B-G. 
3.2.2 Defining TFH subsets in lymphoid tissue cell suspension by flow 
cytometry 
In order to further analyse TFH in GALT and peripheral lymphoid tissue, fresh TFH 
from lymphoid tissues were isolated. A panel of flow cytometry antibodies were 
designed to identify TFH as accurately possible and the detection of the TFH transcription 
factor, Bcl-6, was used to investigate TFH cell status. 
 Cells within the CXCR5
high
 population were separated by their expression of CD57 
and PD-1. Three distinct populations of cells were identified within the CXCR5
high
 CD4 






CD57+. A very low frequency 
of PD-1
low
CD57+ cells were also identified (Fig 3.4A). The subsets within the 
CXCR5
high
 CD4 T cell gate were isolated by flow cytometry and RT-PCR was used to 
detect the presence of Bcl-6 mRNA. The two subsets which expressed the highest levels 
of Bcl-6 were PD-1
high 
in tonsil tissue (Fig 3.4B). So few PD-1
low
CD57+ cells were 
isolated that Bcl-6 and the house keeping gene were both undetected in this subset and 
therefore cannot be ruled out as a TFH subset. However from the data that was obtained, 




 (highlighted in red box in Fig 3.4A) 
were considered TFH and this is consistent with other studies (Simpson et al., 2010). TFH 




















Figure 3-4 Identifying TFH subsets within the CXCR5
high
 CD4 T cell population in lymphoid tissue cell 
suspension. 
Tonsil mononuclear cells were stained with flow cytometry antibodies to CD3, CD4, CXCR5, PD-1 
and CD57. A- Example of gating on CXCR5
high
 previously gated on CD3+, CD4+ cells (top FACS plots) 
and the subsets of cells within this gate separated by their expression of PD-1 and CD57 (bottom FACS 
plots) in tonsil and appendix cell suspension. B- CXCR5
high
 CD4 T cell subsets as defined in bottom left 
FACS plot in A were sorted by FACS and bcl-6 expression was determined by real-time PCR in two 
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gate in tonsil (n=10) and appendix (n=4) fresh mononuclear cell suspension. Mann-Whitney statistical 
test performed on C. 
The relative frequencies of TFH expressing CD57 was analysed in fresh tonsil and 
appendix cell suspensions by using the method of gating to identify TFH illustrated in 





population was not significantly different between tonsil and appendix when analysing 
by flow cytometry though a trend towards a higher frequency of CD57+ TFH in tonsil 
can be seen (Fig 3.4C). As a significant difference in the percentage of CD57+ TFH was 
seen between GALT and peripheral lymphoid tissues using IHC methods in figure 3.1, 
this finding is probably a result of the methods used to detect TFH and will be discussed 
below. 
3.2.3  Differences in functional factors expressed by TFH subsets 
To investigate the functional significance of the relatively high frequency of CD57- 
TFH in GALT, functional parameters were explored.  
3.2.3.1  TFH subsets and expression of cytokines  
 To further characterize the CD57+ and CD57- TFH subsets the cytokine profiles 
were investigated. Mononuclear cells from tonsil single cell suspension were 
stimulated for 3 hours with PMA and ionomycin. TFH were identified by flow 
cytometry as being CD3+CD4+CXCR5
high
PD-1+ and subsets of TFH were separated 
by their expression of CD57 (Fig 3.5A). For each subset the frequency of cells 
producing IL-21 and IL4 was determined by intracellular FACS analysis (Fig 3.5A). 
Both subsets of TFH produced IL-21 and IL-4 however a significantly higher 
proportion of single IL-21+ cells and total IL-21+ cells were observed within the 























Figure 3-5 TFH associated cytokine production by TFH subsets 
 Tonsil (n=7) mononuclear cells stimulated with PMA and ionomycin for 3 hours and TFH subsets 
assessed by flow cytometry for IL-21 and IL-4 production A-An example of the gating strategy to 
identify TFH  by flow cytometry in a tonsil and the separation of IL21+ and IL4+ cells within the CD57+ 
and CD57- TFH gates. B- The percentage of CD57+ and CD57- TFH  single positive for IL-21 or IL-4, 
total IL-21+ or IL-4+ and IL-4+IL-21+ cells. Wilcoxon matched pairs statistical test performed on B. 
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TFH have been reported to express cytokines that are more typically associated with 
other T cell subsets. IFNγ production is normally associated with a Th1 phenotype. 
However, intracellular cytokine analysis of IL-21 and IFNγ double positive cells 
showed that a small percentage of CD57+ and CD57-TFH expressed both IL-21 and 
IFNγ (Fig 3.6 A).  
IL-17+ is a proinflammatory cytokine which is most commonly associated with 
Th17 cells. Analysis of IL-17 and IFNγ production by TFH subsets by flow cytometry 
showed that IL-17+ cells were present in both CD57+ and CD57- TFH  populations 
along with IFNγ. Analysis of both single and total IL-17+ cells showed a significantly 
higher percentage of IL-17+ cells within the CD57- TFH subset compared to the CD57+ 
TFH subset (Fig 3.6B).  
 Further characterisation of IL-17 expression in tissue sections of tonsil and 
appendix identified IL-17 secreting cells within the GC microenvironment (Fig 3.6C). 
This is consistent with the identification of IL-17+ cells within the TFH compartment in 
figure 3.6B. However IL-17+ cells are more frequent within the lymphocyte area 
compared to the GC in both tonsil and appendix tissue, probably due to the overall 















 Figure 3-6 Proinflammatory cytokines expressed by TFH subsets 
A-B Tonsil mononuclear cells stimulated with PMA and ionomycin for 3 hours A-Left, an example 
of the flow cytometry separation of IL21+ and IFNγ+ cells within the CD57+ and CD57- TFH gates. 
Right, the percentage of CD57+ and CD57- TFH positive for IL-21 and IFNγ in n=5 tonsil.  B- An 
example of the flow cytometry separation of IL17+ and IFNγ+ cells within the CD57+ and CD57- TFH 
gates and the percentage of CD57+ and CD57- TFH  single positive for IL-17 or IFNγ, total IL-17+ or 
IFNγ + and IL-17+ IFNγ + cells in n=8 tonsil. C- Average number of IL-17 + cells in 1,2 or 3 GCs and 
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average number of IL-17+ cells in 3 10x10mm of interfollicular area at x40 magnification. Mann-
Whitney statistical test performed on A-C. 
3.2.3.2  TFH subsets and expression of CD40L 
CD40L is a co-stimulatory molecule expressed on the surface of TFH and is required 
for B cell maturation and survival within the GC. To assess any differences in CD40L 
expression between TFH subsets, the surface expression of CD40L at basal levels and in 
response to stimulation was analysed by flow cytometry. Tonsil mononuclear cells were 
stimulated with PMA and ionomycin for 15 min, 30 min, 1h, 2h and 3h and CD40L 
expression was assessed at each time point by flow cytometry. 
 At basal levels there was no significant difference in the surface expression CD40L 
between CD57+ and CD57- TFH (Fig 3.7B). The trend in expression of CD40L after 
stimulation over these time points was similar in CD57-, and CD57+ TFH and CD4+ T 
cells (Fig 3.7A). There was no significant difference in the percentage of CD40L+ cells 
between CD57- TFH, CD57+ TFH and total CD4+ T cells after 3 hours of stimulation 
(Fig 3.7C). Also the basal unstimulated level of CD40L did not change after 3 hours in 
all T cell subsets (Fig 3.7A). Therefore no difference in the expression of CD40L was 
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Figure 3-7 CD40L expression on tonsil T cell subsets 
A-Flow cytometry analysis of CD40L expression at different time points either unstimulated or 
stimulated with PMA and ionomycin on 4 different tonsil samples B- CD40L expression on unstimulated 
tonsil (n=5)T cell subsets. C- CD40L expression on tonsil (n=4) T cells after 3 hours of stimulation with 
PMA and ionomycin. Mann Whitney statistical test performed on B and C. 
3.2.4 Analysis of CD57 expression on TFH subsets over time 
As CD57 expression is associated with clonal exhaustion and terminal 
differentiation, it is possible that CD57- TFH are at an earlier stage of differentiation than 
CD57+ TFH and CD57- TFH could possibly be precursors for the CD57+ TFH.  
Therefore to explore whether CD57- TFH differentiate into CD57+ TFH or vice versa, 
both populations of tonsil TFH were sorted by FACS (Fig 3.8A). When cell numbers 
permitted, purity was shown to be 98%. The sorted cells were then labelled with the cell 
tracking molecule CFSE and cultured for 4 days either alone or with allogeneic tonsil 
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mononuclear cells isolated at the same time as the sorted TFH (Fig 3.8A). On day four 
the CD57 expression on the CFSE labelled cells was analysed by flow cytometry. 
No difference in expression of CD57 was observed between CFSE labelled TFH 
cultured alone or with allogeneic tonsil cells (Fig 3.8B & C). After four days of 
culturing approximately 25% of CD57- TFH expressed CD57 (Fig 3.8B). On the other 


















Figure 3-8 Analysis of CD57 expression on sorted TFH subsets 
A- Diagram showing the steps involved in isolating and culturing CFSE labelled TFH cells from 
tonsils. B-The percentage of CD57+ TFH that  lost expressed CD57 after 4days of culturing either alone or 
with tonsil mononuclear cells (n=3). C- The percentage of CD57- TFH that expressed CD57 after 4days of 
culturing either alone or with tonsil mononuclear cells (n=3). Mann Whitney statistical test performed on 
B and C. 
3.2.5  Analysis of factors known to effect TFH cell frequency 
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In order to understand the higher frequency of TFH within GALT compared to 
peripheral lymphoid tissue, factors which have already been shown to effect TFH 
numbers were explored. 
3.2.5.1  Expression of PD-1 on TFH in GALT and Peripheral lymphoid tissue. 
PD-1 is a regulatory molecule that controls the proliferation and cytokine production 
of TFH. PD-1 expression on lymphoid tissue cell suspensions was analysed by FACS. 
Tonsil tissue was used as an example of peripheral lymphoid tissue and appendix as an 
example of GALT due to their high lymphoid tissue content.  
 Analysis of PD-1 on CXCR5-, CXCR5+ and CXCR5
high
 tonsil and appendix cell 
suspensions showed a high correlation of PD-1 with CXCR5 on CD4+ T cells (Fig 3.9A 
and B). CXCR5 is highly expressed on TFH and is a defining feature. However, analysis 
of the CXCR5
high
 CD4+ T population, showed no significant difference in the frequency 
of PD-1
high















Figure 3-9 Expression of CXCR5 and PD-1 on CD4 T cells in tonsil and appendix cell suspensions. 
Whole tonsil and appendix mononuclear cell suspension analysed by flow cytometry. A- CXCR5 
expression on CD3+ CD4+ T cells. CXCR5
high
 cells are defined as the cells expressing levels of CXCR5 
higher than the main body of cells and these cells are shaded in blue on these FACS plots. CXCR5+ are 
defined as those cells with higher fluorescence than the control and CXCR5- are those cells with 
fluorescence under the level of the control B- Histogram of PD-1 expression on CXCR5
high
, CXCR5+ and 
CXCR5- populations (gates shown on left). C Percentage of PD-1+ cells in the CXCR5
high
 fraction of 
CD4+ T cells in tonsil (n=6) and appendix (n=4). Mann Whitney statistical test performed on C. 
3.2.5.2 Frequency of Follicular T regulatory cells in lymphoid tissues 
Another explanation for the higher frequency in T cells in GALT GCs could be a 
difference in Tfr frequency. Tfr are a distinct population of T cells that reside in GCs 
and have regulatory properties. Tfr are related to natural Tregs but play a distinct role in 
GC regulation (Linterman et al., 2011). A reduction in Tfr is suggested to lead to a 
reduction in the regulation of TFH and a higher frequency of TFH (Linterman et al., 
2011). Therefore the frequency of Tfr was explored between tonsil and appendix.  
Analysis of whole tonsil and appendix cell suspension by FACS revealed a higher 
frequency of Tregs in appendix compared to tonsil (Fig 3.10A). In order to assess Treg 
frequency within different tissue microenvironments, analysis of foxp3+ Tregs on tonsil 
and appendix tissues was studied by IHC.  
 The percentage of foxp3+ T cells within the interfollicular area of appendix was 
significantly greater than in tonsil, which is consistent with the data obtained by FACS 
(Fig 3.10A & C). There was also a trend towards a higher percentage of foxp3+ T cells 
within appendix GCs compared to tonsil, though the difference was not significant (Fig 
3.10B). Overall this data shows a higher frequency of Tregs within appendix tissue 
compared to tonsil and a trend towards a higher frequency of Tfr.   
108 
 











 T cells in tonsil (n=5) and appendix (n=4) cell suspension 
assessed by flow cytometry. B Average percentage of foxp3 + T cells within 1, 2 or 3 GCs from tonsil 
(n=5) and appendix (n=5) C- Average percentage of foxp3 + T cells within 3 10x10mm lymphocyte areas 
at x40 magnification from tonsil (n=5) and appendix (n=5). Mann Whitney statistical test performed on 
A-C. 
3.3 Discussion 
3.3.1  A higher relative density of TFH in GALT compared to peripheral 
lymphoid tissue 
A relatively high frequency of plasma cells secreting polyspecific and autoreactive 
immunoglobulins generated through a germinal centre response has been observed in 
the gut mucosa (Benckert et al., 2011). Differences in TFH between GALT and 
periphery lymphoid tissue have been observed in this study. As TFH play an important 
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part in the selection and generation of plasma cells it is possible that the differences in 
TFH may contribute to the differences in specificity of plasma cells found at these sites. 
In this chapter, the relative density of TFH within different lymphoid tissues was 
studied. A higher relative density of TFH was observed in GALT GCs compared to 
peripheral lymphoid tissue GCs. This has not previously been reported in the literature. 
 It is thought that TFH frequencies are kept under a tight control to create a selective 
pressure which selects high affinity B cells to leave the GC to become plasma and 
memory B cells (Good-Jacobson et al., 2010, Linterman et al., 2011). The higher 
relative density of TFH  in GALT could lower the selective pressure on GC B cells, 
allowing the generation of plasma cells with a lower affinity for the antigen (Linterman 
et al., 2011). GC B cells with a lower affinity for the antigen have the possibility of 
being poly-specific or autoreactive which could explain the observation of  autoreactive 
and poly-specific gut plasmablasts by Benckert et al. (2011). 
3.3.2  TFH subsets differ in frequencies between GALT and peripheral 
lymphoid tissue.  
In this investigation, two subsets of TFH have been identified that can be 
distinguished from one another by their expression of CD57. The proportions of CD57+ 
and CD57- TFH differ between GALT and peripheral lymphoid tissue. There is a higher 
relative density of CD57- TFH in GALT but the relative density of CD57+ TFH is 
consistent in all lymphoid tissues. Therefore the higher frequency of TFH in GALT 
compared to peripheral lymphoid tissues and is due to a higher frequency of CD57- TFH. 
 Kim et al. (2005) demonstrated that CD57+ TFH were more efficient at inducing 
production of IgM, IgG, IgA and IgE by GC B cells than CD57- TFH (Kim et al., 2005, 
Kim et al., 2001). However, Rasheed et al. (2006) claimed that CXCR5
high
 ICOS+ TFH 
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had the greatest B cell helper ability regardless to CD57 expression in terms of inducing 
IgG production .  
In this study the relative density of CD57+ TFH was the same in peripheral 
lymphoid tissue and GALT. Therefore even if CD57- TFH are less able to induce 
antibody production than CD57+ TFH, they still contributed to a higher relative TFH 
density that could lower the selective pressure in the GALT GC microenvironment. 
3.3.3  Detecting TFH subsets in cell suspension. 
Some discrepancy can be seen between data sets generated by analysing the 
percentage of CD57+ TFH by immunohistochemistry or by flow cytometry in this study. 
The average percentage of CD57+ TFH  detected in tonsil by IHC is 90%, whereas the 
average percentage of CD57+ TFH detected by FC is 57%.  
The percentage of CD57+ TFH was lower when tissues were analysed by flow 
cytometry compared to analysis by immunohistochemistry which would suggest that 
non-TFH are also contained within the CD57- TFH gate. This is possibly due to FACS 
techniques being more sensitive and therefore cells with different levels of surface 
antigen expression are detected. Alternatively this may be a consequence of the 
definition of TFH in cell suspensions.  Unfortunately, a distinguishing marker of TFH has 




 population has been demonstrated to 
be a highly effective inducer of antibody production (Rasheed et al., 2006, Wang et al., 
2011a). However activated T cells also display similar surface markers as TFH such as 
CXCR5 and PD-1 (Ansel et al., 1999). Though flow cytometry may not be a precise 
way to analyse the frequency of TFH in lymphoid tissues, the advantage is the ability to 




3.3.4  Differences in cytokine production between  TFH subsets 
Difference in the cytokine profile of CD57+ and CD57- TFH was explored in this 
study. Previous studies demonstrated that TFH can secrete a number of different 
cytokines but classically TFH are known to secrete IL-21 and IL-4 (Yu and Vinuesa, 
2010). In this chapter it was demonstrated that both CD57+ and CD57- TFH were able to 
produce IL-21 and IL-4 and a small proportion of TFH dual expressed IL-21 and IL-4. 
However, a significantly higher percentage of CD57- TFH expressed IL-21 compared to 
CD57+ TFH. 
IL-21 has been implicated in the generation and survival of GC B cells and it has 
been proposed that the effect of IL-21 on GC B cells is an indirect consequence of the 
role of IL-21 in TFH development (Nurieva et al., 2008). However a recent study has 
demonstrated that IL-21 can also have a direct effect on GC B cell survival by 
promoting or maintaining Bcl-6 expression needed for effective affinity maturation 
(Linterman et al., 2010). Therefore in GALT, the higher frequency of CD57- TFH which 
produce more IL-21, could promote the survival of B cells with lower specificities 
which are potentially auto or poly-reactive, through direct effects on Bcl-6 expression 
and this could contribute to the altered immunoglobulin profile in GALT. 
In this chapter, analysis by FC demonstrated that a small percentage of both CD57- 
and CD57+ TFH produce IL-17. IL-17+ cells were also observed in GCs by IHC, which 
is consistent with the notion that a proportion of TFH express IL-17. Also a small 
frequency of IFNγ producing cells was detected in both TFH subsets and along with dual 
IL-17 and IFNγ producing cells. 
There is some debate in the literature as to whether or not TFH produce IL-17 and 
IFN-γ. Nurieva et al. (2008) states that in mice, TFH do not produce IL-17. However, 
Bauquet et al. (2009) reported IL-17 expression by TFH in mice immunised with 
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MOG(35–55) emulsified in CFA. Therefore the antigen type may influence the 
cytokines that TFH secrete. IFN-γ is expressed by TFH in murine models of viral 
infections and TFH in IL-21 reporter mice express IFNγ in response to non-specific 
stimulation (Luthje et al., 2012, Johnston et al., 2009). Bcl-6, is suggested to repress the 
production of IL-17 and IFN-γ but the effect in TFH seems to be that these cytokines are 
expressed at lower levels but can then be expressed at higher levels in response to 
certain antigens (Nurieva et al., 2009).  
A higher proportion of IL-17+ cells were detected within the CD57- TFH population 
compared to CD57+ TFH. Elevated levels of IL-17 have been associated with 
autoimmune disease (Chen et al., 2010, Wong et al., 2000). Depletion of IL-17 or IL-17 
deficient mice has preventative effects or lessens autoimmune disease severity (Nakae 
et al., 2003, Hofstetter et al., 2005). In particular, down regulation of circulating IL-17+ 
with a TFH phenotype has been associated with the amelioration of lupus like symptoms 
in mice (Wu et al., 2008). As a higher proportion of CD57- TFH produce IL-17, they 
may promote the generation of autoreactive B cells more than CD57+ TFH. Since CD57- 
TFH are found at a higher density in GALT, the IL-17 they produce may contribute to 
the autoreactive B cells found in the gut. 
3.3.5  CD40L expression by TFH subsets 
Further analysis of the CD57- and CD57+ TFH subsets in tonsil demonstrated that 
they both upregulate CD40L upon stimulation. CD40L is stored intracellularly and upon 
activation, CD40L is shuttled to the cell surface where it engages with CD40 on B cells 
to provided survival signals for the maturation of GC B cells (Koguchi et al., 2012, 
Elgueta et al., 2009). In this study there was no significant difference in the frequency of 
CD40L+ CD57- and CD57+ TFH after 3 hours of stimulation therefore suggesting that 
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both TFH subsets can equally provide the same level of B cell help through CD40-
CD40L interactions. 
Another point to consider is that in this chapter TFH subsets from tonsils were used 
to study cytokine production and CD40L expression. However, it is possible that in 
GALT the TFH cytokine profile may be different. Due to difficulties in obtaining 
sufficient number of lymphocytes from gut tissue, it was not possible to analyse 
cytokine production of TFH cells in GALT. However sufficient cells numbers were 
collected from one healthy appendix sample and data indicates that TFH cells subsets 
from appendix show a similar pattern of cytokine production as those in the tonsil (data 
not shown). 
3.3.6 CD57- TFH could be precursors of CD57+ TFH 
In this study, the expression of CD57 on TFH subsets was analysed after four days of 
culturing. On day four, a higher percentage of TFH gained CD57 expression than lost 
expression of CD57 suggesting that TFH are more likely to progress from CD57- to 
CD57+ rather than the other way round. Previous publications suggest that TFH cells 
develop when T cells from the T cell zone which are cognate for invading antigen are 
activated and migrate to the T cell-B cell border. Interactions with B cells activate 
signalling pathways that allow the T cell to enter the GC as a pre-TFH (Baumjohann et 
al., 2011, Kerfoot et al., 2011). It is possible that newly formed pre-TFH are the CD57- 
TFH observed in GCs and as TFH develop further they start to express CD57 (Kim et al., 
2001).  
The gut environment is constantly being challenged by antigens from the gut lumen 
and TFH are constantly being induced. The increase in frequency of CD57- TFH in 




However, it is also possible that the difference in the percentage of cells converting 
from CD57+ to CD57- and vice versa, is related to differences in the rate of cell death 
between CD57- and CD57+ TFH. As CD57+ TFH may be clonally exhausted, their rate 
of death may be greater than CD57- TFH. Therefore, it would appear that a smaller 
proportion of cells were progressing from CD57+ to CD57-. 
3.3.7  PD-1 and TFH frequency 
PD-1 expression on TFH was explored in this study because engagement of PD-1 on 
the surface of TFH with one of its receptors, PD-L1 or PD-L2, controls TFH responses 
and proliferation (Hams et al., 2011). However there is conflicting opinions to the effect 
of PD-1 deficient on GC B cells. Good-Jacobson et al. (2010) describes a population of 
higher affinity GC B cells arising from PD-1 signalling deficiency but this was due to a 
high death rate of GC B cells and only high affinity B cells remained.  Depletion of PD-
1 has also been linked with the development of autoimmunity (Nishimura et al., 1999, 
Nishimura et al., 2001). Autoimmunity in PD-1 deficient mice may in part be due to the 
expansion of TFH and altered TFH cytokine profile which leads to a dsyregulated 
antibody response (Hams et al., 2011, Kawamoto et al., 2012).  
 Theoretically, a lower expression of PD-1 on TFH would relieve the regulatory 
effects of PD-1 and could lead to an increase in the TFH population and less stringent 
selection of GC B cells. However the expression of PD-1 was comparable on TFH in 
GALT and peripheral lymphoid tissue, therefore a lower expression of PD-1 does not 
account for the higher frequency of TFH cells observed in GALT.  
A recent study by Kawamoto et al. (2012), highlights the importance of PD-1 in the 
regulation of IgA specificity in the gut. In the gut of pdcd1-/- mice, IgA had an altered 
specificity to gut bacteria and therefore an altered bacteria colonisation ensued. An 
expansion of TFH was observed in  pdcd1-/- GALT and GC B cells underwent less 
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stringent clonal selection (Kawamoto et al., 2012).   Overall it seems that PD-1 can alter 
the dynamics of germinal centre responses by the frequency of cells that express it in 
mice in this study and potential also in humans based on the data in this thesis. 
3.3.8 Role of follicular T regulatory cells in the frequency of TFH 
Linterman et al. (2011) recently described a population of Tregs which reside in 
GCs and appear to control TFH numbers and are termed follicular T regulatory cells. As 
there is a higher frequency of TFH in GALT compared to peripheral lymphoid tissue, 
this might suggest that GALT has a lower frequency of Tfr. Surprisingly, the data in 
figure 3.11 suggests that there is a higher frequency of Tregs in the gut and a trend 
towards a higher percentage of Tfr in appendix compared to tonsil.   
However, in GALT, the higher frequency of Tregs and Tfr could be a result of the 
higher frequency of TFH. It is possible that GCs with a higher number of TFH contain a 
higher number of Tfr to keep the number of TFH at a constant frequency. Therefore the 
higher frequency of TFH seen in GALT is not due to a dysregulation of Tfr but 
regulatory T cells in the gut are also at a higher frequency to correlated with the higher 
frequency of TFH and therefore set both of these T cell populations at equilibrium. 
3.4 Conclusions 
Overall, in this chapter several differences between GALT and peripheral lymphoid 
tissue TFH have been observed that may contribute to the differences in the properties of 
plasma cells induced at these sites. In conclusion:  
 A higher relative density of TFH was observed in GALT compared to 
peripheral lymphoid tissues.  
 Two subsets of TFH have been identified by their expression of CD57. The 
proportions of these two subsets differ between lymphoid tissues. 
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 The higher relative density of TFH in GALT is due to a higher frequency of 
CD57- TFH.  
 CD57- TFH are possibly newly formed or precursors for CD57+ TFH and 
their higher frequency in GALT could reflect a higher turnover of TFH. 






4 Chapter 4: Investigation of Clonally Related Cells Within 
and Between T Follicular Helper Cells and Regulatory T 
Cells Subsets 
4.1   Introduction 
At the time that this project was started the literature on TFH was beginning to gather 
pace and issues of lineage and plasticity were largely unknown. However recently, 
several studies have investigated the origin and development of TFH and the field has 
moved on. Analysis of TFH by affymetrix micoarrays revealed that they have a distinct 
transcriptional profile which differs from Th1 and Th2 cells (Chtanova et al., 2004). It 
has been demonstrated in mice that TFH cells can develop from antigen specific native 
CD4 T cells that are activated within the lymphoid tissue and independently of other T 
cell subsets (Baumjohann et al., 2011, Nurieva et al., 2008). Epigenetic studies suggest 
that TFH cells can also arise from other Th subsets as active marks have been found on 
tbx21, rorc and gata3 loci in TFH-like cells (Lu et al., 2011). These genes encode the 
master regulators for Th1, Th17 and Th2 lineages respectively. Studies using an IL-4 
reporter mice have demonstrated that IL-4 producing TFH cells within the germinal 
centre also express GATA3 during a helminth infection (Zaretsky et al., 2009). As 
GATA3 is the master transcriptional factor that controls Th2 lineage, this may indicate 
that these TFH are derived from a Th2 lineage (Zaretsky et al., 2009). 
In 2009, Tsuji et al demonstrated that foxp3+ Tregs transferred into CD3ε-/- mice 
were able to down-regulate foxp3 and reside within the GCs of PP. They gained TFH 
like features such as the expression of Bcl-6, CD40L, PD-1 and CXCR5 and were able 
to aid B cell expansion and plasma cell formation (Tsuji et al., 2009). This suggested a 
possible developmental link between Tregs and TFH cells. 
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Tregs promote tolerance and repress immune responses whereas TFH have a “helper” 
phenotype and promote a mature humoral immune response. These two lineages could 
be seen as having opposing roles in the immune system. Tsuji et al. (2009) suggests that 
in the gut the same signals are needed for the generation of TFH and Tregs, such as 
antigen engagement through the TCR. It is then the environment that the cell is in that 
influences whether its fate is to become a Treg or TFH. This relationship may be 
important in the gut to tip the balance of Treg and TFH in favour of a humoral response 
or immune suppression.  
However, the majority of studies into T cell plasticity have used murine models and 
there is very little evidence that TFH are developmentally related to Tregs in humans.  
To look at the developmental relationship between cell subsets in humans requires a 
different approach to that used in murine models. As it is not possible to track a cells 
fate in vivo by, for example, adoptive transfer or use of reporter genes in humans, 
evidence of developmental origins can only be studied retrospectively or in vitro.  
During T cell development, the TCR gene segments are rearranged creating near unique 
DNA sequences. The TCR sequence is retained by any progeny of that cell. Therefore 
clonally related T cells can be identified by analysis of the TCR DNA sequence. By 
using this method, common ancestry or the developmental relationship between TFH and 
Tregs can be explored. 
4.1.2 Aims: 
To identify and isolate Treg populations from lymphoid tissue by flow cytometry 
for further analysis. 
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To investigate any clonal relationship between TFH and Tregs and within these T cell 
populations from peripheral blood and tonsil by sequence analysis of rearranged TCRγ 
sequences amplified by clone specific primers. 
To investigate any clonal relationship between TFH and Tregs and within these T cell 
populations from tonsil by sequence analysis of rearranged TCRβ sequences from a 
restricted TCRβ repertoire. 
4.2  Results 
The initial stage of this study involved optimization of staining and gating for 
identification of Tregs and their subsets in tonsil tissues which will be described below. 
Parameters for identification of TFH were optimised in chapter 3.  
4.2.1  Isolating regulatory T cells from lymphoid tissue 
In order to study the potential for a clonal relationship between TFH cells and Tregs, 
purified populations of cells were isolated from lymphoid tissue by flow cytometry. 
Most studies of human Tregs that use flow cytometry to identify Tregs, use blood. It 
was therefore important to ensure that an equivalent population was identified and 
isolated from tonsils.  




 cells were present in tonsil (Fig 
4.1A). However, further analysis of this T cell subset by inclusion of PD-1 and 
CD45RA in the panel of antibodies identified heterogeneity that has not been described 
before and this was analysed further (Fig 4.1B).  
Foxp3, a transcription factor that is commonly used to identify Tregs, was used to 




 gate included Tregs  
(Fontenot et al., 2003). The PD-1
high
 cells were mainly Foxp3- and therefore not classed 





 and CD45RA-PD-1- cells expressed higher levels of foxp3 (Fig 
4.1C).  The latter two subsets are consistent with the phenotypes of Treg cells described 
by others (Miyara et al., 2009). 
A high expression of PD-1 is associated with TFH (Fig 4.2A). Therefore to further 






T cells in tonsils, the expression 






 cells in tonsils also 









 population identified in 
tonsil was not observed in blood (Fig 4.2 A and B). As both PD-1 and CXCR5 are 
expressed by TFH this suggests that TFH localise within the gates used for isolation of 
Treg when tonsil tissue rather than blood is analysed.  Therefore, to isolate Tregs from 
tonsil without contamination by TFH, a new gating strategy that gated out the PD-1+ T 



























Figure 4-1 Foxp3 expression in cell subsets within the CD127lowCD25high T cell population. 
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One example tonsil lymphocytes analyzed by flow cytometry to identify Treg cells (n=3). A- An 




 within the CD4 




 gate separated by 






















Figure 4-2 Expression of TFH cell markers within the CD127
lowCD25high T cell population. 
Flow cytometry analysis of T cell subsets in paired blood and tonsil from one healthy individual. A-
Histogram of PD-1 expression in tonsil CXCR5
high























 T cell population. Lymphocytes from blood (top) and tonsil cell suspension (bellow). 
4.2.2  Frequency of Treg subsets in lymphoid tissue and peripheral 
blood. 
Tregs can be divided into three subsets based on their expression of CD45RA and 
CD25.  Naïve Tregs are CD45RA+, CD25
intermediate





 and activated T regs are CD45RA-, CD25
high
. The frequency of activated 
Treg subsets was similar in tonsil and peripheral blood. However there was a higher 

























Figure 4-3 Frequencies of Treg subsets in tonsil and blood. 





T cells (far left), gating for PD-1
low











 T reg by CD45RA and CD25 (far right). B- Percentage of Treg subsets 
generated by the gating strategy in A in unpaired tonsil and blood. Mann-Whitney statistical test 
performed on B. 
4.2.3  Searching for clonality between T cell populations by comparing 
germline TCR-γ chain sequences. 
The first method used to investigate the possibility that a clone of T cells could span 
different T cell subsets, was sequence analysis of unused rearrangements of the TCRγ 
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chain. Clones of T cells within each subset and that span these two T cell subsets were 
sought by comparison of the junctional sequences generated at the TCR gamma locus. 
The method devised by Golby et al. (1999) initially used to identify and analyse groups 
of sequences from populations of T cells. Subsequently identical TCR sequences were 
sought by designing primers specific to the junctional region of the TCRγ chain. 
4.2.3.1  Direct analysis of diversity and comparison of sequences. 
 Fresh peripheral blood from a healthy donor was sorted for T reg cells and circulating 
TFH cells (cTFH) and tested for evidence of clonality between circulating populations of 
TFH and Treg. T regs were sorted by the phenotype CD4+CD25+CD127
low
 (Fig 4.4A) 
and cTFH cell by CD3+CD4+CD57+CXCR5+ (Fig 4.4B). The DNA was extracted from 
both of these subsets and 11 PCRs  using the Vγ11, Vγ101 and Jγ11 primers described 
by McCarthy et al. (1992) were performed for each T cell subset. The PCR products 
were cloned and 5-7 clones from each PCR were sequenced.  
Sequence analysis of 102 TCRγ sequences from both cTFH and Tregs showed that 
both of these populations of T cells were extremely diverse and there were no repeated 
sequences even between sequences from the same PCR. No related sequences between 
cTFH and Tregs were identified. Analysis of the number of nucleotides used in the 
junctional region of these clones revealed that Treg TCRγ sequences had significantly 







Figure 4-4 Sequence analysis of sorted Treg and cTFH  
A and B- FACS plots of cell sort on fresh peripheral lymphocytes from a healthy individual. A- 




T reg cells (P6). B- CD3+CD4+ cells sorted for CXCR5+CD57+ 
TFH. C- Number of nucleotides in junctional  region in T reg and cTFH. D- Comparison of the number of 
nucleotides in the junctional region between T reg and TFH. Unpaired T statistical test performed on D. 
4.2.3.2 4.2.3.2 Searching for related cells with clone specific PCR primers 
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To amplify clonally related T cells, clone specific primers were designed to 
sequences with N regions greater than 12bp and originating from both cTFH and Treg 
populations. The clone specific primers were complimentary to the junctional region but 
2 or more nucleotides at the end of junctional region were not included in the primer. 
The end nucleotides of the junctional region not encoded by the primer were used to 
confirm colonality between sequences (Fig 4.5). 
10        20        30        40        50        60        70        80  
|         |         |         |         |         |         |         |












D10 primer                             GGGATGGGCCTGGGTAG
E11 seq TTCTGGGGTCTATTACTGTGCCACCTGGGACAGG
CATCTCCCCACACGCTATGGGGTGAGG
||||||||||||||||||         TTATAAGAAACTCTTTGGCAGTGGAACAACACTTG








E03 primer                            TGGGACGCACGATAATTT
F04 seq TTCTGGGGTCTATTACTGTGCCACCTGGGATAG
TTAGGAGTTAGTATGCAT
|||||||||||||||||||   GAATTATTATAAGAAACTCTTTGGCAGTGGAACAACACTTG
F04 primer                                ATAGTTAGGAGTTAGTATG
F09 seq TTCTGGGGTCTATTACTGTGCCACCTGGGACGGG
CGAACGTGTTGTGGGGG
||||||||||||||||||   TTATAAGAAACTCTTTGGCAGTGGAACAACACTTG








F07 primer                           CTGGGATGGGCTGGCTC
J14 seq TCTGGGGTCTATTACTGTGCCACCTGGGACGG
CGCCGCCGCGAAAACAAAC
||||||||||||||||||   TTATAAGAAACTCTTTGGCAGTGGAACAACACTTGAATCACTAG












Figure 4-5 Clone specific primers to TCRγ junctional regions of sequences from circulating T cell 
populations. 
Original TCRγ sequences separated into the V segment, junctional region and J segment with the clone specific 
primer below.  The 2 or more nucleotides of the junctional region not included in the primer are underlined. 
 13 primers were designed from sequences originating form cTFH and Treg. PCRs 
were performed using the clone specific primers and the PCR product which yielded the 
original sequence. All 13 clone specific primers amplified a sequence of the correct size 
(positive control) (Fig 4.6A). The clone specific primers were tested with DNA from 
multiple donor whole lymphocytes as a negative control. 4 clone specific primers 
amplified products of the correct size and were excluded for possibly being non-specific 
(Fig 4.6B). The remaining 9 clone specific primers were used in PCRs with the DNA 
from all the cTFH and Treg PCR products generated using Vγ11, Vγ101 and Jγ11 
primers (Fig 4.6C).  
The only primer designed from a TFH cell TCRγ sequence, F09, did not pick up any 
other products of the same size in any of the PCRs (table 4.1). Primer E08 yielded 
bands of the correct size in 5 other Treg PCR products and A07 gave a band of the 
correct size in one other Treg PCR product but neither of these primers produced a band 
with any of the cTFH PCR products. Primers E12, A08 and D10 yielded products of the 
correct size with both TFH and Treg PCR products (table 4.1).  These PCR products of 
the correct size amplified by E12, A08 and D10 clone specific primers from DNA 
originating from cTFH were cloned and two examples from each PCR were sequenced. 
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Figure 4-6 Screening for related clones in Treg and TFH cell subsets using clone specific primers  
PCR products run on 10% polyacrylamide gel. A- Positive control for the 13 clone specific primers 
where the primers were used to amplify the DNA from the original PCR reaction that the clone was 
sequenced from. B- Negative control for the primers using a multi donor buffy coat DNA amplified for 









Primer TFH target T reg target 
TFH F09 0/10 0/11 
Treg E08 0/11 5/10 
Treg A07 0/11 1/10 
Treg E12 1/11 1/10 
Treg A08 1/11 1/10 
Treg D10 1/11 1/10 
Treg E11 0/11 0/10 
Treg F04 0/11 0/10 
Treg J14 0/11 0/10 
Table 4-1  Number of PCR reactions which gave a band of the correct size for each primer. 
The ratios represent how many PCR products yielded a band of the correct size when the clone 
specific primer was applied out of all the other PCR products for that T cell subset. The PCR product 
from which the original sequence came from is not represented. 
The cTFH sequences, amplified by the Treg clone specific primers A08, D10 and 
E12, were not identical to the original Treg sequences. Even though the PCR product 









Figure 4-7 Alignment of sequences amplified by 
TCRγ clones specific primers 
A-A0815 and A0824 from a TFH PCR compared to the 
original A08 sequence and primer. B D1025 and D1030 
from a TFH PCR compared to the original D10 sequence 
and primer.  C- E1244 and E1242 from a TFH PCR 
compared to the original E12 sequence and primer. 
10        20        30        40        50        60        70        80        90
|         |         |         |         |         |         |         |         |
A08 Original         TTCTGGGGTCTATTACTGTGCCACCTGGGACGGGCCGCGAACGCCAGGCATTATAAGAAACTCTTTGGCAGTGGAACAACACTTG
A08 primer                                         CGGGCCGCGAACGCCAG
A0815 CGGGCCGCGAACGCCAGCGGGCCGTGGAACAACACTTGGGCAGTGGAACAACACTTG
A0824 GCGAACGCCAGCATCGAATTATTATAAGAAACTCTTTGTNCAGTGGAACAACACTTG
10        20        30        40        50        60        70        80        90      
|         |         |         |         |         |         |         |         |      
D10 Original TTCTGGGGTCTATTACTGTGCCACCTGGGATGGGCCTGGGTAGAGTATTATAAGAAACTCTTTGGCAGTGGANCAACACTTG
D10 primer                             GGGATGGGCCTGGGTAG
D1025 TGATTCTGGGGTCTATTACTGTGCCACCTCTGGATTATTATAAGAAACTCTTTGGCAGTGGAACAACACTTG
D1030 GGGATGGGCCTGGGTAGAAGAAACTCTTTGGCAGTGGAACAACACTTG
10        20        30        40        50        60        70        80  
|         |         |         |         |         |         |         |  
E12 Original      TTCTGGGGTCTATTACTGTGCCACCTGGGATAGCGAGGAGCCTACCATATTATAAGAAACTCTTTGGCAGTGGAACAACACTTG
E12 primer                                    GATAGCGAGGAGCCTAC
E1244 GATAGCGAGGAGCCTACATTATTATAAGAAACTCTTTGGCAAGTGGAACAACACTTG






Thus, no evidence of clonal relatedness between Treg and cTFH from blood was 
observed. 
4.2.4  Searching for clonality between T cell populations from 
peripheral lymphoid tissue 
No clonality was found in circulating populations of T cell populations and this 
could be due to vast diversity and number of T cells found within peripheral blood and 
therefore clonally related cells may be found more readily in tissue. Therefore, the 
methods above were applied to T cell subsets from lymphoid tissue.  
4.2.4.1  Direct analysis of diversity and comparison of sequences 
Several TFH and Treg subsets were sorted from two tonsils (TON-12 and TON-14) 
by flow cytometry to explore clonality not only between TFH and T reg but also within 
TFH subsets and Treg subsets. TFH cells were defined as CD3+CD4+CXCR5
high
PD-1+ 
as described in chapter 3 and TFH subsets were divided into CD57+ and CD57- subsets. 
However, CD57+ and CD57- CXCR5
high
PD-1- T cells (non-TFH) were also sorted to 
explore if there is a clonal relationship between these subsets and TFH (Fig 4.8A). Treg 






 as described in figure 4.3A and 




PD-1+ CD4 T cells 




 CD4 T cells were sorted at the 







Phenotype Population name 
CD3+CD4+CXCR5
high
PD-1+CD57+ CD57+ TFH 
CD3+CD4+CXCR5
high
PD-1+CD57- CD57- TFH 
CD3+CD4+CXCR5
high
PD-1-CD57+ CD57+ non-TFH 
CD3+CD4+CXCR5
high
























 Control T cells 
Table 4-2 Phenotype and population name of sorted T cell subsets. 
2 or 3 TCRγ chain PCRs were performed for all subsets of T cells described in table 
4.2. Rather than sequencing a number of PCR products from all the T cell subsets which 
would be costly and time consuming, only PCR products of CD57+ TFH and PD-1+non-
Treg subsets were sequenced in the first instance. In figure 4.1 PD-1 non-Tregs were 





 gate could indicate that they are related to Tregs. CXCR5 was also 
expressed on a proportion of PD-1 non-Tregs which could indicate that they are TFH. 
Sequence analysis of PD-1 non-Tregs may give an insight into whether these cells are 
related to Tregs, TFH or both. 
From TON-12, 23 sequences were analysed from the CD57+ TFH cell subset and 24 
sequences were analysed from the PD-1+non-Treg subset. From TON-14, 23 sequences 
were analysed in the CD57+ TFH cell subset and 22 sequences were analysed from the 
PD-1+non-Treg subset. Analysis of these sequences found that the T cell populations 
were extremely diverse as all the sequences were different to each other and no clonally 
related sequences were observed. No significant difference in the number of nucleotides 
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at the junctional region was found between PD-1+ non Tregs and CD57+ TFH (Fig 
4.8C). This might indicate that PD-1+ non-Tregs are more similar to TFH than Tregs as 





















Figure 4-8 Generation of clone specific primers from TCRγ chain sequences. 
A and B- Examples of gating for sorting T cell populations by flow cytometry. A- An example of the 
FACS gating for subsets of CXCR5
high
 CD4 T cells. Cells in gates P6, P7, P8, P9 were sorted. B- An 




 T cells (top). An example of gating for 




 gate (bottom). Cells in gates P4, P7, P12 and P13 were sorted. 
C- number of nucleotides in the junctional region of the TCRγ in PD-1+ non Tregs and CD57+ TFH. 
Mann-Whitney statistical test performed on C. 
4.2.4.2  Searching for related cells with clone specific PCR primers 
From the TCRγ sequences, clone specific primers were designed to junctional regions 
longer than 12 bp. For TON-12, primers were designed to 3 sequences from the CD57+ 
TFH and 4 sequences from the PD-1+non-Tregs. From TON-14, primers were designed 
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to 2 sequences from CD57+ TFH and 4 sequences from the PD-1+non-Treg (table 4.2). 
In the cases where the junctional regions were relatively short, two primers were 
designed.  One primer of 16 nucleotides in length, indicated in red, and the other 18 








Table 4-3  TCRγ chain sequences used to generate clone specific primers 
Sequences from tonsil 12 and tonsil 14 T cells with N segments containing 12 or more nucleotides. Nucleotides highlighted in red are the primer sequence. Where both a 16 and 
18 nucleotide primer was designed, the two extra nucleotides in the 18 nucleotide primers are highlighted in green.
PCR Sequence V segment N segment J segment
TON 12 CD57+ TFH PCR 1 A1 TTCTGGGGTCTATTACTGTGCCACCTGGGACAGG CTTTCGCCCCTACGGTATAT GGG CTCTTTGGCAGTGGAACAACACTTG
TON 12 CD57+ TFH PCR 2 B2 TGATTCTGGGGTCTATTACTGTGCCACCTGGGACAGG CCATAACTATAAAGACGCTAACATCC GAAACTCTTTGGCAGTGGAACAACACTTG
TON 12 CD57+ TFH PCR 3 B6 TTCTGGGGTCTATTACTGTGCCACCTGGGAT GGGCGGGAGAGGG ATTATAAGAAACTCTTTGGCAGTGGAACAACACTTG
TON 12 PD-1+ non-Treg PCR 1 D1 TTCTGGGGTCTATTACTGTGCCACCTGGGA GCTTCTACGTACCGC TAAGAAACTCTTTGGCAGTGGAACAACACTTG
TON 12 PD-1+ non-Treg PCR 2 D3 TGATTCTGGGGTCTATTACTGTGCCACCT GGGAC GGGCGAAGGGTAT TGC ATTATTATAAGAAACTCTTTGGCAGTGGAACAACACTTG
TON 12 PD-1+ non-Treg PCR 3 D12 TTCTGGGGTCTATTACTGTGCCACCTGGGACA AGAATCAACCCAGCCGACGG AAGAAACTCTTTGGCAGTGGAACAACACTTG
TON 14 CD57+ TFH PCR 1 E1 TCTGGGGTCTATTACTGTGCCACCTGGGAT GGTCCCCGTAGTGT GAAACTCTTTGGCAGTGGAACAACACTTG
TON 14 CD57+ TFH PCR 2 E9 TTCTGGGGTCTATTACTGTGCCACCT GGGATAG CCCCTACGGACCTT TTATTATAAGAAACTCTTTGGCAGTGGAACAACACTTG
TON 14 PD-1+ non-Treg PCR 1 G2 TTCTGGGGTCTATTACTGTGCCACCTG ACCCCGAAAAACGTC TTATAAGAAACTCTTTGGCAGTGGAACAACACTTG
TON 14 PD-1+ non-Treg PCR 1 G7 TGATTCTGGGGTCTATTACTGTGCCACCTGGGAC TTTACCTTGTGGGAGGTGTTGG AGAAACTCTTTGGCAGTGGAACAACACTTG
TON 14 PD-1+ non-Treg PCR 2 H1 TTCTGGGGTCTATTACTGTGCCACCT GGGAC CGCACCAACAT TTC TTATTATAAGAAACTCTTTGGCAGTGGAACAACACTTG




The primers were tested with the PCR product from which the sequence was originally 
identified as a positive control and all but one primer (D3 18) passed this positive test 
(Fig 4.9A). To negatively test for non-specific binding of the clone specific primers, 
DNA from whole lymphocytes from multiple donors was used as a template. The 



















































































Tonsil 12 clone specific 
primers













Figure 4-9 Positive and negative test PCRs for clone specific primers 
A- Positive control PCR to test clone specific primers designed from sequences in table 2. Purified PCR 
product from which the sequences originated was used as a DNA template. B- Negative control PCR to 
test clone specific primers where DNA extracted from multiple donor buffy coats was used. 
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From TON-12, one clone specific primers from the CD57+ TFH (B2 primer) and 2 
clone specific primers (D1 16 and D12 primers) from the PD-1+non-Treg passed this 
selection process. From TON-14, one clone specific primers (E1 16 primer) from the 
CD57+ TFH and 2 clone specific primers (G2 18 and H1 16 primers) from the PD-
1+non-Treg passed (Fig 4.9B). 
The selected clone specific primers were used with DNA from PCR product from all 
the other T cell subsets originally sorted from the tonsil which included Treg subsets 
and TFH subsets (Fig 4.8A and table 4.2). 
 For TON-12, there were no other sequences of the correct size amplified by the 
CD57+ TFH B2 primer and PD-1+non-Treg D1 16 primer apart from the original 
positive control (Fig 4.10A and B). The PD-1+non-Treg D12 primer amplified 
sequences of the correct size in DNA from CD57- TFH, CD57+ TFH cells, another PD-
1+non-Treg PCR product and CD45RA- Treg cells (Fig 4.10C). 
For TON-14, the CD57+ TFH E1 primer amplified sequences of the correct size from 
CD57- TFH and CD45RA- Tregs (Fig 4.11A). The PD-1+non-Treg G2 primer amplified 
sequences of the correct size from CD57- TFH and CD57+ TFH (Fig 4.11B). The CD57+ 
TFH H1 primer amplified sequences of the correct size from CD45RA- Tregs and the 





































































































Figure 4-10 TON 12 PCR products amplified by clone specific primers 
Purified PCR product from amplified TCRγ sequence from all sorted T cell subsets was used as a 
template for clone specific primers and TCRγ J primers. The PCR containing DNA from which the clone 
originated is highlighted in red.  A- PCR PCR products using B2 clone specific primer. B- PCR products 





































































































Figure 4-11 TON 14 PCR products amplified by clone specific primers 
Purified PCR product from amplified TCRγ sequence from all sorted T cell subsets was used as a 
template for clone specific primers and TCRγ J primers. The PCR containing DNA from which the clone 
originated is highlighted in red.  A- PCR products using E1 16 clone specific primer. B- PCR products 




PCR products which yielded a band of the correct size were cloned and sequenced 
but none of them matched the original sequence that the primer was designed from (Fig 
4.12). Therefore despite extensive searching no clonal relationship was found within T 





Figure 4-12 Comparative alignment of sequences 
amplified by clone specific primers 
A- J3 and J4 from CD57+ TFH PCR 1, J13 and J14 
from CD57- TFH PCR 2, J19 and J21 from control T 
cells PCR 2 and J27 from PD-1+non-Treg PCR 2 
compared to the original D12 sequence and primer. 
B- J39 and J44 from CD57- TFH PCR 1 and J47 
from CD45RA- Treg PCR 2 compared to the 
original E02 sequence and primer. C J49 and J50 
from CD57+ TFH PCR 3 and J63 and J64 from 
CD57-TFH PCR 1 compared to the original G2 
sequence and primer. J69 and J72 from CD45RA- 
Treg PCR 1 and J77 from control T cells PCR 1 
compared to the original H01 sequence and primer.  
10        20        30        40        50        60        70         
|         |         |         |         |         |         |         
G2 original          TTCTGGGGTCTATTACTGTGCCACCTGACCCCGAAAAACGTCTTATAAGAAACTCTTTGGCAGTGGAACAACACTTG
G2 18 primer                                 ACCTGACCCCGAAAAAC
J 63                                         ACCTGGGATAGGCGTCTCGGTAAAATTATAAGAAACTCTTTGGCAGTGGAACAACACTTG
J 64                                         ACCTGACCCCGAAAAANCGGGTATTATAAGAAACTCTTTGGCAGTGGAACAACACTTG
J 49                                         ACCTGACCCCGAAAAACCCCTATTATAAGAAACTCTTTGGCAGTGGAACAACACTTG
J 50                                         ACCTGGGATGGGCCGGGTTTATTATAAGAAACTCTTTGGCAGTGGAACAACACTTG
10        20        30        40        50        60        70        80           
|         |         |         |         |         |         |         |
D12 original        TTCTGGGGTCTATTACTGTGCCACCTGGGACAAGAATCAACCCAGCCGACGGAAGAAACTCTTTGGCAGTGGAACAACACTTG
D 12 primer                                        AAGAATCAACCCAGCCGA
J 27                                                            GCCGAGTGGAGATTGGGGATGCTTCTGGGGGAGGGCAGTGGAACAACACTTG
J 21                                                       TCGCACGGCACCTGAGCGGCATCTGGAGGGAGGGGCAGTGGAACAACACTTG
J 13                                                  AATCAACCCAGCCGACCAAATAAGAAACTCTTTGGCAGTGGAACCACACTTG
J 14                                                  AATCAACCCAGCCGACCAAATAAGAAACTCTTTGGCAGTGGAACCACACTTG
J 19                                               AAGAATCAACCCAGCCGATTGGAAACTCTTTTNAAGGGGAACAACACTTG
J 4                                                AAGAATCAACCCAGCNNAGATAAGAAACTCTTTGGCAGTGGAACAACACTTG
J 3                                                AAGAATCAACCCCCCTTNNAAAAGAAACTCTTTGGCAGTGGAACAACACTTG
10        20        30        40        50        60        70        80   
|         |         |         |         |         |         |         |   
H01 original            TTCTGGGGTCTATTACTGTGCCACCTGGGACCGCACCAACATTTCTTATTATAAGAAACTCTTTGGCAGTGGAACAACACTTG
H1 16 primer                                       GACCGCACCAACAT
J 77                                                     ACCAACATTATCATTATTATTATAAGAAACTCTTAAAGNGGGGAACAACACT
J 72                                               GACCGCACCAACCCCTTTTAATAAGAAACTCTTTGGCAGTGGAACAACACTTG





10        20        30        40        50        60        70        80   
|         |         |         |         |         |         |         |   
EO1 Original             TCTGGGGTCTATTACTGTGCCACCTGGGATGGTCCCCGTAGTGTGAAACTCTTTGGCAGTGGAACAACACTTG
E1 16 primer                                        GGGATGGTCCCCGTAG
J 34 GGGATGGTCCCCGTAGGGATAAGAAACTCTTTGNCAGGGGAACAACACTTG
J 39                                                GGGATGGTCCCCGTAGGGATAAGAAACTCTTTGGCAGTGGAACAACACTTG
J 44                                                GGGATGGTCCCCGTAGTTGAAACTCTTTGGCAGTGGAACAACACTTG
J 47                                                GGGATGGTCCCCCCTTTNNNNATTATTATAAGAAACTCTTTGGCAGTGGAACAACCCTTTT
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4.2.5 Searching for clonality between T cell populations by comparing  
TCR-β chain sequences. 
No evidence of clonality was found between or within any of the T cells subsets 
studied when analysing the TCRγ by either analysing the sequences or with clone 
specific primers. This might have been due to the high diversity of sequences which 
were identified by the TCRγ chain primers. In order to increase the probability of 
identifying related TCR sequences from different T cell subsets and within T cell 
populations, a method of detecting only part of the population was applied. A similar 
concept enabled identification of clonally related B cells in a diverse population by 
using PCR primers to a fraction of the total immunoglobulin repertoire (Boursier et al., 
2005). 
 Primers to TCRβ V03 and J1.5 were designed so only a small fraction of the TCRβ 
repertoire would be amplified. The DNA from TON-14 CD57+TFH, CD57- TFH, 
CD45RA+ Treg, CD45RA- Treg and control T cells isolated by the method shown in 
figure 4.8 A and B and table 4.2, was used as the template in the TCRβ repertoire PCRs. 
For each subset of T cells, different DNA was amplified in 5 TCRβ PCRs (Fig 4.13). 
The PCR product was cloned in bacterial plasmids and sequenced.  83 sequences were 








Figure 4-13 TCRβ PCR products from 
Treg and TFH subsets 
PCR products from PCRs amplifying 
V03 and J1.5 TCRβ sequences. 5 different 
PCRs were performed for each T cell subset 
and the PCR product was run on 1.5% 
Agarose gel.  The correct product size was 
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Table 4-4 TCR beta sequences from Tonsil 14 sorted T cell subsets 
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Each row represents a unique TCR beta sequence and the number of times the sequence appeared in 
a single PCR is indicated by the number in that cell.   
48 unique sequences were identified. A smaller number of unique TCRβ sequences 
were amplified in each PCR using this method due to a high frequency of repeated 
sequences within PCR products. The repeated sequences in each PCR were a 
consequence of the PCR only. This meant that performing more PCRs for sequencing is 
more advantageous than sequencing more colonies from the same PCR to increase the 
data set of sequences from different cells. 
Two examples of the same gene rearrangements in different PCRs were observed. 
The first example (light grey row) was a gene rearrangement derived of DNA from 
CD57+ and CD57- TFH as well as from the control T cell population (table 4.3). The 
second gene rearrangement (dark grey row) was observed in several different PCR 
products containing DNA from CD57+ TFH and also from control T cells (table 4.3). 
However, no clonality was observed between tonsil TFH and Treg subsets using this 
method of sequence analysis of a fraction of the TCRβ repertoire.  
4.3  Discussion 
4.3.1  Frequencies of Treg subsets in peripheral blood and lymphoid 
tissues. 
In this chapter, a method of detecting Tregs in lymphoid tissue was established. In 





 gate used to identify Tregs. Adjustments to the gating strategy 
excluded this population. Using this gating strategy, comparisons between Treg subsets 
in tonsil and blood found a higher frequency of memory Tregs and a lower frequency of 
naive Tregs within tonsil tissue. 
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Most analysis of the properties of human Tregs uses circulating Treg populations 
found within peripheral blood. However lymphoid tissue is believed to play an 
important part in the maturation and induction of Tregs. Naive Tregs produced in the 
thymus circulate in the blood and enter lymphoid tissue where they can become 
activated (Lee et al., 2007). Once activated, Tregs gain the ability to home to non-
lymphoid tissues (Lim et al., 2006, Lee et al., 2007).  As Tregs mature from a naive 
phenotype to an activated phenotype they lose their expression of CD45RA. Both naive 
and memory/active Tregs have been previously reported to reside in tonsil tissue 
alongside non-treg T cells and tonsil CD4+CD25+ Tregs have been shown to be 
suppressive (Lim et al., 2006, Taams et al., 2001). Lim et al. (2006) suggests that a 
higher frequency of naive CD45RA+ Tregs (49%) is found in tonsil compared to 
peripheral blood (17%) as naive Tregs home straight to lymphoid tissue and emerge into 
the peripheral blood as CD45RA- activated/ memory Tregs. However the finding in this 
chapter were that there are less naive CD45RA- Tregs in tonsil compared to blood. 
Discrepancies in the frequency of CD45RA+ and CD45RA- Tregs could be due to 
differences in methods used to detecting Tregs. Lim et al. (2006) detected Tregs by 
foxp3 and CD4 only whereas in this study CD4, CD127 and CD25 where used together 
to isolated Tregs. Foxp3 is also transiently upregulated on activated non suppressive T 
cells and these cells could be included when only foxp3 expression is used to detect 
Tregs (Wang et al., 2007). 
The higher frequency of memory CD45RA- Tregs and lower frequency of 
CD45RA+ Tregs detected in tonsil tissue in this chapter could reflect the tonsil as a site 
of activation and therefore Tregs are constantly losing the expression of CD45RA. 
Whereas the blood would containing newly emerging naive Tregs as well as activated 
Tregs from lymphoid tissues which could lower the frequency of activated Tregs.  
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4.3.2  Are T follicular helper cells and regulatory T cells 
developmentally related? 
In this chapter no clonality was identified between circulating populations of TFH 
and Tregs. TCRγ and TCRβ sequence analysis of tonsil TFH and Treg also found no 
clonality between these populations. 
There could be several reasons as to why no developmental relationship has been 
observed between TFH and Tregs in this study, but a developmental relationship was 
identified in the study by Tsuji et al. (2009) For example, this phenomenon could be an 
idiosyncratic effect only seen in CD3ɛ-/- mice.  
It is possible that the environment is important in the conversion of Tregs to TFH. In 
the CD3ɛ-/- mice, conversion of foxp3+ T cells to TFH-like cells only occurred in PP 
and not in spleen or lymph nodes (Tsuji et al., 2009).  The gut naturally has autoreactive 
antibodies generated through GC responses. It is possible that the TFH cell progeny from 
natural Tregs would be reactive to auto antigens. It is possible that the mucosal 
environment favours the conversion of Tregs from a regulatory phenotype to a helper 
phenotype. However why this could only occur in the gut and if it occurs in humans at 
all remains unclear. Unfortunately, due to time constraints and difficulty in obtaining 
and isolating TFH and Treg subsets from fresh gut tissue, we were unable to study 
clonality of TFH and Treg from human gut mucosa.  
Several studies have analysed the shared TCR repertoire between Treg and Tconv in 
disease models (Wong et al., 2007, Nguyen et al., 2010). Only a very few shared TCR 
sequences were identified between Treg and Tconv in one study of EAE in mice and 
none were identified when analysing an antigen specific TCR in the context of diabetes 
(Wong et al., 2007, Nguyen et al., 2010). This suggests that clonal relationships 
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between Tregs and other T cell lineages are extremely rare and may be difficult to 
identify. 
Recently the microRNA, miR-10A has been identified as a possible regulator of the 
plasticity between Treg and TFH. MiR-10A targets Bcl-6 and prevents the conversion of 
Treg to TFH (Takahashi et al., 2012). This suggests that the conversion of Treg to TFH is 
prevented. 
Since the publication by Tsuji et al. (2009) describing the generation of TFH from 
Tregs in CD3ɛ-/- mice, an increasing body of evidence, including the findings in this 
chapter, suggests that this process does not occur in humans. 
4.3.3  Clonality between T follicular helper subsets 
When analysing part of the TCRβ repertoire, related sequences were found in PCRs 
from CD57- and CD57+ TFH. This suggests that CD57+ and CD57- TFH are related 
developmentally as suggested in chapter 3. As related sequences are repeated over 
several different PCRs and therefore must be from different cells, this suggests that TFH 
are clonally expanded which concurs with other studies (Golby et al., 1999).  
Related sequences were also observed in both TFH subsets and the control T cell 
subset. As the control population is not a distinct T cell lineage but a simply defined as 
a non-Treg population, it is possible that related TFH are contained within the control 
population. On the other hand, the related sequences could be from another T cell 
lineage such as Th17 or Th1 that converted to TFH or share a common progenitor (Lu et 
al., 2011). However additional sequence analysis of different T cell lineages would need 
to be done to explore this possibility further. 
4.3.4 Searching for clonality within a diverse population 
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 When analysing the TCRγ chain, a large amount of diversity was seen within the T 
cell subsets. Though clone specific primers were used to try to select for related clones 
between the subsets, sequencing of the PCR product showed that sequences of similar 
sizes were picked up but none were clonally identical. 
 Clonally related T cells may not have been detected due to the diversity of the 
sequences initially amplified with the TCRγ primers. However, when a specific family 
of TCRβ genes was analyzed, two cases of clonality within the TFH subsets were 
detected. This demonstrated that this is probably a better technique for analyzing 
clonality between T cell subsets. However still no clonality was found with in the Treg 
population or between Tregs and TFH when using a more specific method.   
4.3.5  Improving cell isolation methods 
If future studies were to continue to look for clonality between TFH and Tregs by 
sequence analysis of the TCR, there are still improvements to be made in the isolation 
of T cell subsets. Similarities in surface antigen expression between TFH cells and Tregs 
do pose a problem when looking at clonality. A contamination could give a false 
positive result. Recently a population of Treg cells have been described in GCs and 
termed follicular regulatory T cells (Tfr) (Linterman et al., 2011). These are most 





PD-1+ gate (Fig 4.1C).  Though as no clonality was found between Tregs and TFH in 
this study, this could mean that the Tfr are not developmental related to either Tregs or 
TFH or any clonality was simply not detected. Separating Tfr from TFH could be 
achieved by sorting foxp3+ T cells from the TFH pool. However the intranuclear staining 
required to detect foxp3 could compromise the integrity of the DNA. This would be a 
challenge that would have to be overcome in future studies. 
149 
 
4.4  Conclusions 
In this chapter several methods were designed for the detection of T cell subsets and 
clonally related cells. In conclusion: 
 A new FACS gating strategy was established for isolating Treg subsets from 
lymphoid tissues. 
 A difference in the frequency of naive and memory Tregs was observed 
between tonsil and blood. 
 a method of amplifying and sequencing a fraction of the TCRβ repertoire 
detected clonally related T cells, proving it as a viable method. 
 No clonality was found between Treg and TFH subsets from blood or 
lymphoid tissue. 
 Two cases of clonality were found between and within TFH subsets. 
However, during the investigation, data on TFH increased. The data in this chapter 
suggests no developmental relationship between Tregs and TFH and this is consistent 
with the current literature. Rather than pursuing this further and confirming the identity 
of Tregs by, for example, functional analysis, a decision was made to move on and 






5 Chapter 5: Immune modulatory T cell subsets in 
Inflammatory Bowel Disease 
 
5.1  Introduction 
UC is an inflammatory disorder of the colonic mucosal layer. The inflammatory 
infiltrate includes an increase in Ig producing plasma cells, with the biggest relative 
increase being in cells secreting IgG1 (Scott et al., 1986). 
Local production of autoantibodies has been identified in the mucosa in UC. 
Specificities include pANCA and tropomycin 5 (Hibi et al., 1990, Targan et al., 1995, 
Onuma et al., 2000, Abad et al., 1997). However the exact role the autoantibodies play 
in the pathogenesis of the disease, if any, is not known. It is possible that they could be 
a consequence or cause in the disease process. Whatever their significance, the 
emergence of autoantibodies in UC suggests that TFH may have a role, since TFH are 
involved in regulating the specificity of B cell responses by affecting selection and can 
bias the B cell response against autoantibody production (Meyer-Hermann et al., 2006, 
Victora et al., 2010).  
 
Features such as the production of autoantibodies, the predominant IgG1 response and 
the Th2 –like T-effector profile in UC lesions suggests that UC could be a humoral 
mediated disease (Fuss et al., 1996, Scott et al., 1986, Onuma et al., 2000). In contrast, 
there is a strong Th1 association and an overall pro-inflammatory phenotype in CD, 
which also results in a general increase in the production of IgG antibodies (Fuss et al., 
1996, Scott et al., 1986). The effector B lineage cells of the gut are normally induced in 
the GALT (Brandtzaeg et al., 1999, Boursier et al., 2005). However the properties of 
immunoglobulins produced in diseased mucosa from UC patients have features 
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associated with a peripheral response (Thoree et al., 2002, Meenan et al., 1997). 
 
SNPs in the IL-2/IL-21 locus have been associated with UC (Festen et al., 2009). It 
is not known whether the SNPs reflect association of alleles of IL-2 or IL-21.  However 
enhanced IL-21 expression is found in inflamed mucosa from both UC and CD patients 
(Monteleone et al., 2005). IL-21 is an inflammatory cytokine but it is also important in 
the generation of TFH and a mature immunoglobulin response and TFH themselves 
produce a large amount of IL-21 (Ozaki et al., 2002, Vogelzang et al., 2008, Chtanova 
et al., 2004).  IL-21 has been shown to be increased in autoimmune disease such as SLE 
and mouse models of lupus (Terrier et al., 2012, Linterman et al., 2009, Bubier et al., 
2009, Ozaki et al., 2004).  The SNP association at the IL-2/ IL-21 locus might reflect an 
involvement of TFH in the pathogenesis of UC. 
 
It has been suggested that the appendix could have a role in the pathogenesis of UC. 
Several studies found a significant negative correlation between appendectomy and the 
development of UC (Andersson et al., 2001, Naganuma et al., 2001). Comparisons 
between normal appendix and colon revealed that there is a trend towards a higher 
density of IgG+ cells in appendix (Bjerke et al., 1986). The appendix contains abundant 
GALT and dysregulation of the B cell response in the GALT of appendix might result 
in B cells homing to the colon and secreting proinflammatory complement fixing IgG 
autoantibodies that may contribute to the development of UC (Brandtzaeg, 2010, 
Halstensen et al., 1993). 
 
There is a loss of immune regulation within the gut in IBD. Patients with immune 
dysregulation, polyendocrinopathy, enteropathy, and X-linked (IPEX) syndrome, which 
is caused by mutation in the Treg transcription factor, FOXP3, often have intestinal 
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inflammation similar to IBD (Gambineri et al., 2003). This is mirrored in mice lacking 
Treg derived IL-10, which have severe colitis due to uncontrolled immune responses to 
luminal antigens (Kühn et al., 1993). However, transfer of Tregs into CD4+CD45RB
high
 
T cell induced mouse models of colitis slowed disease progression (Mottet et al., 2003). 
This demonstrated the importance of Tregs in controlling mucosal immune responses, 
suggesting that dysfunctional or reduced numbers of Tregs could be involved in the 
pathogenesis of IBD. However, the conclusions of previous studies on Tregs in IBD 
vary depending on how Tregs were identified and the controls used. Some studies have 
found an increase in intestinal Tregs in the lamina propria and mesenteric lymph nodes 
in CD compared to non-IBD controls and have demonstrated that they are functionally 
suppressive in vitro (Kelsen et al., 2005, Saruta et al., 2007). However a study in a 
SAMP1 / YitFc (SAMP) spontaneous mouse model of ileitis that is similar to human 
CD, concluded that Tregs are dysfunctional in vivo (Ishikawa et al., 2012). A study of  
Tregs in blood and colonic mucosa from patients with IBD or diverticulitis, used as an 
inflammatory disease control, demonstrated a reduced frequency of Treg in the blood of 
patients with active  IBD compared to controls (Maul et al., 2005).  Although the 
number of Tregs were higher in the mucosa in IBD compared to healthy controls, there 
were fewer Tregs in IBD than observed in diverticulitis (Maul et al., 2005).  The lower 
number of Tregs in blood and mucosa in both active UC and active CD compared to 
inflammatory controls may be a consequence of apoptosis of Treg in IBD (Maul et al., 
2005, Veltkamp et al., 2011). 
 
TFH in IBD have not been studied in detail. It is possible that an equilibrium between 
immune regulators such as TFH and Tregs is important for immune homeostasis and that 
this becomes unbalanced in IBD.  The appendix tissue is thought to be involved in the 
development of UC and in this chapter TFH and Treg subsets in IBD, control tissue and 
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peripheral blood were analysed by imunohistochemistry and flow cytometry and in 
particular comparisons between UC appendix and other intestinal mucosa were made. 
5.1.1  Aims: 
 To determine if there is any difference in the frequency or phenotypic diversity 
of TFH in UC compared to controls that might reflect a role of TFH in the 
generation of autoantibodies and inflammation in UC. 
 To determine if there is any difference in the frequency of circulating TFH in 
IBD compared to healthy controls. 
 To determine if there is any difference in the frequency of mucosal and 
circulating Tregs in UC compared to controls that may be related to the 
dysregulation of humoral immune responses. 
5.2 TFH subsets in inflammatory bowel disease. 
5.2.1 TFH frequency in the IBD gut tissue 
As TFH are involved in the selection and generation of plasma cells through a GC 
response, it is possible that an altered TFH population contributes to the altered humoral 
pathology seen in UC. In order to study TFH in IBD paraffin embedded gut tissue from 
bowel cancer, UC and CD patients who underwent a right hemicolectomy, were 
obtained. Blocks of control normal ileum, appendix and colon were selected from 
uninvolved areas of right hemicolectomy specimens from patients undergoing resection 
for bowel cancer. Blocks of ileum, appendix and colon in which the tissue was involved 
in the disease but where tissue architecture was not obscured by ulceration or fibrosis, 
were selected from the UC and CD resections. 
 To identify and analyse GCs in tissue sections from all the tissue types described 
above, sections were stained for CD21, which is expressed by follicular dendritic cells. 
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Differences in GC size were determined with the use of a microscope eye piece 
graticule and the average size of GCs in a tissue block was plotted. 
 In UC, GCs in the appendix were significantly smaller compared to those in cancer 
appendix (Fig 5.1A and B). GCs in UC ileum and colon also tended to be smaller than 
in control tissue but the difference was not significant. 
Next, serial tissue sections from each tissue block were double stained for CD57 and 
CD3. The relative TFH density was determined by the same method as described in 
3.2.3. The number of CD57+ cells, CD3+ cells and haematoxylin only stained cells 
within GCs were counted and expressed as a ratio of TFH to non-T cells and a relative 
TFH density was generated. 
 A significantly higher relative TFH density was observed in UC appendix GCs 
compared to cancer appendix GCs (Fig 5.1 A and C). However the relative TFH density 
in UC ileum and colon GCs was comparable between cancer ileum and colon GCs and 
there was no significant difference in the relative density of TFH in CD gut tissue GCs 
compared to cancer gut tissue GCs (Fig 5.1C). 
 The average relative density of CD57+ TFH in UC appendix GCs was significantly 
higher than in cancer appendix GCs but there were no other differences between the 
tissue types tested (Fig 5.1C). There was a trend for the average relative density of 
CD57- TFH in UC appendix to be lower than in control tissues but there were no 
significant differences as the average relative density of CD57- TFH was diverse within 
data sets (Fig 5.1C).  
Overall this data suggests that even though the GCs in UC appendix are small there 












Figure 5-1 GC size and TFH ratio in cancer, UC and CD gut tissue. 
A- Paraffin embedded serial tissue sections from cancer and UC appendix IHC stained for CD21 
(left) and CD57 in brown and CD3 in pink(right). B-The average area of >3 GC on each tissue section 
calculated by the  number of 1mm
2 
filled by the CD21+ area on a 10mm x 10mm graticule at 10x 
magnification. C- The average ratio of all CD57+ and CD3+ T cells to non T cells in GCs (left). The 
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average  ratio of CD57+ T cells to non T cells within GCs (middle). The average  ratio of CD3+ only T 
cells to non T cells within GCs (right). Mann Whitney statistical test performed on B and C. 
 
The relative density of TFH was high in tissue sections of UC appendix, but in order 
to study the overall frequency of TFH, fresh appendix cell suspension from cancer, UC 





 and the frequency of CD57+ TFH within this gate was also 
analysed. 
There was no significant difference between the frequency of TFH in CD compared 
to controls.  Statistical tests could not be performed for the UC data set due to the low 
number data points. The average percentage of TFH in UC was 5.5% compared to an 
average of 3.9% in control appendix (5.2A). There were no differences in the 
frequencies of CD57+ TFH between control, UC and CD appendix (5.2 B).  
A B
 
Figure 5-2 FACS analysis of TFH frequencies in cancer, UC and CD appendix 
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 TFH population. Mann-Whitney statistical test performed on A and B. 
5.3 Identification of circulating TFH cells 
In Chapter 3 TFH were analysed in lymphoid tissues. In this chapter potentially 
equivalent populations were sought in blood. 
Subsets of circulating ‘TFH-like’ cells have been described by several different 
groups and therefore termed circulating TFH (cTFH) (Simpson et al., 2010, Morita et al., 
2011). As different subset ratios of TFH were observed in UC tissue compared to cancer 
tissue, the frequency of cTFH in IBD and healthy controls was analysed.  
The phenotype of cTFH was found to be very different to TFH in lymphoid tissues. 
Both circulating and tissue TFH can be identified by their high expression of CXCR5. In 
lymphoid tissue there is dual expression of CD57 with CXCR5 on CD4 T cells, but on 
circulating CD4 T cells CD57 is expressed mainly on CXCR5- populations (Fig 5.3A). 
An antibody panel including CXCR5 and PD-1 was used to identify cTFH in this study 
as this is most commonly used (Bossaller et al., 2006). 
 The expression levels of PD-1 staining on CXCR5
high
 cells was lower on circulating 
CD4 T cells than in lymphoid tissue, where TFH are PD-1
high
 (Fig5.3A and B). In figure 




used to identify TFH in 
lymphoid tissue (Yu and Vinuesa, 2010). However as cTFH express lower levels of PD-




 cells and lie within the larger box in figure 





T cells, as described by others (Simpson et al., 2010). 
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Patients with active IBD were separated from patient in remission or with inactive 
disease. A significantly higher frequency of cTFH was observed in patients with active 
CD compared to healthy controls (Fig 5.3C). However the frequency of cTFH within this 
data set is highly variable. Analysis of cTFH and the patients’ age, gender and 
medication within the active CD group showed no association between frequency of 























 Figure 5-3 Frequency of TFH in peripheral blood of patients with IBD 
Circulating TFH cells and associated co-stimulatory markers analysed by flow cytometry. A-B Paired 
blood and tonsil mononuclear cells analysed for TFH associated markers by flow cytometry. Gating on 
CD3+CD4+ T cells prior to FACS plots shown. Top left and right plot- expression of PD-1 and CXCR5 
on blood and tonsil T cells. Bottom left and right plot-expression of CD57 and CXCR5 on blood and 
tonsil T cells B- Histogram of PD-1 expression on CXCR5+ cells, previously gated on CD3+CD4+ T 
cells in an example of paired tonsil and blood. C- percentage of PD-1+CXCR5+ TFH in CD4 T cell 
population from healthy controls (n=10), inactive UC (n=10), inactive CD (n=10), active UC (n=10) and 
active CD (n=11)  as defined by quadrant 2 on FACS plot A top left. Mann Whitney statistical test 
performed on C. 
 
5.2.3 CD40L expression in inflammatory bowel disease 
CD40L is induced on T cells by activation and is essential for GC formation and the 
survival of B cells in a GC (Quezada et al., 2004). Therefore the frequency of CD4 T 
cells with surface CD40L was analysed by flow cytometry (Fig 5.4A). 
 There was no difference in the frequency of CD40L+ T cells between any groups 
analyzed apart from in blood from patients with active CD compared to healthy controls 
(Fig 5.4B). However this apparent increase in the frequency of CD40L+ T cells in CD 
compared to healthy controls is due to one particularly high data point. Using the 
Grubbs test, the point circled in figure 5.4B was identified as a significant outlier. When 
this point is excluded there is no longer a significant difference and therefore there is 


















Figure 5-4 Frequency of CD40L+ CD4 T cells in peripheral blood of patients with IBD 
Analysis of CD40L on CD4 T cells in PBMCs from healthy controls and IBD patients by FACS A- 
Representative FACS plots with prior gating on CD3+CD4+T cells of healthy blood isotype (left) and 
CD40L (right). B- Percentage of  CD40L+ cells within CD4+ T cells from the blood of  healthy controls 
(n=9), inactive UC (n=11) inactive CD (n=10), active UC (n=10)  and active CD (n=11)  patients . C- 
Graph in B without the data point circled. Mann Whitney statistical test performed on B and C. 
 
5.3 Analysis of TFH associated molecules 
5.3.1  Expression of CXCL13 in IBD gut tissue. 
FDC and germinal centre stromal cells secrete CXCL13 that attracts B cells and T 
cells expressing CXCR5 (Cyster et al., 2000). Altered CXCL13 expression might be 
associated with the size of GCs by altering the recruitment of cells (Marchesi et al., 
2009). To investigate if CXCL13 expression contributes to the distorted GC phenotype 
observed in UC, tissue sections of ileum, appendix and colon from cancer and IBD 
patients were stained for CXCL13 by IHC. The average number of CXCL13+ cells 
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within the GC, lymphocytic infiltrate and LP was determine by counting cells in a 
defined area using an eyepiece graticule, a figure considered to reflect cell density. 
The average density of CXCL13+ cells was highly variable within all data sets (Fig 
5.5).  There was no significant difference in the average number of CXCL13+ cells in 
the GC or lymphocytic infiltrate between UC, CD and cancer tissue (Fig 5.5A and B). 
However as the data sets were small and there was a wide spread of data within them, it 
is possible that the variability might mask any genuine biological differences.  
However, a significant difference in the density of CXCL13+ cells per high power field 
was observed between UC appendix LP and LP in UC colon and ileum (Fig 5.5C).  As 
the data set was small, this difference would have to be verified using further samples, 







Figure 5-5 IHC analysis of CXCL13 in cancer, CD and UC gut mucosa 
Sections of paraffin-embedded ileum, appendix and colon from cancer, UC and CD patients IHC single 
stained for CXCL13. The average number of CXCL13+ cells per 10mmx10mm graticule at x60 
magnification was plotted. A- Average number of CXCL13+ cells in GCs. B- Average number of 
CXCL13+ cells lymphocytic infiltrate. C- Average number of CXCL13+ cells in lamina propria. Mann 
Whitney statistical test performed on A, B and C. 
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5.3.2  IL-17+ cells in all gut tissue microenvironments. 
 In figure 3.6 it was demonstrated by flow cytometry that TFH can produce IL-17 and 
IL-17+ cells were identified in GCs by IHC. Excess IL-17 production has been 
associated with the development of autoantibodies, inflammation, and the production 
and secretion of mucosal antibodies (Nakae et al., 2003, Hofstetter et al., 2005, Cao et 
al., 2012). Therefore the expression of IL-17 in ileum, appendix and colon tissue from 
IBD patients and controls was assessed by IHC, and the number of cells per high power 
field in different microenvironments was determined.  
Very few IL-17+ cells were identified in any of the tissues tested (Fig 5.6) IL-17+ 
cells were identified is some GCs but there was no significant difference between gut 
tissue from UC, CD and cancer patients (Fig 5.6A).  
There was a trend towards a higher number of IL-17+ cells in the CD appendix LP 
but there was only a significant difference between CD appendix and CD colon (Fig 
5.6C).  
In one case of CD the number of IL-17+ cells in the appendix was high in GCs, 








Figure 5-6 IHC analysis of IL-17 in cancer and IBD gut 
Paraffin embedded sections of ileum, appendix and colon from cancer, UC and CD patients IHC 
single stained for IL-17 and the average number of CXCL13+ cells per 10mmx10mm graticule at x60 
magnification was plotted A- Average number of IL-17+ cells within GCs, B- Average number of IL-17+ 
cells within lymphocytic infiltrate C- Average number of IL-17+ cells within lamina propria. Mann 




5.4  Regulatory T cells in Inflammatory Bowel Disease 
5.4.1  Regulatory T cells in IBD gut tissue 







 Tregs were analysed in cancer, UC and CD appendix cell 
suspensions by flow cytometry using the parameters described in figure 4.2.   
Due to small data sets, statistical analysis could not be performed on the UC 
appendix data. However there was no significant difference in the overall frequency of 
Tregs within the CD4 T cell population between cancer and CD appendix (Fig 5.7A). 
Analysis of the naive, memory and activated Treg subsets also showed no significant 
differences in these subsets between cancer and CD appendix (Fig 5.7B). 
 Therefore overall no difference in Treg frequency was observed between cancer, CD 





Figure 5-7 Frequency of Tregs in cancer, UC and CD appendix. 
Fresh appendix mononuclear cells from cancer (n=4), CD (n=3) and UC (n=2) patients were analysed 






Tregs in CD4+ T cells. B- 
Percentage of naive CD45RA+ Tregs, memory CD45RA-CD25++ Tregs and activated CD45RA-
CD25+++ Tregs within the Treg population. Mann Whitney statistical test performed on A and B. 
To investigate whether Treg frequency changes in different areas of the gut or 
different microenvironments in IBD, tissue sections of ileum, appendix and colon from 
cancer, UC and CD patients were stained by IHC to detect the Treg transcription factor, 
foxp3. The number of foxp3+ cells per field was counted in 3 different gut micro-
environments; germinal centres, lymphocytic infiltrate and LP.  
There were no significant differences in the frequency of foxp3+ cells in the T cell 
population between control, UC and CD tissue in any of the micro-environments (Fig 
5.8). However a significantly higher proportion of foxp3+ cells was observed in the 
167 
 
lymphocyte infiltrate and LP in control appendix compared to the cancer ileum and 
colon (Fig 5.8B and C). The proportion of foxp3+ cells was also significantly higher in 
the lymphocytic infiltrates of the appendix compared to the lymphocytic infiltrates of 
the ileum and colon in UC patients (Fig 5.8B). A similar trend of a higher frequency of 
foxp3+ T cells in the appendix compared to the ileum and colon was seen in the LP of 







Figure 5-8 IHC analysis of Foxp3+ T cells in cancer and IBD gut 
Paraffin embedded sections of ileum, appendix and colon from cancer, UC and CD patients single stained 
for foxp3 and CD3. A- Percentage of foxp3+ cells T cells within GCs, B- Percentage of foxp3+ cells T 
cells at x60 magnification in 10mmx10mm within lymphocyte infiltrate C- Percentage of foxp3+ cells T 
cells at x60 magnification in 10mmx10mm within lamina propria. Mann-Whitney statistical test 
performed on A, B and C. 
5.4.2  Circulating Subsets of Regulatory T cells in Inflammatory Bowel 
Disease 
 
Previous studies have reported a decrease in CD25
high
 circulating T regs in active 
IBD compared to inactive IBD (Maul et al., 2005). Since these studies, CD127 has been 
introduced alongside CD25 to more accurately identify Treg (Liu et al., 2006). 




 Tregs in active and inactive UC and 
CD and healthy controls by flow cytometry was performed.  





within the CD4+ T cell pool in patients with active UC compared to healthy controls 
that nearly reached statistical significance (p 0.052) (Fig 5.9A and C). However there 
was no difference in the percentage of Tregs in active CD compared to inactive CD or 
healthy controls (Fig 5.9A and C). 
Naive Tregs can be separated from activated/memory Treg by their expression of 





 Treg gate was higher than healthy controls and inactive 
UC (Fig 5.9B and D). However when the percentages of CD45RA+ and CD45RA- 
Tregs were analysed within the whole CD4+ T cell population it is apparent that the 
CD45RA- Tregs were significantly decreased in active UC and the percentages of 
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CD45RA+ Tregs were equivalent to that found in inactive UC and healthy controls (Fig 
5.9E and F). 
The transcription factor, foxp3, can also be used to identify Tregs (Hori et al., 2003). 







 Tregs in any patient groups (Fig 5.10A). 




 CD4 T cells and the CD45RA+ and 





 Tregs are foxp3+ in all patient groups consistent with the hypothesis 

























Figure 5-9 Analysis of  circulating T reg subsets in IBD by flow cytometry 
PBMCs from healthy control, patients with inactive UC and CD and patients with active UC and CD 




 Tregs in 
the CD4 population (A and C) and the frequency of Tregs in the CD4 population (B and D) in healthy 
controls (n=10), inactive UC (n=10), inactive CD (n=10), active UC (n=10) and active CD (n=11). C- An 
example of gating for separating CD45RA+ and CD45RA- Tregs in the Treg population (left) and the 
frequency of CD45RA+ in the Treg population (right) in healthy controls (n=10), inactive UC (n=10), 
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inactive CD (n=10), active UC (n=10) and active CD (n=11). Percentage of CD45RA+ (E) and CD45RA- 
Tregs (F) in the CD4 population in healthy controls (n=10), inactive UC (n=10), inactive CD (n=10), 




Figure 5-10 Analysis of foxp3 expression in circulating Treg subsets in IBD  




 cells and foxp3+CD25
high
 cells frequency in the CD4 T cell 





 cells, CD45RA+ Tregs and CD45RA- Tregs from healthy controls (n=3), CD (n=4) 
and UC (n=3) patients. Wilcoxon matched pairs statistical test performed in A. 
The CD45RA- population includes memory and activated Tregs that can be 
separated by their expression of CD25 (Miyara et al., 2009). Memory Tregs are 
CD45RA-CD25++ and activated Tregs are CD45RA-CD25+++.  The frequency of 
these two Treg subsets within the Treg population was analysed by flow cytometry. 
The frequency of circulating memory Tregs was significantly lower in active UC 
compared to inactive UC and healthy controls (Fig 5.11A and B). The frequency of 
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activated Tregs was also significantly lower in the blood of patients with active UC 
compared to inactive UC and healthy controls (Fig 5.11A and C). However there was 
no significant difference in the frequency of circulating Treg subsets between UC and 
CD patients possibly due to patients with CD having diverse and varied Treg 
frequencies (Fig 5.11B and C).  









Figure 5-11 Analysis of activated and memory Treg subsets 




 Treg population by flow cytometry in 
healthy controls, inactive UC and CD patients and active UC and CD patients PBMCs. A- An example of 
separating naive CD45RA+ Tregs, memory CD45RA-CD25++ Tregs and active CD45RA-CD25+++ 




 Treg population by FACS in healthy controls, inactive UC, inactive 





 Treg population in healthy controls (n=10), inactive UC (n=10), inactive CD (n=10), active UC 





population in healthy controls (n=10), inactive UC (n=10), inactive CD (n=10), active UC (n=10) and 
active CD (n=11). 
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5.5  Discussion 
5.5.1  Role of the appendix in UC 
In this chapter differences were observed in UC appendix compared to other UC gut 
mucosa and to cancer and CD tissue.  
  GCs in UC appendix were significantly smaller than GCs in cancer appendix, or 
GCs in UC mucosa outside the appendix. 
 A higher relative density of TFH was seen in appendix GCs in UC compared to 
appendix GCs in cancer and CD or in GCs in other UC mucosa. 
 TFH in appendix GCs in UC were mainly CD57+, whereas GCs in the ileum and 
colon in UC contained a substantial proportion of CD57- TFH like in CD and 
cancer tissue.   
In addition to these differences in GCs in UC appendix compared to GC’s in other 
tissues and GCs in appendix in other conditions, more CXCL13+ cells were observed in 
the UC appendix LP compared to UC colon and ileum LP. Though CXCL13+ cells 
have not been reported in the LP of healthy or IBD tissue, Marchesi et al. (2009) 
suggest that CXCL13 within the effector tissue of the gut may recruit lymphocytes 
during inflammation and increase lymphoid tissue formation.  Also, in general, a higher 
frequency of Tregs was identified in appendix compared to other mucosal sites. 
An association between the appendix and UC has been demonstrated by several 
studies that found a negative correlation between appendectomy and disease 
development. Large cohort studies show that patients who had appendectomies due to 
non-perforating appendicitis before the age of 20 were less likely to develop UC 
compared to controls (Andersson et al., 2001, Naganuma et al., 2001).  Several studies 
have compared the appendectomy rate in CD patients to control groups. However, the 
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majority of studies have not found a significant correlation but this may be due to CD 
patients undergoing appendectomies at the onset of disease before or at the time of 
diagnosis (Radford-Smith et al., 2002, Radford-Smith, 2008). 
Radford-Smith et al. (2002) suggested two hypotheses to explain why the removal 
of the appendix may protect against the onset of UC. Firstly Radford-Smith et al. (2002) 
proposed that individuals who undergo an appendectomy may be genetically different 
or are under the influence of different environmental factors to individuals that develop 
UC. For example, patients than undergo appendectomies may be predisposed to 
developing appendicitis whereas patients with UC are not predisposed to appendicitis 
but are predisposed to developing UC. Secondly Radford-Smith et al. (2002) proposed 
that removal of the appendix may affect immune modulation of the gut mucosa. 
 In TCRα mutant mice that spontaneously develop an inflammatory disease like UC, 
fewer mice developed IBD over the 6-7 months of observation after removing the 
appendix at 1 month old (Mizoguchi et al., 1996). This data would suggest that 
removing the appendix at an early age modifies the gut immune responses and supports 
Radford-Smith et al. (2002) hypotheses. However, though mouse models give an insight 
into the disease progression of UC-like disease after an appendectomy, there are several 
differences in the mouse and human appendix such as size and possibly function. 
Therefore direct comparisons cannot be made between mouse models and human 
disease.  
The data in this thesis might support both hypotheses of Radford-Smith et al. 
(2002).  On the one hand, the distinctive properties of the GCs in the appendix in UC 
implies that they may have encountered an environmental pathogen that initiated a 
distinctive immune response, or that the response in appendix of patients with UC might 
be genetically different so that GCs in appendix in patients with UC develop differently.  
On the other hand, the higher frequency of Treg in the appendix in general, compared to 
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other sites in the gut, suggests that appendix may have a unique role in maintaining 
mucosal immune homeostasis therefore that removal of the appendix may cause 
immune modulation in the intestine that could protect against UC.  Subsequent likely 
events are discussed in the paragraphs below. 
5.5.2  Possible support of autoantibody production by TFH in UC 
 
A very high relative density of TFH was seen exclusively in appendix GCs in UC, 
when analysed by IHC. A high density of TFH has been proposed as a mechanism for 
supporting the development of autoreactive B cells (Linterman et al., 2009). A higher 
frequency of TFH could theoretically reduce the competition between GC B cells for TFH 
interactions and cytokines (Meyer-Hermann et al., 2006). Therefore B cells that would 
otherwise die due to selective pressure may instead receive the signals needed to 
survive. Limiting TFH numbers usually ensures that B cells specific for the antigen 
mature however an excess of TFH would allow less antigen specific B cells to survive 
and these could be autoreactive (Linterman et al., 2011). Several different autoreactive 
antibodies have been associated with UC and the high density of TFH observed in UC 
may contribute to the local production of autoreactive B cells (Onuma et al., 2000, 
Targan et al., 1995). 
In TCRα mutant mice that develop UC-like disease, an increase in autoantibodies 
similar to those found in UC were found in the appendix lymphoid tissue compared to 
Peyer’s patches of these mice (Mizoguchi et al., 1996). In this study a high relative 
density of TFH was only observed in the appendix lymphoid tissue in UC which suggests 
that appendix GCs could be an early induction site of autoantibodies in UC. This is 
consistent with the hypothesis that the appendix is involved in the development of UC 
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and removing the appendix modulates the mucosal immune system which prevents the 
onset of UC (Radford-Smith et al., 2002). 
5.5.2.1  TFH phenotype in UC appendix 
The frequency of CD57+ TFH obtained by FACS analysis shows no differences 
between cancer, UC and CD appendix. However a difference in the relative density of 
CD57+ TFH was observed between UC and cancer appendix by IHC. This is probably 
due to FACS being able to detect non TFH, such as activated T cells which also express 
CXCR5 that localise in gut LP (Sarra et al., 2010a). Therefore it is possible that an 
increase in activated T cells in UC masks any difference in the frequency of CD57+ TFH 
when analysing by flow cytometry.   
Analysis of TFH by IHC shows that TFH in UC appendix were mainly CD57+ 
whereas CD and cancer appendix contained a substantial proportion of CD57- TFH. The 
high relative density of CD57+ TFH observed in the UC appendix resembles the 
phenotype of TFH in peripheral rather than mucosal lymphoid tissues ( Fig 3.2 and Fig 
5.1). 
An increase in the production of IgG, in particular IgG1, is associated with UC and 
this isotype is more commonly induced in peripheral lymphoid tissues (Scott et al., 
1986). Also IgHJ1 usage was detected in the UC mucosal IgG population and IgHJ1 is 
associated with the peripheral immunoglobulin repertoire (Thoree et al., 2002). It is 
possible that in UC appendix the high proportion of CD57+ TFH may support CSR to 
IgG and a peripheral-like GC response. 
 Brandtzaeg (1995) also suggests that other features of IBD reflect that of the 
peripheral immune system rather than the mucosa immune system. Vascular endothelial 
cells in IBD mucosal tissue express adhesion molecules similar to those found in 
peripheral lymphoid tissue and gut derived lymphocytes in IBD  have the ability to bind 
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to peripheral vessels (Salmi and Jalkanen, 2001, Salmi et al., 1994). Normally intestinal 
T cells are unreactive to certain microbrial antigens but primed T cells from the  mucosa 
of IBD patients having similar microbial specificities as those in the periphery (Pirzer et 
al., 1991). As the gut is a specialised microenvironment where immune cells are in close 
proximity to the luminal pathogens, strict regulation of responses and minimal 
inflammatory responses are needed to maintain the integrity of the gut (Barnes and 
Powrie, 2009). Therefore if an immune response similar to a peripheral immune 
response occurs in the gut it could result in mucosal inflammation. 
It has been suggested by Brandtzaeg (2010) that the change in immunoglobulin profile 
might be a defence mechanism. Secretory IgA is a first line defence mechanism, which 
mediates immune exclusion (Mantis et al., 2011). In inflammatory bowel disease, there 
in an increase in IgA+ plasma cells, but fewer IgA express the J chain which result in 
less IgA being secreted into the lumen (Brandtzaeg, 2010, Kett et al., 1988). This could 
leads to a reduction in the first line defence mechanisms. However IgG is increased, 
possibly as less IgA is secreted into the lumen and gut microbial bacteria are not 
sufficiently controlled. The IgG in IBD possibly acts as a second defence mechanism 
when the immune system has already been compromised as IgG is efficient at 
opsonising pathogens and activating complement (Brandtzaeg, 2010). The difference in 
TFH could be a result of the need to switch from sIgA to IgG due to the breeching of the 
intestinal defences. A change in TFH phenotype could promote movement towards a 
more systemic type response or it could be associated with a reduction in sIgA that 
might subsequently result in an increase in IgG which then compromises the mucosal 
defences (Macpherson et al., 2008).  
 The high proportion of CD57+ TFH was observed exclusively in UC appendix 
and not in the colon or ileum. This suggests the appendix may be the origin on the 
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peripheral-like response in UC, predominantly a disease of the colon. If so, this would 
support Radford-Smith et al. (2002) hypothesis that the appendix is able to modify the 
gut responses. 
5.5.2.2 Higher frequency of Treg in appendix tissue 
In both cancer and UC tissue there was a higher frequency of Tregs in appendix 
lymphocyte infiltrate compared to colon and ileum lymphocyte infiltrate when analysed 
by IHC. The frequency of Tregs was also significantly higher in cancer appendix LP 
compared to cancer colon and ileum LP and a similar trend was seen in UC and CD 
mucosal tissues. Therefore it appears that the appendix generally has a higher frequency 
of Tregs compared to other intestinal sites. A higher frequency of Tregs is possibly 
required in the appendix as a higher proportion of IgG+ cells reside in it compared to 
colon and IgG has greater proinflammatory properties than IgA  (Bjerke et al., 1986).  
5.5.3  Circulating immunomodulatory cells in inflammatory bowel 
disease 
5.5.3.1  Circulating TFH in IBD 
No difference in the frequency of cTFH was observed between active UC and 
inactive UC patients and healthy controls but an increase in cTFH was observed in active 
CD compared to healthy controls.  
CXCR5 and PD-1 are also found on activated cells (Ansel et al., 1999, Agata et al., 
1996). As well as the high frequency of circulating CXCR5+PD-1+ cells found in CD in 
this study, an increase in CXCR5+IL21+ cells has been observed in CD intestinal 
mucosa compared to UC and controls (Sarra et al., 2010a). It is possible that this is due 
to an increase in activated cells rather than an increase in TFH.  This is especially relevant 




There is still some speculation as to whether circulating TFH are related to TFH found 
in GCs. It has been demonstrated that cTFH are able to provide help to B cells and aid 
the generation of antibody secreting cells in response to antigen, however without 
exogenous stimulation, the amount of B cell help is far less than with GC-TFH  (Schaerli 
et al., 2000, Vinuesa and Cook, 2011, Morita et al., 2011). Therefore studying GC-TFH 
maybe more disease relevant than studying cTFH. 
5.5.4  CXCL13 expression in IBD 
   CXCL13 is important for the positioning of GC B and T cells and in the gut of 
CXCL13 deficient mice, small GC like clusters of T and B cells are able to form around 
the T cell zone but they lack the distinctive structure of peyer’s patches in wild type 
mice (Ansel et al., 2000). However, aberrant expression of CXCL13 is associated with 
autoimmunity as elevated levels of CXCL13 have been observed in the serum of 
patients with SLE (Wong et al., 2010, Schiffer et al., 2009). As CXCL13 plays a role in 
the size and morphology of GCs and is linked to the generation of autoantibodies, the 
number of CXCL13+ cells within the gut of IBD patients and controls was assessed in 
this chapter. 
Some differences in the number of CXCL13+ cells were observed in the lamina 
propria of UC tissues. However no difference in the number of CXCL13+ cells was 
observed between UC and control GCs. This is in agreement with observations made by 
Carlsen et al. (2002) where the expression of CXCL13 in UC GALT was similar to that 
in healthy GALT. This would suggest that altered expression of CXCL13 does not 
contribute to the small GC phenotype in UC or the production of disease associated 
autoantibodies.  
CXCL13 is a secreted chemokine and therefore secreted CXCL13 is probably not 
visualized by IHC. Though there are equivalent numbers of CXCL13+ cells in UC and 
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control tissues, it is possible that the amount of CXCL13 they express is different; 
however, this has not yet been addressed.  Carlsen et al. (2004) suggest that monocytes 
and macrophages significantly contribute to the levels of CXCL13 within inflamed UC 
gut tissue instead of FDC. It is possible that the source of CXCL13 could affect the 
morphology of the GC however there is no evidence to support this.  
Interestingly, overall, equivalent numbers of CXCL13+ cells were observed in the 
lymphocytic infiltrate and GCs. Previous data has reported CXCL13+ cells in the 
mantle zone and high endothelial venules in healthy GALT to recruit lymphocytes into 
lymphoid tissue and retain them (Carlsen et al., 2002, Ebisuno et al., 2003). The 
CXCL13+ cells seen in the lymphocytic infiltrate maybe associated with these cells. 
However more research is needed in this area to establish the role of CXCL13 and 
CXCR5+ cells in the development and progression of UC. 
5.5.5  IL-17 expression in IBD 
In this study no significant difference in the number of IL-17+ cells was observed 
between UC, CD and cancer patients. However other studies have suggested that IL-17 
is increased in IBD and a particularly high increase in IL-17+ cells is observed in both 
UC and CD mucosa (Fujino et al., 2003). Fujino et al. (2003) also observed a difference 
in the number of IL-17+ cells in inactive and active IBD patients. IL-17+ cells were 
more prevalent within active lesions in the intestine of patients with IBD (Fujino et al., 
2003). The results in this chapter may differ from  Fujino et al. (2003) results as a 
consequence of the type of tissue selected for this study. In figure 5.6 the IBD tissue 
was selected for being from part of the gut which was involved in the disease but only 
contained chronic inflammation. It maybe that an increase in IL-17+ is only found in 
acutely inflamed IBD tissue. 
5.5.6  Regulatory T cells in IBD 
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In this study, no difference in the number of intestinal foxp3+ T cells was observed 
in IBD and control tissue by IHC. Previous studies have found an increase in foxp3 
mRNA in both UC and CD intestinal tissue compared to control tissue (Wang et al., 
2011b) and an increase in the number of Foxp3 T cells within inflamed lesions 
compared to non-inflamed tissue (Maul et al., 2005). The apparent discrepancy between 
the data presented here and that of others, could be due to the nature of the tissue 
sampled.  Maul et al. (2005) only found a significant difference in the number of foxp3+ 
T cells in severely inflamed tissue from IBD patients and even then the difference was 
not large. Interestingly, Maul et al. (2005) observed that there was a higher frequency of 
Tregs within the mucosa of diverticulitis inflammatory controls compared to IBD tissue 
and therefore suggested that there is in fact a deficiency in the number of Tregs in IBD. 
The equivalent frequency of Tregs within CD and UC intestinal mucosa and control 
cancer tissue is potentially consistent with the hypothesis proposed by others that CD 
and UC are deficient in Tregs, but this is difficult to gauge. 





gate when analysed by flow cytometry (Liu et al., 2006). In this study the activated and 




Treg population are reduced in 
active UC. Previous studies have also shown an overall reduction in the frequency of 
circulating Tregs in both active UC and CD compared to inactive disease (Maul et al., 
2005).  If the Treg population is depleted of activated Tregs which have the highest 
suppressive function, this could possibly lead to the loss of tolerance as seen in UC 
(Miyara et al., 2009). 
The decrease in Treg frequency observed in the blood is believed to be due to the 
Tregs migrating to the site of inflammation in the gut mucosa (Saruta et al., 2007). 
Tregs increase in the inflamed tissue as a mechanism to control or resolve the immune 
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response. However, Maul et al. (2005) reported an increase in peripheral blood and 
mucosal Tregs in inflammatory diverticulitis controls, suggesting that there is actually a 
deficiency in the frequency of circulating Tregs in IBD. Supporting the theory that the 
decrease in Tregs in the peripheral blood of patients with active UC is not due to the 
Tregs migrating to the site of inflammation, no increase in Treg frequency was observed 
in CD or UC intestinal mucosa compared to cancer intestinal mucosa in this study.  
Previous studies have shown that Tregs are functionally suppressive in vitro in IBD, 
therefore suggesting that numerical deficiencies in Tregs is more likely to contribute to 
the dsregulation of immune responses observed in IBD (Saruta et al., 2007).  Analysis 
of functional properties of Tregs in IBD was not explored in this thesis due to time and 
financial constraints.  
5.6  Conclusions 
In this chapter the frequency and phenotype of TFH and Treg were explored in 
context of IBD. The findings were: 
 The relative density of TFH is increased and GCs were smaller in UC 
appendix compared to control appendix. 
 TFH in UC appendix are mainly CD57+ and resemble the TFH population in 
peripheral lymphoid tissues. 
 The frequency of Tregs is higher in appendix than colon or ileum. 
 Circulating memory and active Treg frequencies are decreased in active UC 
compared to inactive UC and healthy controls but no difference in Treg 




6 Chapter 6: Overview  
6.1 Definition of TFH in tissue sections, cell suspensions and blood. 
In this thesis TFH have been analysed in tissue sections by immunohistochemistry, 
and in cells isolated from tissues and from blood by flow cytometry. In this thesis the 
‘gold standard’ for TFH definition was considered to be that TFH should be located 
within a germinal centre.  Therefore immunohistochemistry is the only method that can 
identify them unambiguously.  When cell isolates were made it was necessary to depend 
on cell surface markers to identify TFH.  This is problematic in that some of the markers 
used are not TFH specific and despite rigorous analysis and comparison between blood 
and tissues, an element of uncertainty remains. The subsets of TFH identified in tissue 
sections were not apparent in the same way in cell suspension, and the first thought 
when trying to understand these differences is to challenge the content of the cell 
suspensions.  In the future it would be interesting to pursue this more stringently and to 
combine further markers to resolve this issue. Only then could truly meaningful 
functional in vitro experiments be designed. 
It would be useful in the future to be able to compare appendix and tonsil tissues in 
more detail in cell suspension. Unfortunately these tissues were not available in 
sufficient quantity during the time of this study, but many interesting questions remain.  
This is particularly important considering the intriguing profile of the appendix in UC.  
It would be interesting to know, for example, how TFH from these different sites differ 




6.2 Differences in the TFH population in peripheral lymphoid tissue 
and GALT – implications for the pathogenesis of inflammatory 
bowel disease 
In the first results chapter of this thesis, the density of TFH in germinal centres from 
different microenvironments was compared. The ratio of TFH to B cells was observed to 
be higher in the germinal centres of GALT compared to the germinal centres of 
peripheral lymphoid tissue. A higher density of TFH has been linked with autoimmunity 
since this is thought to reduce the stringency of selection in the germinal centre 
microenvironment. The higher density of TFH in GALT may be associated with the 
greater tendency for plasma cell precursors generated in GALT to go on to produce IgA 
with autoreactive and polyspecific components compared with systemic IgG responses. 
In chapter 5 of this thesis it was observed that TFH in the appendix in UC were 
present with higher density than either healthy GALT or other inflamed intestinal sites. 
This observation may be associated with the known local autoantibody production in 
UC and the inflammatory response, since selection pressure that would normally reduce 
the probably of autoantibody production would be lower. 
Immunohistochemical analysis demonstrated that GCs in GALT contained a greater 
proportion of TFH that lacked the antigen CD57 compared to those in peripheral immune 
responses. It is possible that CD57+ TFH develop from CD57- TFH since CD57 is known 
to be associated with end stage differentiation.   
The high density of TFH in UC appendix was comprised almost exclusively of 
CD57+ TFH. TFH in the UC are like peripheral lymphoid tissue in that the CD57- subset 
is relatively rare but are at a much high density than healthy peripheral lymphoid tissue 
or GALT. In addition, the GCs in the appendix in UC tend to be very small. The 
unusual composition of GCs in the appendix in UC may be related to disease 
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pathogenesis. Although the autoantibodies in UC are not known to be pathogenic, the 
immunological profile that generates a relatively high frequency of autoantibodies and a 
relative increase in IgG production may be relevant to the development of the 
inflammatory response. This may be a consequence of changes in the balance between 
immune modulatory T cells subsets as will be described below. 
6.3 Two types of T cells with synergistic effects:  regulatory T cells 
and T follicular helper cells 
The immune system is constantly battling to maintain a balanced homeostatic 
equilibrium between activation and suppression. A successful immune response can be 
initiated by a pathogen and end with resolution of the infection and down regulation of 
the response. TFH cells are involved in the generation of an immune response whereas T 
regs are involved in regulation and resolution and therefore these two cell types might 
be considered to be synergistic in their functions. In this thesis no evidence of a clonal 
relationship between TFH and Treg was found, though it remains possible that TFH and 
Tregs could function antagonistically and may be dependent in different ways on a 
common set of parameters.  
A method for studying T cell plasticity in humans based on analysis of clones was 
refined in this thesis. Although no relationship between Treg and TFH was found, 
clonality within the TFH population was identified. Current methods for defining T cell 
plasticity involve culturing cells and observing switches from one profile to another. 
The advantage of the method developed in this thesis is that interrelatedness between T 
cell subsets could be investigated in vivo. It would be interesting in the future to use this 
method to determine whether T cell plasticity defined in vitro, for example between 
Th17 and Th1, is apparent in vivo. It would also be necessary to confirm T cell profiles 
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by functional study in vitro in such an experiment for comparison and confirmation of T 
cell lineage. 
Overall, in this thesis, differences in TFH have been described in different anatomical 
setting and in inflammatory disease. Future studies should be able to identify the 
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